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Ansamycin natural products have historically been a rich source of new drugs for 
the treatment of bacterial infections and cancer. The C17-benzene ansamycins in 
particular have shown excellent preclinical results as potential anti-fungal and anti-cancer 
medicines. However, their thorough clinical evaluation has been hampered by the 
absence of a concise synthetic strategy. In order to address this issue, recently developed 
hydrogenative carbon-carbon bond forming methods were applied toward a short total 
synthesis of C17-benzene ansamycins. This class of natural products provides a 
challenging testing ground for these methods while facilitating the further development 
of compounds, which may be used as treatments for life threatening diseases. 
In the first synthetic approach to the C17-benzene ansamycins key bond 
formations include direct iridium catalyzed carbonyl crotylation from the alcohol 
oxidation level followed by chelation-controlled dienylation to form the stereotriad, 
which is attached to the arene via Suzuki cross-coupling. The diene-containing carboxylic 
 viii 
acid is prepared using rhodium catalyzed acetylene-aldehyde reductive C-C coupling 
mediated by gaseous hydrogen. Finally, ring-closing metathesis delivers the cytotrienin 
core. 
The second approach toward triene-containing C17-benzene ansamycins resulted 
in the syntheses of trienomycins A and F, which were prepared in 16 steps (longest linear 
sequence) and 28 total steps. The C11-C13 stereotriad was generated via enantioselective 
ruthenium-catalyzed alcohol CH syn-crotylation followed by chelation-controlled 
carbonyl dienylation. Finally, diene-diene ring closing metathesis to form the 
macrocycle. The present approach is 14 steps shorter (LLS) than the prior syntheses of 
trienomycins A and F, and eight steps shorter than any prior synthesis of a triene-
containing C17-benzene ansamycin.  
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 1 
1 BACKGROUND C17-BENZENE ANSAMYCINS 
1.1 Introduction 
Natural products have been a source of new medicines1 as well as the inspiration 
for numerous drug discovery programs.2 The identification and development of 
pharmacophores derived from natural products has led to new small molecule medicines.3 
The ability to access useful quantities of these compounds through isolation from natural 
sources or synthetic organic chemistry is a crucial aspect of this development process. 
Roughly 20% of the top-selling small molecule drugs are polyketides isolated 
from soil bacteria,3 and it is estimated that polyketides are five times more likely to 
possess drug activity compared to other classes of natural products.4 Unfortunately, less 
than 5% of the polyketide producing soil bacteria is amenable to culture.5 Hence, as 
methods to access polyketide structures through fermentation and synthesis improve, it is 
anticipated that polyketides will become even more important in medicine. An important 
polyketide subclass is the triene-containing C17-benzene ansamycins.6 Even though this 
class of natural products has displayed potent anti-fungal and anti-tumor activity in vitro, 
they have received less interest from the scientific community as lead compounds. One 
plausible reason for the lack of development is the absence of tractable synthetic routes to 
synthesize analogues for a drug discovery program. The main body of this work will 
summarize the prior synthetic work in the area of C17-benzene ansamycin synthesis and 
will later describe my efforts to simplify the synthesis of this class of natural products by 
developing synthetic approaches that would enable analogue synthesis. 
 2 
1.2 Isolation and bioactivity 
Among macrolactam antibiotics, ansamycins constitute a class of natural products 
characterized by a cyclic structure consisting of an aromatic moiety (naphthalene or 
benzene) and a polyketide chain that forms a bridge linking an aromatic moiety 
(Scheme 1.1). The word "ansa" is Latin for handle, and it refers to the bridging 
polyketide chain as a basket handle around an aromatic group.7 The benzene and 
naphthalene ansamycins can be further distinguished by the length of the ansa chain. The 
benzene ansamycins are divided into two groups: C17 ansa chain and C15 ansa chain. 
Representative members of the C17- and C15-benzene ansamycins are trienomycin A 
(1.1a) and geldanamycin (1.2) respectively. Currently, there are several structural 
analogues of geldanamycin under investigation in clinical trials for the treatment of 
cancer.8 Naphthalene ansamycins are divided in three groups based on ansa chain length: 
C23, C17, and C9 members. Several members of the napthalenoid class have exhibited 
potent antibiotic activity. In particular, rifamycin B (1.3) discovered  in  the  late  1950’s  in  
soil samples taken from the south of France,9 was the first ansamycin commercialized for 
the treatment of bacterial infections.10 
 3 
 
Scheme 1.1    Classification of macrolactam antibiotics 
In 1967, the first C17-benzene ansamycin, mycotrienin I (1.4a), was isolated from 
a strain of Streptomyces by Coronelli.11 Since then over 30 related compounds have been 
isolated from different Streptomyces and Bacillus strains (Figure 1.1).6 While these 
compounds share the same ansa chain, it is the combination of substituents on the 
benzene moiety and at C11 that dictates if the compound exhibits potent or weak, 
 4 
anti-fungal or anti-tumor activity. For example, mycotrienin II (1.5a), which contains a 
hydroquinone moiety and an alanine derived C11 side chain, displayed potent anti-fungal 
activity.12 When the C11 side chain is absent, as shown in mycotrienin I (1.4h) and 
mycotrienol II (1.5h), most of the biological activity is diminished.13 The structure of 
trienomycin A (1.1a) differs from mycotrienins I and II only at the benzene 
substitution.14 Trienomycin A (1.1a) possesses a phenol instead of a quinone or 
hydroquinone, yet displays none of the anti-fungal activity seen in the mycotrienins and 
instead shows potent inhibitory activity on HeLa-S3 cells (ED50 = 128 nM).15 In 1997, 
cytotrienin A-D (1.6a-d) were isolated, and found to possess a cyclopropyl amino acid 
side chain at C11.16 Remarkably, cytotrienin A (1.6a) induces apoptosis in human acute 
promyelotic leukemia (HL-60 cells, ED50 = 7.7 nM). A distinct set of ansamycins, 
thiazinotrienomycins A-E (1.7a-e), were isolated in 1995 containing a benzothiazine ring 
system.17 Thiazinotrienomycin E (1.7e) was of particular interest because it demonstrated 
potent activity toward a variety of human cancer cell lines. 
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Figure 1.1  C17-benzene ansamycins 
 6 
1.3 Structural elucidation  
The structure of C17-benzene ansamycins were not known until the relative 
stereochemistry of mycotrienin I (1.4a) was determined using NMR experiments by 
Zeeck and co-workers.18 In 1990, Smith and co-workers elucidated the absolute 
configuration of trienomycins A-C through degradation and independent synthesis of 
those degradation products.19 Treatment of trienomycin A (1.1a) with an excess of 
(Boc)2O furnished tris-BOC 1.8, subsequent reductive ozonolysis provided diol 1.9 
(Scheme 1.2). Esterification of diol 1.9 provided the bis-Mosher ester 1.10, which after 
comparison to NMR spectra of authentic samples, allowed the assignment of the 
stereocenter at C3 to the (R)-configuration.  
 
Scheme 1.2  Degradation and elucidation of C3 stereochemistry 
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In order to assign the absolute configuration of the C11-C13 stereotriad, the C11 
side chain of trienomycin A (1.1a) was cleaved with LiAlH4 and subsequent acetonide 
protection provided intermediate 1.11 (Scheme 1.3). After an ozonolysis and dimethyl 
sulfide reduction, keto aldehyde 1.12 was isolated. The enantiomer of this degradation 
product 1.13 was obtained through an enantioselective synthesis to establish the absolute 
stereochemistry of keto aldehyde 1.12 as 11S,12S,13R. This degradation approach was 
also used to elucidate the structure of thiazinotrienomycin E (1.7e),20 which contains the 
identical stereochemistry on the C1-C17 ansa chain as trienomycin A (1.1a). Finally, the 
benzene moiety of trienomycin A (1.1a) was   oxidized   with   Fremey’s   salt   to   provide  
mycotrienin I (1.4a).21 These correlation studies provided strong evidence that 
C17-benzene ansamycins have identical absolute stereochemistry along the ansa chain. 
 
Scheme 1.3  Degradation and elucidation of C11-C13 stereochemistry 
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1.4 Prior total syntheses of C17-benzene ansamycins  
The synthetic challenges involved with the C17-benzene ansamycins can be 
summarized into five major obstacles: (1) construction of the C11-C13 stereotriad, (2) the 
trisubstituted olefin, (3) the (E,E,E)-triene, (4) macrocyclization to form the 
21-membered lactam, and (5) a protecting group strategy that allows access to the natural 
product. There have been four major syntheses of C17-benzene ansamycin published 
from laboratories of Smith, Panek, and Hayashi. Each major synthesis will be reviewed, 
focusing on how the five major obstacles were overcome. 
1.4.1 SMITH’S SYNTHESIS TRIENOMYCIN A AND F 
After elucidating the relative and absolute stereochemistry of trienomycin A 
(section 1.3), Smith and co-workers disclosed the first total synthesis of a C17-benzene 
ansamycin in 1995.22 The successful synthetic strategy used an alkylation to join allylic 
iodide 1.14 and sulfone 1.15 (Scheme 1.4). Formation of the marocylic ring and (E,E,E)-
triene moitey was accomplished using a bis-Wittig olfination with phosphonium salt 
1.16. The resulting compound provided a divergent intermediate, which was further 
elaborated into both trienomycin A (1.1a) and F (1.1f). 
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Scheme 1.4 Smith’s  trienomycin  retrosynthesis 
The forward synthesis began with an Evans aldol reaction between 1.17 and 
aldehyde 1.18 to furnish the desired syn-aldol product 1.19 (Scheme 1.5). Removal of the 
chiral auxiliary and conversion to aldehyde 1.20 required four steps. Construction of the 
C11-C13 stereotriad was completed by using the allyboration protocol developed by 
Brown to furnish alcohol 1.21. Exposure of 1.21 to TBAF, followed by acetonide 
protection and ozonolytic cleavage afforded keto aldehyde 1.12, which was identical to 
the sample obtained from degradation studies of trienomcyin A (1.1a). Conversion of 
keto aldehyde 1.12 to allylic iodide 1.14 was accomplished in three major transfomations. 
The first of which requried the chemoseletive reduction of keto aldehyde 1.12, protection 
of the resulting alcohol as the TBS ether, and using the one-pot procedure of Negishi23 to 
obtain acetylene 1.22 in three steps. Installation of the trisubsititued Z-olefin was 
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accomplished by treatment of acetylene 1.22 with tert-butyllithium and 
methylchloroformate to deliver an acetylenic ester. With the acetylenic ester in hand, 
conjugate addition of lithium dimethyl cuprate delivered the trisubsititued olefin 1.23. 
After reduction of the methyl ester with DIBAL-H, treatment of the resulting alcohol 
with methanesulfonyl chloride/LiCl, and then NaI in acetone provided the unstable allylic 
iodide 1.14. 
 
Scheme 1.5 Synthesis of allylic iodide 1.14 
Preparation of sulfone 1.15 began with readily available acid 1.24, which was 
subjected to borane reduction and bromination to provide bromide 1.25 (Scheme 1.6). 
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Displacement of the bromide, protection of the phenol as a TBDPS ether, and a catalytic 
reduction of the nitro group furnished aniline 1.26. Amide bond formation with lactone 
1.27 using the Weinreb protocol provided alcohol 1.28. Protection of the alcohol as the 
TBS ether gave access to sulfone 1.15 in seven steps from commerically available 
material. 
 
Scheme 1.6 Synthesis of sulfone 1.15 
The coupling of sulfone 1.15 and allylic iodide 1.14 furnished sulfone 1.29 as a 
mixture of disastereomers in 91% yield (Scheme 1.7). Desulfonylation with Na(Hg) 
amalgum provided amide 1.30. The protecting group strategy for amide 1.30 proved to be 
critical for the bis-Wittig installation of the triene. Through experimentation they found 
that the (2,2,2-trichloromethoxy) methyl group was suitable. Exposure of amide 1.30 to 
KH and chloromethyl 2,2,2,-trichloroethyl ether, followed by global desilylation, and 
then oxidation furnished dialdehyde 1.31. The keystone of this synthetic approach was 
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the macrocyclization with phosphonium salt 1.16 to install the (E,E,E)-triene and deliver 
macrocycle 1.32 in 21% yield. After three protecting group manipulations, diol 1.33 was 
obtained. This compound can also be accessed by semi-synthesis from 
trienomycin A (1.1a).24 
 
Scheme 1.7  Assembly of relay intermediate 1.33 
 To complete the synthesis, a flexible strategy was used starting from diol 1.33, 
which was available from their degradation work. The respective side chains for 
trienomycin A and F were installed in a three step sequence at C11 (Scheme 1.8). The 
esterification was not selective and the C11/C13 regioisomers had to be separated by 
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HPLC. Finally, desilylation provided access to both trienomycin A and F25, from the 
respective intermediates. Completion of the first total syntheses of trienomycin A and F 
enabled confirmation of the structures and provided a flexible strategy amenable to 
accessing other members of the trienomycin family.  
 
Scheme 1.8 Smith’s strategy for trienomycin A and F 
1.4.2 PANEK’S SYNTHESIS OF MYCOTRIENINS 
Building on the strategy developed by Smith, the mycotrienins were disconnected 
at the C16-C17 bond to give two fragments, allylic iodide 1.34 and sulfone 1.35, that can 
be joined through alkylation. The synthesis of both fragments successfully apply the 
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asymmetric (E)-crotylsilane   reagents   developed   in   Panek’s   laboratory.26 The 
macrocyclization and (E,E,E)-triene formation were accomplished through the use of a 
stitching cross-coupling employing enedistannane 1.36. This strategy has been 
successfully applied in the syntheses of rapamycin27 and dynemycin.28 The synthesis was 
completed though a common intermediate, which allowed for access to both mycotrienol 
(1.4h) and mycotrienin I (1.4a) (Scheme 1.9).29 
 
Scheme 1.9 Panek’s  retrosynthesis  of  mycotrienin  I (1.4a) and mycotrienol (1.4h) 
The synthesis of allylic iodide 1.34 contains several challenges in the construction 
of C11-C13 stereotriad and trisubstituted (Z)-olefin. Treatment of keto-dibenzylacetal 
1.37 and (E)-crotylsilane reagent 1.38 with catalytic acid furnished benzyl ether 1.39 in 
80% yield and 30:1 diastereoselectivity. Exposure of benzyl ether 1.39 to the ester 
enolate of benzyl acetate followed by acetylation and subsequent ozonolytic cleavage 
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provided aldehyde 1.40 in 70% yield over three steps. Assembly of the stereotriad was 
completed via a chelation controlled asymmetric allylsilane addition to aldehyde 1.40 to 
give alcohol 1.41. Three further synthetic operations were used to protect alcohol 1.41 as 
a TIPS ether and convert an alkene moiety to the dimethyl acetal 1.42. Hydrogenation of 
the benzyl protecting group facilitated a spontaneous cyclization to a lactone, which after 
elimination of the C14 acetoxy group gave lactone 1.43. Reductive opening of the 
lactone, proctection of the secondary alcohol, and conversion of the primary alcohol to an 
iodide provided access to intermediate 1.34 in 15 steps (LLS) from commerical material. 
 
Scheme 1.10 Synthesis of allylic iodide 1.34 
Coupling of the two major fragments was accomplished by generation of the 
lithium dianion of sulfone 1.35 (prepared in 10 steps) with LiHMDS to facilitate a 
benzylic alkylation with allylic iodide 1.34 (Scheme 1.11). Reductive desulfonylation 
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with Na(Hg) amalgum provided adduct 1.44. Selective deprotections, oxidation, and 
homologation furnished bis-vinyl iodide 1.45. From common intermediate 1.45, both 
mycotrienin natural products were accessed.  
The hallmark of the synthesis was a bis-Stille cross-coupling between 
enedistannane 1.36 and bis-vinyl iodide 1.45, which simultaneously constructed the 
(E,E,E)-triene and induced macrocyclization. Subsequent oxidation of the aromatic moity 
and global deprotection furnished mycotrienol (1.4h) in 24 steps (LLS) from commerially 
available material. To complete the synthesis of mycotrienin I (1.4a), Panek and 
co-workers returned to intermediate 1.45 preformed the bis-Stille cross-coupling and a 
selective deprotection of the C11 hydroxyl group to give alcohol 1.46. This allowed for 
the installation of the side chain and completion of mycotrienin I (1.4a) in 28 steps (LLS) 
from commerially available material. 
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Scheme 1.11  Panek’s  strategy for mycotrienin I (1.4a) and mycotrienol (1.4h) 
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1.4.3 SMITH’S SYNTHESIS OF THIAZINOTRIENOMYCIN E 
Smith and co-workers collaborated with Hosokawa and co-workers to assign the 
relative and absolute stereochemistry20 of the thiazinotrienomycin E (1.7e) and 
subsequently developed a new synthetic route.30,31 The synthesis borrowed from their 
earlier work on the trienenomycins and implemented several improved preparations of 
advanced intermediates. The C11 side chain would be installed at the end to allow 
flexibility in accessing other members of the family. The C16-C17 bond would arise from 
an alkylation of benzylic sulfone 1.47 with allylic iodide 1.48. In a deviation from their 
prior work on trienomycin A and F (Scheme 1.7), the (E,E,E)-triene would be 
disconected to sulfone 1.49 and aldehyde 1.50 (Scheme 1.12). 
 
Scheme 1.12  Smith’s  thiazinotrienomycin  retrosynthesis 
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The preparation of allylic iodide 1.48 commenced with the assembly of the 
stereotriad utilizing aldehyde 1.51 via an anti-selective crotylation reagent developed by 
Brown (Scheme 1.13). Subsequent protection and ozonolytic cleavage furnished 
-methyl aldehyde 1.52. Lithium-halogen exchange of vinyl iodide 1.53 allowed for the 
alkylation of aldehyde 1.52, which was subsequently deprotected and selectively oxidized 
to afford ketone 1.54. Directed reduction with Me4NBH(OAc)3 set the C13 stereocenter, 
followed by acetonide protection and selective TBS deprotection provided alcohol 1.55. 
A quantitative protection-deprotection sequence on alcohol 1.55 delivered alcohol 1.56. 
Subsequent Mitsunobu displacement and oxidation furnished sulfone 1.49. Construction 
of (E,E,E)-triene moiety entailed addition of aldehyde 1.50 (available in eight steps) to 
the anion of sulfone 1.49. After the triene was constructed three additional operations 
provided access to allylic iodide 1.48, which was obtained in 17 steps (LLS) from 
commerically available material. 
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Scheme 1.13 Synthesis of allylic iodide 1.48 
Alkylation of benzylic sulfone 1.47 (available in 12 steps) with allylic iodide 1.48 
provided triene 1.57 in 64% yield as a mixture of diastereomers (Scheme 1.14). An eight 
step sequence commencing with a reductive desulfuration followed by a series of 
protecting group manipulations and oxidations was used to access acid 1.58. From acid 
1.58, a two step precedure was developed to deprotect the aniline and form the 
macrocylic  with  Mukaiyama’s  salt  to  give  macrolactam 1.59. A selective cleavage of the 
C11-C13 acetonide furnished diol 1.60. To finish the synthesis and confirm the structure 
of the thiazinotrienomycins, the same three step protocol to install the C11 side chain 
used in the trienomycins and mycotrienins was employed. Finally, cleavage of the MOM 
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ether with 3 N HCl furnished thiazinotrienomycin E (1.7e) in 33 steps (LLS) from 
commerically available material. 
 
Scheme 1.14  Smith’s strategy for thiazinotrienomycin E (1.7e) 
1.4.4 HAYASHI’S SYNTHESIS CYTOTRIENIN A 
In 2008, Hayashi and co-workers,32 reported a total-synthesis of 
cytotrienin A (1.6a). They sought to construct the triene through a diene-diene ring 
closing metathesis (RCM), which required the synthesis of bis(diene) 1.61 
(Scheme 1.15). Proof of concept studies had been reported by Panek,33 validating the 
 22 
feasablity of a diene-diene RCM to furnish the (E,E,E)-triene. Futher disconnection at the 
C16-C17 bond and C1 amide bond required three major fragments: allylic iodide 1.62, 
benzylic sulfone 1.63, and dienoic acid 1.64. Noteworthy in their work was the use of 
proline catalysis to construct the C11,C12, and C3 stereocenters. 
 
Scheme 1.15  Hayashi’s  retrosynthesis  of  cytotrienin A (1.6a) 
Initial attempts of a large scale organocatalyzed aldol between aldehyde 1.65 and 
propanal 1.66 were found to be problematic (Scheme 1.16). By conducting the reaction 
without solvent and using a modified proline cataylst 1.67, the desired diol 1.68 was 
obtained in good yield and selectivity. Diol 1.68 was protected as PMP acetal 1.69, 
reduced with DIBAL-H to afford an alcohol, and oxidized to furnish aldehyde 1.70. 
Exposure of aldehyde 1.70 to a vinylzincate,34 prepared from vinyl iodide 1.71 with 
t-BuLi and Me2Zn delivered stereotriad 1.72 in good yield and selectivity. Remarkably, 
Hayashi and co-workers were able to construct the C11-C16 fragment containing the 
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stereotraid and (Z)-trisubsituted olefin in just five steps. In order to elaborate stereotriad 
1.72 into a tractable synthentic intermediate an additional seven steps were needed to 
obtain alcohol 1.73. Esterification with acid chloride 1.74 furnished intermediate 1.75, 
which after two additional steps, provided access to allylic iodide 1.62 in 15 steps (LLS) 
from commerical material. 
 
Scheme 1.16 Synthesis of allylic iodide 1.62 
Acid 1.64 was synthesized via proline catalyzed -aminoxylation of aldehyde 
1.76 to provide an unstable intermediate 1.77. The crude mixture was immediately 
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subjected to an olefination and treated with CuSO4/MeOH to afford alcohol 1.78 in 46% 
yield over three steps. A seven step sequence was necessary to methylate the C3 hydroxyl 
group, install the diene, and oxidize the C1 hydroxyl group to carboxylic acid. Thereby 
completeting to synthesis of the major fragment acid 1.64 in 12 steps from commerically 
available material (Scheme 1.17). 
 
Scheme 1.17 Hayashi’s  synthesis  of  acid 1.64 
Construction of the C16-C17 bond by alkylation of the lithium dianion of sulfone 
1.63 with allylic iodide 1.62 gave fragment 1.79 in 78% yield as a mixture of 
diastereomers (Scheme 1.18). Elaboration of the C11 side chain required selective azide 
reduction without affecting the nitro group. This was accomplished in four steps to 
provide advanced sulfone 1.80. The chemoselective reduction of the C17 sulfone in the 
presence of the nitro group proved to be difficult as well. Thus, seven steps were 
necessary to accomplish the sulfone reduction, construction of the diene, and several 
protecting group manipulations to deliver diene 1.81. From diene 1.81 reduction of the 
nitro group, coupling of acid 1.64, and protecting group adjustments provided a globally 
TES protected bis(diene) 1.61 in six steps. In order to cleave the protecting groups in the 
final steps, it was important to have a TES ether at C13, as the TIPS ether at C13 could 
 25 
not be removed after the RCM. Finally, conclusion of the synthesis with a diene-diene 
RCM and deprotection of the TES ethers delivered cytotrienin A (1.6a) in 35 steps (LLS) 
from commerially available material. 
 
Scheme 1.18  Hayashi’s  strategy for cytotrienin A (1.6a) 
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1.5 Conclusions  
The potent anti-fungal and anti-cancer activity of C17-benzene ansamycins 
compelled researchers to learn more about their structure, biological target, and synthetic 
approaches. Each of the completed syntheses confirmed the proposed structure and 
improved methodologies used to construct these complex natural products. However, 
those routes were not efficient and were unable to modify the structures as needed for a 
drug discovery program. Our intention was to develop a shorter and more versatile 
synthetic route that combines the best chemistry of the previous syntheses with our newly 
developed metal-catalyzed transformations. In doing so, this would develop a synthetic 
route that uses roughly half of the steps as the previous syntheses, thereby enabling future 
drug discovery efforts. 
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2 CARBON-CARBON BOND FORMING HYDROGENATIONS  
2.1 Introduction and scope 
One of the most significant challenges facing the field of synthetic organic 
chemistry is the development of more efficient protocols for known transformations. The 
reduction of the number of steps required for a given target is a metric for improvement 
that has received extra attention from the scientific community.35 Another measurement 
is atom efficiency,36 which takes into account some of the pre-activation required to 
access the starting materials for a reaction and the amount of stoichiometric waste created 
from a reaction. An ideal reaction would be one wherein all of the reagents react together 
to produce a single more complex product without any waste generation.37 The 
prototypical examples of such reactions are hydrogenation and alkene hydroformylation 
(Figure 2.1). In hydrogenation, hydrogen is added across an olefin to produce a single 
product without the generation of waste by-products. In hydroformylation, an olefin is 
hydrogenated with carbon monoxide to furnish the product of reductive C-C bond 
formation. In contrast to conventional hydrogenation where hydrogen is added across a 
single functional group, the elements of molecular hydrogen were added over two 
functional groups coupled with C-C bond formation. The expansion of this concept in the 
laboratory of Professor Michael Krische has led to a generalized process wherein the 
hydrogenation of unsaturated moieties with diverse imine or carbonyl compounds 
delivers products of C-C coupling. A direct result of this research has been the 
development of hydrogen-mediated variants of classical organometallic transformations. 
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Figure 2.1 Atom economical transformations 
 In classical methods for the construction of allylic and homo-allylic alcohols, 
organometallic reagents are used to facilitate the stereoselective addition to carbonyl 
compounds (Figure 2.2). These reagents require pre-activation and generate 
stoichiometric amounts of metal waste. An alternative to these transformations would be 
to employ a C-C bond forming hydrogenation allowing the construction of those motifs 
with less pre-activation and waste.  
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Figure 2.2  Hydrogenative C-C coupling as an alternative to classical organometallic 
reagents 
In an effort to provide context, a brief overview of classical methods for 
enantioselective construction of allylic and homo-allylic alcohols through carbonyl 
vinylation, allylation, and crotylation will be discussed. Subsequently, alternative 
transformations using hydrogenative C-C bond forming reactions that are relevant to this 
 30 
body of work will be presented. Finally, contributions to the development of a 
two-directional asymmetric carbonyl allylation reaction are also shown. 
2.2 Catalytic enantioselective carbonyl vinylation reactions 
2.2.1 STOICHIOMETRIC ORGANOMETALLIC APPROACHES 
2.2.1.1 Vinylzinc approaches 
In 1988, Oppolzer reported the first catalytic asymmetric addition of divinylzinc 
to aliphatic aldehydes providing chiral allylic alcohols in high yield and selectivity 
(Scheme 2.1).38 That seminal work was followed by a modification of the protocol where 
an alkyne was hydroborated to furnish a vinylborane, which was then transmetallated 
with dimethylzinc. The resulting vinylzinc reagent participated in a catalyzed addition to 
an aldehyde. The transmetallation approach proved to be an effective method for the 
construction of allylic alcohols,39 and was employed in the synthesis of 
(R)-(-)-muscone.40 An additional modification of this strategy was reported by Wipf, 
which employed a vinylzirconocene to access the vinylzinc reagent. 41,42 Although these 
strategies have been broadly utilized in several applications,43 the drawback is that they 
require multiple equivalents of organometallic reagents for the pre-activation of the 
nucleophilic partner to make a single C-C bond. This is problematic if the protocols are 
used on a very large scale; the excess of metal reagents lead to undesirable and costly 
amounts of waste.  
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Scheme 2.1 Enantioselective vinylzinc additions 
2.2.1.2 Direct alkyne approaches 
 Pioneering work by Ojima44 and Montgomery45 demonstrated the feasibility of a 
direct coupling of alkynes to aldehydes using nickel catalysis and a stoichiometric 
reluctant. Later, Jamison and co-workers46 reported the enantioselective coupling of 
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alkynes with aldehydes to furnish chiral allylic alcohols without the need for 
pre-activation of the nucleophilic partner (Scheme 2.2). This major advancement in 
catalytic enantioselective vinylation was followed by a report from Montgomery47 that 
employed a non-metallic reductant and a chiral N-heterocyclic carbene ligand. Although 
the pre-activation component was removed, the atom economy of this transformation 
could be further improved by using hydrogen as the terminal reductant.  
 
Scheme 2.2 Enantioselective coupling of alkynes to aldehydes 
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2.2.2 RHODIUM-CATALYZED ENANTIOSELECTIVE HYDROGENATIVE VINYLATIONS OF 
ALDEHYDES 
Initial success by Krische and co-workers with the hydrogenative coupling of 
unsaturated systems to aldehydes and ketones demonstrated the importance of employing 
cationic metals in C-C bond forming hydrogenation.48 By employing a chirally modified 
cationic rhodium catalyst they reported the first enantioselective hydrogenative coupling 
of 1,3-diynes to various glyoxals to furnish optically enriched -hydroxy ketones as 
achieved (Scheme 2.3).49 With this promising preliminary result, further investigations 
were conducted to expand the scope of unsaturates beyond diynes. 
 
Scheme 2.3  Coupling of 1,3-diynes to glyoxals 
In 2006, the importance of a Brønsted acid additive was realized in the coupling 
of conjugated alkynes and -ketoesters to furnish products of carbonyl addition 
(Scheme 2.4).50 Different enynes and -ketoesters were used to explore the reaction 
scope, thus demonstrating uniformly high yields and selectivity across a range of 
substrates. Further investigation of the acid additive expanded the substrate scope to 
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include heteroaromatic aldehydes and ketones (Scheme 2.4).51 Subsequent studies 
showed the combination of a chiral phosphoric acid and an achiral ligand can also 
provide the indicated product. The effect the chiral acid resulted in lower yield and 
selectivity compared to using chiral ligands. Further experimentation with pyruvates and 
glyoxalates, suggested that protonation of the heterocyclic moiety is responsible for 
asymmetric induction.  
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Scheme 2.4  Hydrogenative coupling of enynes 
Despite extensive optimization, the reaction scope was still limited to conjugated 
alkynes and activated aldehydes. However, it was reported that by using a cationic 
rhodium catalyst a mixture of acetylene and hydrogen gas, aldehydes could undergo 
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hydrogenative coupling to furnish products of Z-butadienylation (Scheme 2.5).52 When a 
chiral ligand was employed in the reaction, highly optically enriched allylic alcohols 
were obtained. In this report (R)-MeO-BIPHEP furnished allylic alcohols with 
(S) stereochemistry. 
 
Scheme 2.5  Enantioselective (Z)-butadienylation via hydrogenative coupling 
In a useful application of this unique reaction, Krische and co-workers reported  
catalyst directed hydrogenative couplings of acetylene to L-glyceraldehyde acetonide and 
other -chiral aldehydes (Scheme 2.6).53 Formal syntheses of eight L-hexoses were 
accomplished employing the hydrogenative (Z)-butadienylation from L-glyceraldehyde 
acetonide. This provided additional confirmation of stereochemistry and demonstrated 
the usefulness of this method. Interestingly, catalytic systems employing 
(R)-MeO-BIPHEP furnished allylic alcohols with (R) stereochemistry, this is the opposite 
direction of stereo-induction as the prior report (Scheme 2.5). 
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Scheme 2.6  Application of hydrogenative acetylene coupling 
A mechanism for the hydrogenative (Z)-butadienylation was extensively studied 
through computational methods, detection of reaction intermediates with ESI mass 
spectrometric analyses, and diversion of intermediates into alternative reaction 
products.54 The evidence gathered in those experiments supports the following 
mechanism (Scheme 2.7): starting at cationic rhodium 2.1, two molecules of acetylene 
coordinate and dimerize to form a rhodacyclopentadiene 2.2. This intermediate was 
detected with ESI mass spectrometric analysis and diverted into other products. From 
rhodacyclopentadiene 2.2, carbonyl insertion of the aldehyde furnishes an intermediate 
oxa-rhodacycloheptadiene 2.3. The rhodium oxygen bond cleavage is facilitated by the 
Brønsted acid co-catalyst; a hypothesis supported by computation, mass spectrometry, 
and diversion experiments. Protonation of the oxo moiety on the rhodacycle and binding 
of the carboxylate furnishes intermediate 2.4. The carboxylate moiety can assist in H-H 
bond cleavage through a six-membered transition state to deliver complex 2.5, which 
upon reductive elimination of a hydride furnishes 2.6. Finally, disassociation of complex 
2.6 provided the dienylation product 2.7 and cationic rhodium 2.1, which can re-enter the 
catalytic cycle. 
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Scheme 2.7  Proposed mechanism hydrogenative acetylene coupling  
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2.3 Catalytic enantioselective carbonyl allylation and crotylation 
reactions 
2.3.1  STOICHIOMETRIC ORGANOMETALLIC APPROACHES 
The stereoselective construction of chiral homoallylic alcohols by addition of a 
chiral organometallic reagents to aldehydes has been among the most important methods 
for the construction of natural products.55 Of the many reagents available for this 
transformation, chiral boron reagents have received the most attention since the first 
report by Hoffmann56 (Figure 2.3). Significant contributions by Brown,57,58 Roush, 59,60 
Reetz, 61 and others62 has led to a diverse class of similar reagents. However, these 
reagents require pre-activation and generate stoichiometric amounts of waste 
by-products, therefore they are considered inefficient in terms of atom economy.37 The 
following section will focus on catalytic methods that have, in part, addressed these atom 
efficiency issues.  
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Figure 2.3  Reagents for enantioselective carbonyl allylation 
2.3.1.1 Catalytic chiral Lewis acids and bases 
The field of catalytic enantioselective allylations has seen significant growth over 
the  past  two  decades  since  Yamamoto’s  report  of  the  first  examples  of  chiral  Lewis  acid-
catalyzed enantioselective allylation of aldehydes (Scheme 2.8).63 This protocol 
employed chiral acyloxy borane catalysts, which increased the electrophilicity of the 
aldehyde and furnished the products of methallylation and allylation. This breakthrough 
spurred further development of numerous chiral Lewis acids, which remains an active 
area of research.62 In 1993, the laboratories of Umani-Ronchi 64 and Keck65 
independently reported highly enantioselective allylation protocols employing allyltin 
reagents with a BINOL modified titanium based Lewis acid catalyst. Although there have 
been numerous chiral Lewis acid systems developed, only the titanium based BINOL 
system has been reliably employed for complex systems.66 Even though some chiral 
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Lewis acid catalysis utilizes toxic tin based reagents, they can provide optically enriched 
homoallylic alcohols in high yields and selectivities. Further development of this area is 
needed to broaden the scope to include less toxic allyl donors and improve selectivity for 
substituted donors. 
 
Scheme 2.8  Chiral Lewis acid catalyzed carbonyl allylations 
An alternative approach to chiral Lewis acids, which activate the electrophile for 
nucleophilic addition, is chiral Lewis base catalysis. It involves the catalyst activating the 
allyl donor, thereby increasing its nucleophilicity, as well as coordinationing to the 
electrophile, which involves a six-centered transition structure.67 This concept was 
initially brought to fruition by Denmark in 1994,68 which upon further investigation of 
the mechanism69 led  to  the  development  of  a  2,2‘-bispyrrolidine-based bisphosphoramide 
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catalyst.70 This new catalyst enabled a wide range of chlorosilane reagents to react with 
aldehydes furnishing products of allylation, crotylation, and prenylation in high yields 
and selectivities (Scheme 2.9). 
 
Scheme 2.9 Chiral Lewis base catalyzed carbonyl allylations 
2.3.1.2 Catalytic enantioselective Nozaki–Hiyama–Kishi reactions 
After the original reports of the Nozaki–Hiyama–Kishi (NHK) reaction, there 
have been numerous efforts to develop a catalytic enantioselective version of this 
reaction.71 A protocol developed by Fürstner and co-workers required catalytic amounts 
of chromium, employed manganese as a reducing agent, and a trialkylchlorosilane to 
perpetuate the reaction.72 That important breakthrough was followed by a report from the 
laboratory of Umani-Ronchi, which employed a chirally modified chromium salen 
complex and Fürstner’s  modified  conditions   to  affect   the  first  catalytic  enantioselective  
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allylation (Scheme 2.10).73 Further development of this protocol led to a selective 
crotylation,74 and a method to obtain the opposite diastereoselectivity (Scheme 2.10).75 
Although the yields and selectivity were moderate, it did demonstrate the feasibility of 
asymmetric induction via salen modified catalysts. Chiral ligand development for the 
NHK reaction has continued to receive attention from the scientific community, and 
several improvements have been made to expand the scope of allylic halides that react 
with aromatic and aliphatic aldehydes at synthetically useful levels of selectivity.71,76 
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Scheme 2.10 Catalytic enantioselective Nozaki–Hiyama–Kishi reactions 
2.3.2 ENANTIOSELECTIVE IRIDIUM-CATALYZED TRANSFER HYDROGENATIVE 
CARBONYL ALLYLATION AND CROTYLATION 
The traditional reactivity for allyliridium intermediates can be characterized as 
electrophiles, which will undergo addition from nucleophiles.77 In 2008, Krische and 
co-workers reported an inversion of this reactivity, where instead of the allyl donor 
reacting with electrophilic character, the allyliridium complex demonstrated nucleophilic 
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character by providing the products of carbonyl addition. 78 The use of both an acid and 
base additive in the reaction, seems counter-intuitive, but further investigation revealed 
that both additives were required to facilitate formation of the cyclometallated 
iridium-catalyst (Scheme 2.11).79 A single-crystal X-ray diffraction analysis confirmed 
the structure of cyclometallated catalyst and the complex was found to be a relevant 
intermediate in the proposed catalytic cycle. The reaction scope was broad with respect to 
aldehydes and alcohols furnishing the products of carbonyl allylation in uniformly high 
yields and selectivity. Most importantly, this new method obviated the use of 
stoichiometric amounts of pre-metallated reagents. These aspects of the reaction 
warranted further investigation into the scope of allyl donors and electrophilic substrates. 
 
Scheme 2.11 Enantioselective iridium-catalyzed transfer hydrogenative allylation 
Following the initial report that -methyl allyl acetate would affect carbonyl 
crotylation,78 it was found that when the cyclo-metallated iridium complex was employed 
as a precatalyst, products of carbonyl crotylation were obtained in good to excellent yield 
with anti-diastereoselectivity (Scheme 2.12). 80,81 A variation of the precatalyst has shown 
to be highly effective in the reductive coupling of 1,1-dimethylallene to aromatic and 
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aliphatic alcohols or aldehydes providing products of reverse prenylation in good yields 
and selectivity.82 These  reactions  employ  variations  of  the  cyclometallated  iridium  π-allyl 
C,O-benzoate complexes and are stable enough that they can be purified via column 
chromatography.83 The continued investigation of new allyl donors and precatalysts by 
Krische and co-workers has led to a new family of carbonyl allylation processes 
(Figure 2.4).84,85 
  
 47 
 
Scheme 2.12 Enantioselective iridium-catalyzed transfer hydrogenative crotylation 
and reverse prenylation 
 
Figure 2.4 Scope of allyl donors 
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 A general mechanism based on the collective data has been proposed, which 
begins with an iridium catalyst dehydrogenating the reactant alcohol through a β-hydride 
elimination to produce an aldehyde and an iridium hydride (Figure 2.5).86 The hydride 
complex can be deprotonated to generate an anionic iridium intermediate, which then 
reacts with the allyl donor to furnish the allyliridium intermediate. This allylmetal 
intermediate can react with the aldehyde component through a closed six-center transition 
state, which serves as the basis for the high levels of anti-diastereoselectivity observed. 
Finally, protonolysis of the newly formed iridium alkoxide with the reactant alcohol 
furnishes the crotylation product and regeneration of reactive intermediates so that the 
catalytic cycle can continue. 
 
Figure 2.5 Proposed general mechanism for iridium-catalyzed transfer hydrogenative 
couplings 
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2.3.3 ENANTIOSELECTIVE RUTHENIUM-CATALYZED CARBONYL CROTYLATION 
Significant progress was made with iridium-catalyzed transfer hydrogenative 
couplings, but those protocols were unable to provide highly selective 
syn-diastereoselective crotylation or utilize butadiene for highly selective 
transformations.87 Efforts to develop a highly syn-diastereoselective crotylation process 
led to the investigation of silyl-substituted dienes and ruthenium based catalysts that 
would adopt a transition state geometry required to access the syn isomer. Exposure of 
alcohols or aldehydes to a 2-silyl-substituted diene, in the presence of ruthenium catalyst 
modified by a chiral ligand furnished products of syn-diastereo- and enantioselective 
carbonyl crotylation (Scheme 2.13).88,89 A brief exploration of the substrate scope 
revealed that a range of aliphatic, allylic, aromatic substrates were able to furnish the 
respective crotylation products in good yield with excellent levels of the selectivity. This 
was an important milestone in the development of catalytic systems that would use 
butadiene as an allyl donor to circumvent pre-activation and deliver products of carbonyl 
crotylation without any stoichiometric metal waste. 
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Scheme 2.13 Enantioselective ruthenium-catalyzed syn-crotylation 
A plausible catalytic mechanism begins with the ruthenium catalyst 
dehydrogenating the reactant alcohol through a β-hydride elimination to produce an 
aldehyde and a ruthenium hydride (Figure 2.6). This metal-hydride can react with the 
diene by adding the hydride and metal across the diene to generate an allylruthenium 
intermediate. This allylmetal intermediate can react with the aldehyde component 
through a closed six-center transition state. The silyl group forces the allyl geometry into 
a pseudo (Z)--allyl haptomer, thus conferring high levels of the syn-diastereoselectivity. 
Finally, protonolysis of the newly formed ruthenium alkoxide by the reactant alcohol 
furnishes the crotylation product with regeneration of the reactive intermediates so that 
the catalytic cycle can continue. 
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Figure 2.6 Proposed general mechanism for the ruthenium-catalyzed carbonyl 
crotylation89 
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 In 2012, Krische and co-workers reported a major breakthrough toward their 
ultimate goal of developing by-product-free carbonyl addition processes. 90 Exposure of 
alcohols or aldehydes to butadiene, in the presence of ruthenium catalyst modified by a 
chiral phosphoric acid led to products of anti-diastereo- and enantioselective carbonyl 
crotylation (Scheme 2.14). Further study of the ruthenium catalysts modified by both 
chiral counter ions and ligands led to the development of protocols to control all aspects 
of diastereo- and enantioselective carbonyl crotylation with butadiene.91  
 
 
Scheme 2.14  Enantioselective ruthenium-catalyzed anti-crotylation 90 
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2.4 Two directional allylation 
Nature’s  vast  collection  of  polyketide  natural  products  includes  many  compounds  
incorporating polyacetate derived 1,3-diol or higher 1,3-polyol substructures. While there 
are numerous protocols for the synthesis of these structural motifs, the iterative 
allylmetallation of aldehydes has found exceptionally broad use.92,93 For example, 
asymmetric iterative allylchromation (Nozaki-Hiyama-Kishi coupling),94 
allyltitanation,95,96 allylstannation,97,98 allylsilation,99,100 and allylboration101,102,103 have 
been employed in synthetic approaches to 1,3-diols and higher homologues. Despite 
these advances, use of traditional allylmetallation protocols in iterative two-directional 
syntheses of 1,3-polyol substructures is prohibited by the instability of malondialdehyde. 
In connection with ongoing efforts to exploit catalytic hydrogenation in C-C 
couplings beyond hydroformylation,86,85,88 an enantioselective protocol for carbonyl 
allylation from the alcohol oxidation level was developed in the Krische laboratory under 
the conditions of iridium-catalyzed transfer hydrogenation employing allyl acetate as an 
allyl donor.78,79 Here, the reactant alcohol serves dually as a source of hydrogen and as an 
aldehyde precursor, enabling the formation of highly optically enriched homoallylic 
alcohols directly from the alcohol oxidation level by way of a transient aldehyde. Using a 
chiral iridium C,O-benzoate complex modified by 4-chloro-3-nitrobenzoic acid and 
(R)- or (S)-Cl, MeO-BIPHEP, we reported an iterative two-directional bis-allylation of 
glycols, as demonstrated by the rapid assembly of protected 1,3-polyol substructures with 
exceptional levels of enantiocontrol and catalyst-directed diastereoselectivity.104 Notably, 
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this process successfully exploits 1,3-diols as synthetic equivalents to unstable 
malondialdehydes. 
Malondialdehyde is highly unstable and cannot be isolated in pure form. Although 
malondialdehyde can be generated through the hydrolysis of 
1,1,3,3-tetramethoxypropane, capture of this highly unstable dialdehyde is impeded by 
the fact that it is generated in an aqueous environment, which promotes hydration, 
oligomerization, self-condensation and precludes the use of many organometallic 
reagents. The ability to bypass stoichiometric pre-formation of aldehyde electrophiles in 
carbonyl allylation offers the opportunity to conduct allylations that cannot be performed 
efficiently from the aldehyde oxidation level. We reasoned that 1,3-propanediols could 
serve as a synthetic equivalent to malondialdehyde via successive generation and capture 
of mono-aldehyde intermediates. Accordingly, the asymmetric allylation of propylene 
glycol 2.8a was explored. To our delight, using the cyclometallated catalyst generated in 
situ from [Ir(cod)Cl]2 (5 mol%), (S)-Cl,MeO-BIPHEP (10 mol%), 4-chloro-3-
nitrobenzoic acid (20 mol%) and Cs2CO3 (40 mol%) in dioxane solvent (0.2 M), the 
coupling of allyl acetate (1000 mol%) to 2.8a at 90 oC delivers the C2-symmetric 
homoallylic diol (S,S)-2.9a in   70%   isolated   yield   and  ≥   99%  enantiomeric   excess  with  
≥30:1   diastereoselectivity,   as   determined   by   chiral   stationary   phase   HPLC   analysis  
(Table 2.1). A decrease in the loading of allyl acetate from 10 to 5 equivalents diminished 
the isolated yield of (S,S)-2.9a  to 43% (entry 6).   
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Table 2.1 Optimization of two-directional allylation 
These conditions were applied to propylene glycols 2.8b-2.8e (Scheme 2.15). 
Although yields were slightly diminished in the case of 2-methyl-1,3-propanediol 2.8b 
and 2,2-dimethyl-1,3-propanediol (neopentyl glycol) 2.8c, uniformly high levels of 
enantioselectivity were observed in all cases (≥   99%   ee). Efficient bis-allylation of 2-
methylene-1,3-propanediol 2.8e is especially remarkable in view of the exceptional 
instability anticipated for the corresponding dialdehyde, which to our knowledge, has not 
been reported in the literature. 
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Scheme 2.15 Diol substrates for two-directional allylation 
Since the initial report of this strategy for two directional allylation, this method 
has been used in the construction of a variety of polyketide natural products. For 
example, as highlighted in blue in Figure 2.7, syntheses of roxaticin,105 bryostatin 7,106,107 
cyanolide A,108 and a fragment toward the synthesis of tetrafibricin109 have successfully 
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utilized diols as substrates for an iterative two-directional allylation in the assembly of 
these polyketide natural products. 
 
Figure 2.7  Applications of two-directional allylation in total synthesis 
2.5  Conclusions 
In review, classical methods for the construction of chiral allylic and homo-allylic 
alcohols through carbonyl vinylation, allylation, and crotylation are effective. However, 
they are often accompanied with significant pre-activation and stoichiometric waste 
generation. As an alternative method for the assembly of those structural motifs, C-C 
bond forming hydrogenation has emerged as a general process to rapidly build more 
complex moieties from simple achiral building blocks while reducing pre-activation and 
stoichiometric waste generation. An example of this transformation was demonstrated in 
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the two directional allylation of diols under the conditions of iridium-catalyzed C-C bond 
forming transfer hydrogenation. Diverse glycols 2.8a-2.8e were subjected to highly 
enantioselective carbonyl allylation from the alcohol oxidation level to furnish the 
corresponding C2-symmetric diols 2.9a-2.9e. The development of new catalysts for C-C 
bond forming hydrogenation is progressing synthetic organic chemistry toward new 
levels of efficiency with by-product free methods that can utilize simple feedstock 
chemicals for asymmetric transformations. 
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2.6 Experimental 
General Methods 
All reactions were run under an atmosphere of nitrogen. Tetrahydrofuran (THF) was 
obtained from Pure-Solv MD-5 Solvent Purification System (Innovative Technology). 
Anhydrous 1,4-dioxane was distilled over Na/benzophenone prior to use. Sealed tubes 
(13x100 mL) were purchased from Fischer Scientific and were dried in oven overnight 
and cooled under a stream of nitrogen prior to use. Commercially available allyl acetate 
(Aldrich) and diols were purified by distillation or recrystallization prior to use. Cesium 
carbonate were purchased from Alfa Aesar and used directly without further purification. 
Analytical thin-layer chromatography (TLC) was carried out using 0.2 mm commercial 
silica gel plates (DC-Fertigplatten Kieselgel 60 F254). Infrared spectra were recorded on a 
Perkin-Elmer 1600 spectrometer. High-resolution mass spectra (HRMS) were obtained 
on a Karatos MS9 and are reported as m/z (relative intensity). Accurate masses are 
reported for the molecular ion (M+H or M+Na). Nuclear magnetic resonance spectra (1H 
NMR and 13C NMR) were recorded with a Varian Gemini (400 MHz) spectrometer for 
CDCl3 solutions and chemical shifts are reported as parts per million (ppm) relative to 
residual CHCl3 δH (7.26 ppm) and CDCl3 δC (77.0 ppm), respectively, as internal 
standards. Coupling constants are reported in Hertz (Hz). 
  
 60 
 
(4S,6S)-Nona-l,8-diene-4,6-diol ((S,S)-2.9a) 
To an oven-dried sealed tube under one atmosphere of nitrogen gas charged with 
[Ir(cod)Cl]2 (13.4 mg, 0.02 mmol, 5 mol%), (S)-Cl,MeO-BIPHEP (26.1 mg, 0.04 mmol, 
10 mol%), Cs2CO3 (52.1 mg, 0.16 mmol, 40 mol%) and 4-chloro-3-nitrobenzoic acid 
(16.1 mg, 0.08 mmol, 20 mol%) was added 1,4-dioxane (1.0 mL) followed by allyl 
acetate (0.4 g, 4 mmol, 1000 mol%). The reaction mixture was allowed to stir at 90 oC for 
0.5 hr and was then allowed to cool to room temperature. 1,3-Propanediol 2.8a (30.4 mg, 
0.4 mmol, 100 mol%) in 1,4-dioxane (1.0 mL) was added to the reaction mixture and the 
reaction mixture was allowed to stir at 90 oC for 3 days, at which point the reaction 
mixture was evaporated onto silica gel. Purification of the product by column 
chromatography (SiO2: ethyl acetate:hexanes, 1:4 to 1:2 with 0.1% TEA) provided (S,S)-
2.9a (43.6 mg, 0.279 mmol, dr ≥ 30:1) as a colorless oil in 70% yield. 
TLC (SiO2): Rf = 0.44 (ethyl acetate:hexanes, 1:1). 
1H NMR (400 MHz, CDCl3):  δ  5.86-5.77 (m, 2H), 5.16-5.10 (m, 4H), 4.02-3.96 (m, 2H), 
2.59 (s, 2H), 2.28-2.24 (m, 4H), 1.64-1.62 (t, J = 6.0 Hz, 2H). 
13C NMR (100 MHz, CDCl3):  δ  134.6,  118.1,  68.1,  42.0,  41.5. 
FTIR (neat):  υ  3354,  3078,  2980,  2932,  2909,  2838,  1717,  1632,  1432,  1330,  1245,  1067,  
1045, 996, 907 cm-1. 
HRMS (CI) Calcd. for C9H17O2 (M+H)+: 157.1229, Found: 157.1225. 
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HPLC: Enantiomeric excess was determined by HPLC analysis of bis-4-nitro-benzoate 
derivative of the product. (Chiralcel OD-H column, hexanes:i-PrOH = 95:5, 1.0 mL/min, 
254 nm), tmajor = 17.0 min, tminor = 37.9 min; ee > 99%. 
 
 
 
(1S,1'S)-1,1'-(Cyclopropane-1,1-diyl)dibut-3-en-1-ol ((S,S)-2.9d) 
To an oven-dried sealed tube under one atmosphere of nitrogen gas charged with 
[Ir(cod)Cl]2 (13.4 mg, 0.02 mmol, 5 mol%), (S)-Cl,MeO-BIPHEP (26.1 mg, 0.04 mmol, 
10 mol%), Cs2CO3 (52.1 mg, 0.16 mmol, 40 mol%) and 4-chloro-3-nitrobenzoic acid 
(16.1 mg, 0.08 mmol, 20 mol%) was added 1,4-dioxane (1.0 mL) followed by allyl 
acetate (0.4 g, 4 mmol, 1000 mol%). The reaction mixture was allowed to stir at 90 oC for 
0.5 hr and was then allowed to cool to room temperature. 1,1-
Bis(hydroxymethyl)cyclopropane 2.8d (40.9 mg, 0.4 mmol, 100 mol%) in 1,4-dioxane 
(1.0 mL) was added to the reaction mixture and the reaction mixture was allowed to stir 
at 100 oC for 3 days, at which point the reaction mixture was evaporated onto silica gel. 
Purification of the product by column chromatography (SiO2: ethyl acetate:hexanes, 1:6 
to 1:3 with 0.1% TEA) provided (S,S)-2.9d (47.5 mg, 0.261 mmol, dr =18:1) as a 
colorless oil in 65% yield. 
TLC (SiO2): Rf = 0.30 (ethyl acetate:hexanes, 1:4). 
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1H NMR (400 MHz, CDCl3):  δ  5.86-5.76 (m, 2H), 5.13-5.06 (m, 4H), 3.58-3.53 (m, 2H), 
3.31 (s, 2H), 2.19-2.14 (m, 4H), 0.55-0.51 (m, 4H). 
13C NMR (100 MHz, CDCl3):  δ  135.5,  117.8,  75.4,  38.3,  27.8,  8.3. 
FTIR (neat):  υ  3377,  3074,  3007,  2976,  2905,  2357,  2326,  1699,  1637,  1423,  1294,  1249,  
1049, 1027, 982, 907 cm-1. 
HRMS (CI) Calcd. for C11H19O2 (M+H)+: 183.1385, Found: 183.1384. 
HPLC: Enantiomeric excess was determined by HPLC analysis of bis-4-nitro-benzoate 
derivative of the product. (Chiralpak AD-H column, hexanes:i-PrOH = 95:5, 1.0 mL/min, 
254 nm), tmajor = 20.7 min, tminor = 22.9 min; ee > 99%. 
 
 
 
(4S,6S)-5-Methylenenona-1,8-diene-4,6-diol ((S,S)-2.9e) 
To an oven-dried sealed tube under one atmosphere of nitrogen gas charged with 
[Ir(cod)Cl]2 (13.4 mg, 0.02 mmol, 5 mol%), (S)-Cl,MeO-BIPHEP (26.1 mg, 0.04 mmol, 
10 mol%), Cs2CO3 (52.1 mg, 0.16 mmol, 40 mol%) and 4-chloro-3-nitrobenzoic acid 
(16.1 mg, 0.08 mmol, 20 mol%) was added 1,4-dioxane (1.0 mL) followed by allyl 
acetate (0.4 g, 4 mmol, 1000 mol%). The reaction mixture was allowed to stir at 90 oC for 
0.5 hr and was then allowed to cool to room temperature. 2-Methylene-1,3-propanediol 
2.8e (35.2 mg, 0.4 mmol, 100 mol%) in 1,4-dioxane (1.0 mL) was added to the reaction 
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mixture and the reaction mixture was allowed to stir at 90 oC for 3 days, at which point 
the reaction mixture was evaporated onto silica gel. Purification of the product by column 
chromatography (SiO2: ethyl acetate:hexanes, 1:5 to 1:3 with 0.1% TEA) provided (S,S)-
2.9e (44.4 mg, 0.264 mmol, dr =19:1) as a colorless oil in 66% yield. 
TLC (SiO2): Rf = 0.35 (ethyl acetate:hexanes, 1:3). 
1H NMR (400 MHz, CDCl3):  δ  5.86-5.75 (m, 2H), 5.17-5.12 (m, 4H), 4.25 (t, J = 6.4 Hz, 
2H), 2.70 (s, 2H), 2.46-2.36 (m, 4H). 
13C NMR (100 MHz, CDCl3):  δ  151.1,  134.7,  118.5,  112.5, 72.3, 40.8. 
FTIR (neat):  υ  3372,  3069,  2980,  2909,  2932,  1637,  1419,  1307,  1254,  1045,  987,  911  
cm-1. 
HRMS (CI) Calcd. for C11H19O2 (M+H)+: 183.1385, Found: 183.1384. 
HPLC: Enantiomeric excess was determined by HPLC analysis of bis-4-nitro-benzoate 
derivative of the product. (Chiralpak AD-H column, hexanes:i-PrOH = 95:5, 1.0 mL/min, 
254 nm), tminor = 20.3 min, tmajor = 22.6 min; ee > 99%.  
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2.7 Spectra relevant to chapter 2 
 
 
Figure 2.8 1H and 13C NMR spectra of compound 2.9a   
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Figure 2.9   HPLC data for compound 2.9a 
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Figure 2.10 1H and 13C NMR spectra of compound 2.9d 
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Figure 2.11 HPLC data for compound 2.9d 
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Figure 2.12 1H and 13C NMR spectra of compound 2.9e 
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Figure 2.13  HPLC data for compound 2.9e 
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3 STUDIES TOWARD THE SYNTHESIS OF C-17 BENZENE 
ANSAMYCINS 
In the course of a research program dedicated to the development of 
carbon-carbon bond forming hydrogenations, we recognized the utility of these new 
methods to quickly synthesize polyketide frameworks relative to traditional methods 
(chapter 2). We identified mycotrienol (1.4h) as our synthetic target, with the aim of 
demonstrating that C-C bond forming hydrogenations can be used to synthesize a 
complex molecule more efficiently than traditional methods. Due to the similarity of the 
C1-C17 ansa chain, a short synthesis of any C-17 benzene ansamycin would by extension 
allow access to any member of this class of natural products. As a measure of synthetic 
efficiency, we chose step count to benchmark our synthesis to the prior art. 
3.1 Initial efforts toward mycotrienol (1.4h)  
For our retrosynthetic analysis, we sought to build on the strategies used in the 
prior syntheses and use modern metal-catalyzed transformations. With that in mind, our 
goal was to develop a synthetic route using roughly half the steps as previous syntheses. 
In order to realize such a dramatic reduction in step count, we planned for two of the key 
fragments to be synthesized using metal catalyzed C-C bond forming methods developed 
by Krische and co-workers (Scheme 3.1). Using a modification of an RCM strategy that 
had been established by Panek33 and Hayashi,32 we envisioned a macrocyclization 
through a butadiene stitching RCM from ene-diene 3.1. Further disconnection at the C1 
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amide bond would entail the synthesis of alcohol 3.2 and acid 1.64, which had been 
previously prepared by Hayashi and co-workers, in the synthesis of cytotrienin A (1.6a) 
(Scheme 1.17). The synthesis of acid 1.64 could be disconnected to diene 3.3, which 
could be constructed with an asymmetric hydrogen-mediated coupling of acetylene with 
aldehyde 3.4. Using this method to set the C3 stereochemistry of diene 3.3 and install the 
diene in one operation would be a distinct advantage in our synthesis. 
 
Scheme 3.1 Mycotrienol (1.4h) retrosynthesis 
Alcohol 3.2 presents a synthetic challenge embodied by three contiguous chiral 
centers and a (Z)-trisubstituted olefin. To construct the stereotriad we envisioned that 
allylation of aldehyde 3.5 would be used to set the C11 stereochemistry. Aldehyde 3.5 
could be prepared via union of allyl alcohol 3.6 with   α-methyl allyl acetate under 
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previously explored iridium-catalyzed crotylation conditions.78,80,81 Importantly, this 
methodology would allow for the construction of the C12-C13 stereocenters while 
avoiding a discreet oxidation of the alcohol to an aldehyde. This might allow aldehyde 
3.5 to be synthesized from alcohol 3.6 with anti-diastereoselectivity. However, due to 
limitations in the methodology it would be necessary to invert the C13 stereocenter to 
access the syn isomer found in the natural product. 
3.1.1 SYNTHESIS OF ALCOHOL 3.2 
This section describes the contributions by Dr. Michael Rössle that led to initial 
synthesis of alcohol 3.2. Beginning with a three step sequence wherein aldehyde 3.7 was 
transformed to -aryl aldehyde 3.8 using a modification of a known procedure 
(Scheme 3.2).110 With -aryl aldehyde 3.8 in hand, the (Z)-trisubstituted olefin was 
installed using the Still-Gennari modification of the Horner-Wadsworth-Emmons 
reaction delivering enone 3.9 in 70% yield.111 Alane reduction of the ester functionality 
provided allylic alcohol 3.6 in 77% yield. Finally, exposure of alcohol 3.6 to the 
hydrogen-mediated crotylation conditions furnished the desired adduct 3.10 in 60% yield 
and high selectivity, albeit with significant erosion of the (Z)-trisubstituted olefin 
geometry.  
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Scheme 3.2  Synthesis of adduct 3.10 
Although adduct 3.10 was formed in good yield, it was an anti-selective 
transformation. To correct this stereochemistry an inversion of the C13 stereocenter was 
performed using a modification of the Mitsunobu reaction to provide ester 3.11 
(Scheme 3.3).112 The major side product of the reaction was SN2’   addition of the 
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carboxylate, and was inseparable from the desired product. A four step sequence of ester 
hydrolysis, protection of C13 alcohol as a TBS ether, selective dihydroxylation, and 
oxidative cleavage delivered aldehyde 3.5 in 49% yield over four steps. For the 
installation of the allyl moiety to aldehyde 3.5, Dr. Rössle originally employed an 
iridium-catalyzed allylation, but under those reaction conditions the C12 stereocenter was 
epimerized. This proved to be an insurmountable problem, thus a chelation controlled 
allylation was investigated. Exposure of aldehyde 3.5 to dimethylaluminum chloride and 
allyltrimethylsilane delivered stereotriad 3.2 in low yield and good selectivity.113 
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Scheme 3.3 Synthesis of stereotriad 3.2 
In summary, the route developed by Dr. Michael Rössle provided stereotriad 3.2 
but there were several issues that had to be addressed: (1) E/Z isomerization in the 
allylation of 3.6, (2) a mixture of SN2’  products  in  the  Mitsunobu  inversion  of  3.10, and 
(3) a low yield in the allylation of 3.5. To address the E/Z isomerization and SN2’  
problems a new route to aldehyde 3.5 was developed using a Suzuki reaction as a major 
disconnection. 
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3.2 Synthetic efforts toward the mycotrienin core 
3.2.1 RETROSYNTHESIS 
Due to the unsuccessful efforts to construct alcohol 3.2 in sufficient quantity and 
purity, we revised our strategy to address the challenges of the previous route. We 
envisioned the C15-C16 bond of alcohol 3.2 would be formed via Suzuki cross-coupling 
of vinyl bromide 3.12 with borane 3.13 (Scheme 3.4). We also reasoned that side 
products resulting from the of SN2’  addition   in   the  Mitsunobu   reaction  associated  with  
the previous route might be suppressed by using anti-vinyl bromide 3.14. To access vinyl 
bromide 3.14 we would employ our iridium-catalyzed anti-crotylation from known 
alcohol 3.15 and -methyl allyl acetate. For the other coupling partner in the key Suzuki 
reaction we planned to access borane 3.13 through a hydroboration of nitro styrene 3.16, 
which would be obtained from arene 3.17. 
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Scheme 3.4  Second generation mycotrienol (1.4h) retrosynthesis 
3.2.2 ACID FRAGMENT 1.64 
Synthesis of acid 1.64 was initially hindered by the inability to find a suitable 
masked carboxylic acid at the C1 position. The substrate scope for the rhodium-catalyzed 
dienylation was limited to aldehydes that contained an electron-withdrawing group near 
the aldehyde (Section 2.2.2). The limitations associated with the narrow substrate scope 
were circumvented by using aldehyde 3.4 in the dienylation reaction, and constructing the 
acid in later steps (Scheme 3.5). Treatment of allyl alcohol with sodium hydride and 
p-toluenesulfonyl chloride furnished compound 3.18, which upon exposure to ozone 
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followed by dimethyl sulfide delivered aldehyde 3.4. Reaction of aldehyde 3.4 under 
rhodium-catalyzed dienylation conditions provided (Z)-diene 3.19 in 83% yield and 
85% ee at best. Unfortunately, (Z)-diene 3.19 proved to be unstable under the reaction 
conditions and at ambient temperatures, and thus the yield of the dienylation reaction was 
difficult to reproduce. Additionally, aldehyde 3.4 was unstable and had to be synthesized 
and purified immediately prior to use, further increasing the difficulty in obtaining 
sufficient quantities of (Z)-diene 3.19. 
 
Scheme 3.5  Synthesis of (Z)-diene 3.19 
3.2.2.1 Initial route toward acid 1.64  
With a route to the diene in place, we sought to install the carboxyl functionality. 
In initial experiments 3.19 was treated with sodium cyanide, but a mixture of compounds 
was obtained in all cases. Methylation of the alcohol before cyanide displacement 
allowed for a simple way to minimize the undesired side reactions. Treatment of 
compound 3.19 with  Meerwein’s   reagent   and  proton   sponge  provided   the  methyl   ether  
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3.20 (Scheme 3.6). We next sought to displace the tosyl alcohol with cyanide, followed 
by conversion of the resulting nitrile to the desired carboxylic acid. Several cyanide 
sources, solvents, and additives were investigated but ultimately reaction of 3.20 with 
potassium cyanide, 18-crown-6 and tetrabutylammonium iodide (TBAI) in DMSO 
delivered nitrile 3.21 in 71% yield. Control experiments showed that both 18-crown-6 
and TBAI were required for the displacement to occur. Additionally, the reaction must be 
monitored closely, as it was found that at extended reaction times decomposition of 
nitrile 3.21 occurs.  
 
Scheme 3.6 Synthesis of nitrile 3.21 
Due to the sensitivity of nitrile 3.21 we sought mild conditions for hydration of 
nitrile to the requiste acid. Treatment of nitrile 3.21 with a homogeneous platinum 
phosphinito catalyst in an ethanol-water mixture allowed for primary amide 3.22 to be 
obtained under mild conditions in 74% yield (Scheme 3.7).114 Our focus then turned to 
the isomerization of the diene, which was set as an undesired isomer during the 
rhodium-catalyzed dienylation reaction (Scheme 3.5). Conversion of amide 3.22 from the 
Z to E isomer was accomplished with catalytic PdCl2(MeCN)2,115 giving the desired (E)-
olefin 3.23 with a ratio of E/Z = 9:1 (Scheme 3.7). It is noteworthy that by applying this 
method, isomerization of the diene took place without migration of the diene. Since we 
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were aware of the sensitivity of the C3 methyl ether, we sought mild conditions for the 
hydrolysis of amide 3.23 to acid 1.64. A two step protocol was used to hydrolyze amide 
3.23 by activation of the nitrogen as a leaving group, and subsequent hydrolysis to 
furnish the carboxylic acid. This procedure did allow access to acid 1.64 but with ~10% 
of the elimination product 3.24 which proved to be inseparable from the desired 
compound. Unfortunately, our route to acid 1.64 had a low overall yield and an 
inseparable side product in the last step, therefore a new route was pursued. 
 
Scheme 3.7 Initial synthesis of acid 1.64 
3.2.2.2 Revised route to acid 1.64 
In order to improve the synthesis acid 1.64, we investigated conditions to convert 
the nitrile to the carboxylic acid in one step in hopes of avoiding elimination of the C3 
methoxy-group. On a model system we found that lithium hydroxide in hydrogen 
peroxide would allow the hydrolysis to take place. In applying this method to the desired 
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system, the order of operations was changed to permit the isomerization of the (Z)-diene 
3.20 to give (E)-diene 3.3 in 82% yield (Scheme 3.8). Thus, with the diene in the required 
geometry, compound 3.3 was then treated to conditions previously used to install the 
nitrile. Due to the high volatility of the nitrile intermediate it was immediately subjected 
to the conditions of hydrolysis. In this way acid 1.64 was obtained in 72% yield over two 
steps from diene 3.3. Our synthesis proceeded in seven steps with 32% overall yield from 
commercially available material and is shorter than the previous report of this compound, 
which required 12 steps in 16% overall yield.32 
 
Scheme 3.8  Second route to acid 1.64 
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3.2.2.3 Absolute stereochemistry confirmation of acid 1.64  
During the course of the synthetic work, we needed to confirm the absolute 
configuration of acid 1.64. The optical rotation measurement was within the limit of 
experimental error of the instrument, therefore unreliable. Also, due to an inconsistency 
in the literature,52,53 it was not clear which chiral ligand would produce the desired 
stereochemistry in dienylation of aldehyde 3.4. To confirm the acid stereochemistry we 
transformed our acid, synthesized with the (R)-MeO-BIPHEP ligand, into a bis-Mosher 
ester and compared to known bis-Mosher ester 1.10 (Scheme 3.9). Exposure of acid 
1.64R sequentially to TMS-diazomethane, ozone, and lithium aluminum hydride 
provided diol 1.9R,  which   after   esterification  with  Mosher’s   acid   provided   bis-Mosher 
ester 3.25. Comparsion of the proton NMR spectra of bis-Mosher ester 3.25 to the known 
bis-Mosher esters 3.26 and 1.10 indicated that the spectra from 3.25 and 3.26 were 
identical.19 Therefore, the acid synthesized from the (R)-MeO-BIPHEP ligand led to 
bis-mosher ester with the C3-stereocenter in the (S)-configuration. This was opposite to 
the stereochemistry found in the natural product, consequently the (S)-MeO-BIPHEP 
ligand was used to construct acid 1.64. 
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Scheme 3.9 Confirmation of acid 1.64 stereochemistry 
3.2.3 REVISED ROUTE FOR ALCOHOL 3.2 
With the route to acid 1.64 in place, we turned our attention to a revised synthesis 
of alcohol 3.2. Using a known procedure116 to access vinyl bromide 3.15, tert-butanol 
was brominated and subsequent elimination provided bromide 3.27 (Scheme 3.10). 
Radical halogenation of 3.27 followed by hydrolysis provided a mixture of two isomers 
with the desired (Z)-isomer as the minor component. Since we were unable to completely 
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separate the mixture, a method to synthesize vinyl bromide 3.15 as a single isomer was 
needed. Through an adaptation of a known protocol,117 propargyl alcohol was 
transformed into boronate intermediate 3.28, which was then treated with CuBr2 to 
furnish vinyl bromide 3.15 as single isomer in 32% yield (Scheme 3.10).    
 
Scheme 3.10 Improved synthesis of vinyl bromide 3.15 
 With access to vinyl bromide 3.15, as a single isomer, we investigated it as a 
substrate in a C-C bond forming transfer hydrogenation. We found that by employing the 
preformed (S)-Segphos complex in the iridium-catalyzed crotylation allowed compound 
3.14 to be obtained in 70% yield with the anti-diastereomer as the major product 
(Scheme 3.11). The relative and absolute stereochemical assignments were inferred based 
on analogy with the literature precedent.79 Importantly, this crotylation reaction 
proceeded without any erosion of the olefin geometry that was observed in the prior 
route. Inversion of the C13 alcohol under modified Mitsunobu conditions112 provided 
ester 3.29, which was subsequently hydrolyzed to furnish syn-alcohol 3.30. Now that the 
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stereochemistry at C13-C12 was in the same configuration as in the natural product, the 
synthesis could continue forward. Exposure of alcohol 3.30 to tert-butyldimethylsilyl 
trifluoromethanesulfonate provided the TBS ether 3.12. With bromide 3.12 in hand, 
efforts turned toward the synthesis of borane 3.13, which was en route to our proposed 
Suzuki cross-coupling. 
 
Scheme 3.11 Synthesis of vinyl bromide 3.12 
The synthesis of borane 3.13 began with a Suzuki reaction of commercially 
available bromide 3.17 and potassium vinyltrifluoroborate to furnish nitro styrene 3.16 
(Scheme 3.12). Hydroboration of nitro styrene 3.16 with 9-BBN provided borane 3.13. 
This borane adduct was prepared and used without isolation or purification due to the 
oxygen sensitivity of the borane. 
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Scheme 3.12 Synthesis of borane 3.13 
Unfortunately vinyl bromide 3.12 was not productive in a Suzuki cross-coupling 
with borane 3.13 (Scheme 3.13). In model studies, other vinyl and aryl bromides were 
successfully coupled to borane 3.13. This difference in reactivity could be attributed to 
interference from the neighboring olefin on the vinyl bromide 3.12, which after oxidative 
addition of palladium might occupy a coordination site on palladium and inhibit the 
reaction. We sought to test this hypothesis by selectively oxidizing the terminal double 
bond of 3.12 to remove the possibility of alkene coordination.  This was accomplished by 
a catalytic dihydroxylation followed by subsequent protection of the intermediate diol to 
furnish acetonide 3.31. With intermediates 3.31 and 3.13 in hand, we sought to join them 
through a sp2-sp3 Suzuki cross coupling (Scheme 3.13). This proved to be challenging as 
most conditions provided adduct 3.32 in low yield. After an optimization that examined 
palladium source, ligand, base, solvent, temperature and time we arrived at the conditions 
that would give adduct 3.32 in modest yield. With access to suitable quantities of adduct 
3.32 in place, it was now possible to determine if the route to 3.2 is viable. 
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Scheme 3.13 Synthesis of acetonide 3.32 
While investigating conditions for the deprotection of acetonide 3.31 to diol 3.33, 
we were unable to deprotect the acetonide while keeping the C13 TBS ether intact 
(Scheme 3.14). Fortunately, we found that periodic acid118 would simultaneously 
deprotect and oxidize the acetonide moiety furnishing aldehyde 3.5 in 99% yield. 
Unfortunately, the chelation controlled addition of allyltrimethylsilane to aldehyde 3.5 to 
furnish 3.2 proceeded in just 20% yield and with a 3:1 diastereomeric ratio. At this 
junction we questioned if a different chelating group at the C13 position would increase 
the yield and selectivity of the allylation reaction. 
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Scheme 3.14 Synthesis of stereotriad 3.2 
3.2.3.1 C13 protecting group swap 
 We proposed that the chelation controlled addition would be improved by 
exchanging the C13 TBS ether for a 4-methoxybenzyl (PMB) ether. To this end, silyl 
deprotection of adduct 3.32 followed by etherification with 4-methoxybenzyl chloride 
(PMB-Cl) and sodium hydride furnished PMB ether 3.34 (Scheme 3.15). Subsequent 
oxidative deprotection of the acetonide moiety with periodic acid delivered aldehyde 
3.35. Exposure of aldehyde 3.35 to dimethylaluminum chloride followed by 
allyltrimethylsilane delivered alcohol 3.36 with excellent selectivity albeit in just 
24% yield. While we were able to demonstrate that the PMB ether was able to provide 
higher levels of selectivity than the TBS ether in the chelation controlled addition of our 
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system, the protecting group swap went against our goal of developing a short route to 
the C17-benzene ansamycins by adding additional steps.  
 
Scheme 3.15 Protecting group swap to synthesize alcohol 3.36 
To reduce the step count we revised the route to access alcohol 3.36 without using 
a protecting group swap. The revised route began at an earlier intermediate; alcohol 3.30 
was treated with sodium hydride, tetrabutylammonium iodide, and p-methoxy benzyl 
chloride to furnish p-methoxy benzyl ether 3.37 (Scheme 3.16). Selective 
dihydroxylation of the less substituted olefin of p-methoxy benzyl ether 3.37 with 
catalytic osmium tetraoxide provided diol 3.38. Acetonide protection of diol 3.38, 
proceeded smoothly to provide vinyl bromide 3.39. Unfortunately, this new coupling 
partner did not perform well in the Suzuki cross-coupling. The major product arose from 
the proto-dehalogenation of vinyl bromide 3.39 to give compound 3.34h. After an 
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investigation of reaction parameters, the formation of this undesired product was unable 
to be suppressed. 
 
Scheme 3.16  Revised Suzuki coupling route to adduct 3.34 
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With few options left to improve the Suzuki reaction, we proposed changing the 
boron-based coupling partner to a potassium trifluoroborate salt.119 Regio-selective 
hydroboration of nitro styrene 3.16 under conditions developed by Miyaura120 provided 
pinacol ester 3.40 in 88% yield as a single regioisomer (Scheme 3.17). Exposure of 
pinacol ester 3.40 to an excess of potassium hydrogen fluoride furnished potassium 
trifluoroborate salt 3.41 in 84% yield. 
 
Scheme 3.17 Synthesis of pinacol ester 3.40 and trifluoroborate salt 3.41 
  
 92 
Having secured potassium trifluoroborate salt 3.41, we investigated the Suzuki 
coupling to vinyl bromide 3.39. Conditions optimized for potassium trifluoroborate salt 
3.41 were benchmarked against the 9-BBN and pinacol borane derivatives (Scheme 
3.18). To our surprise, employing the pinacol ester 3.40 under identical conditions 
provided adduct 3.34 in 48% yield. After this result we began to explore coupling 
conditions for pinacol ester 3.40.  
 
Scheme 3.18 Comparison of boron coupling partners in Suzuki reaction 
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 We found that by lowering the reaction temperature and substituting cesium 
carbonate for sodium hydroxide, the Suzuki coupling of vinyl bromide 3.39 and pinacol 
ester 3.40 provided adduct 3.34 in 75% yield (Scheme 3.19). With this success we were 
able to avoid the TBS ether protecting group swap (Scheme 3.15) and continue forward 
with the synthesis to alcohol 3.36. 
 
Scheme 3.19 Synthesis of PMB stereotriad 3.36 
3.2.4 FRAGMENT UNION AND RCM 
With routes to both alcohol 3.36 and acid 1.64 in place, we investigated their 
union and subsequent macrocyclization. Selective reduction of nitro moiety of alcohol 
3.36 with NaBH2S3121 provided an oxygen sensitive aniline that was immediately coupled 
to acid 1.64 to deliver ene-diene 3.42. In prior syntheses of C17-benzene ansamycins 
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examples of stitching reactions to close the macrocycle and construct the triene moiety 
were performed by laboratories of Smith (Scheme 1.7) and Panek (Scheme 1.11). We 
realized an opportunity to investigate a novel stitching RCM in our synthesis with ene-
diene 3.42 and butadiene to furnish triene 3.43. Unfortunately, no RCM products were 
observed, only unreacted 3.42 was recovered, so we revised our strategy to incorporate a 
diene-diene RCM. 
 
Scheme 3.20  Initial efforts toward a stitching RCM 
In order to construct the target substrate containing two dienes, we returned to 
aldehyde 3.35 (Scheme 3.21). A modification of our current route allowed us to replace 
allyltrimethylsilane with a pentadienyl-trimethylsilane122,123 3.44 in the chelation 
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controlled addition permitting access to diene 3.45 in high selectivity and improved yield. 
Subsequent reduction and coupling to acid 1.64 proceeded efficiently to furnish 
bis(diene) 3.46. Unfortunately, exposure of bis(diene) 3.46 to metathesis catalysts did not 
result in the desired ring-closed product, only unreacted starting material was recovered 
from the reaction. Prior examples of diene-diene RCM on related systems contained silyl 
or acyl groups at C11 hydroxyl group. We speculated that the C11 hydroxyl group may 
be inhibiting the RCM reaction. 
 
Scheme 3.21  Initial efforts toward diene-diene RCM 
Our investigation of the diene-diene RCM continued by examining the role of the 
hydroxyl moiety at the C11 position, accordingly we prepared two additional bis(diene) 
substrates: TBS bis(diene) 3.47 and benzoate bis(diene) 3.48. (Scheme 3.22). Exposure of 
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TBS bis(diene) 3.47 to ruthenium based metathesis catalysts provided trace amounts of a 
ring closure product that was consistent with diene 3.49. Repeating the study of RCM 
catalysts with benzoate bis(diene) 3.48, was more rewarding as trace amounts of RCM 
product with a mass corresponding to triene 3.50 was obtained. From the experiments 
conducted it appears that the C11 substituent has an important role in the RCM reaction. 
Based on this interpretation of the results, we again revised our strategy and target.  
 
Scheme 3.22 Investigation of C11 protecting group in diene-diene RCM 
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3.3 Synthesis of the cytotrienin A core 
The prior success of Hayashi and co-workers (Scheme 1.18) with cytotrienin A 
(1.6a) coupled with our recent experience with a diene-diene RCM led us to investigate 
the cyclopropylamino acid chain at C11 (Scheme 3.23). Elaboration of the side chain 
began with esterification of alcohol 3.36 with acid chloride 3.51 to furnish azide 3.52. 
Selective reduction of the azide 3.52 with 1,3 propanedithiol provided amine 3.53 
without reduction of the nitro group.32 Amide bond coupling of amine 3.53 and 
cyclohexene carboxylic acid delivered amide 3.54. Reduction of the nitro group and 
acylation of the resulting aniline with acid 1.64 afforded bis(diene) 3.55.  
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Scheme 3.23 Synthesis of bis(diene) 3.55 
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Finally, we were able to investigate the diene-diene RCM with the actual 
cytotrienin A (1.6a) side chain. Thus, using the indenylidene analogue of the first 
generation Grubbs’ metathesis catalyst124 bis(diene) 3.55 was converted to the cytotrienin 
A core 3.56 in 43% yield (Scheme 3.24).125 
 
Scheme 3.24  Synthesis of the cytotrienin A core 3.56 
With the cytotrienin A core 3.56 in hand, access to the natural product would be 
possible after a deprotection of the methyl and PMB ether. On a related system Panek and 
co-workers employed a late stage deprotection of aryl-methyl ethers with ceric 
ammonium nitrate (CAN) to gain access to the mycotrienins (Scheme 1.11). Since CAN 
might also cleave PMB ethers we attempted a global ether deprotection (Scheme 3.25). 
Unfortunately, our efforts were not successful; a variety of Lewis and Brønsted acids 
were ineffective in a late state cleavage of the protecting groups. On a model system and 
some of the earlier intermediates the PMB and methyl ethers could be cleaved, but those 
conditions failed to work on the cytotrienin A core 3.56. 
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Scheme 3.25  Efforts to deprotect the cytotrienin A core 3.56 
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3.4  Conclusions 
In summary, we developed an approach to the C17-benzene triene-ansamycins, as 
demonstrated by the synthesis of the cytotrienin A core in 17 steps (LLS) from alcohol 
3.15. The synthesis successfully incorporated metal catalyzed C-C bond hydrogenations 
in the construction of acid 1.64 and stereotriad 3.36. In a departure from all prior 
syntheses the C16-C17 bond was made using a Suzuki cross-coupling. This study served 
as a prelude to a second-generation route, which incorporated a syn-diastereo- and 
enantioselective carbonyl crotylation and the use of a protecting group strategy amenable 
to late-stage cleavage. 
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3.5 Experimental  
General Methods 
All reactions were run under an atmosphere of argon under anhydrous conditions unless 
otherwise indicated. Dichloromethane (DCM), 1,2-dichloroethane (DCE), 
tetrahydrofuran (THF), and toluene (PhMe) were obtained from a Pure-Solv MD-5 
Solvent Purification System (Innovative Technology, inc). Anhydrous solvents were 
transferred using oven-dried syringes. All other commercial reagents were used directly 
without further purification. Analytical thin-layer chromatography (TLC) was carried out 
using 0.2-mm commercial silica gel plates (DC-Fertigplatten Kieselgel 60 F254). 
Visualization of the chromatograms was accomplished using UV light and vanillin, 
anisaldehyde, permanganate, or cerium molybdate stain with heating. Preparative column 
chromatography using silica gel was performed according to the method of Still.126 
Infrared spectra were recorded on a Nicolet 380 FTIR. Analytical high performance 
liquid chromatography (HPLC) spectra were obtained using an Agilent Technologies 
1200 series HPLC. Analytical Gas Chromatography (GC) spectra were obtained using an 
Agilent Technologies 7890A GC system. High-resolution mass spectra (HRMS) were 
obtained on a Waters Micromass Autospec or a Varian FTICR as m/z (relative intensity). 
Accurate masses are reported for the molecular ion (M+1, M or M–1) or a suitable 
fragment ion. Melting points were obtained on a Stuart® melting point apparatus SMP3. 
Proton nuclear magnetic resonance spectra (1H NMR) were recorded with a Varian 
spectrometer (400 MHz or 500 MHz) and reported in parts per million (ppm) referenced  
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to the residual protio solvent signal as an internal standard. Coupling constants are 
reported in hertz (Hz). Carbon nuclear magnetic resonance spectra (13C NMR) were 
recorded with a Varian spectrometer (100 MHz or 125 MHz) and reported in parts per 
million (ppm) referenced to the residual solvent signal as an internal standard. Optical 
rotations were measured on an ATAGO AP-300 automatic polarimeter at a path length of 
1 dm. 
 
Preparation of (S)-Ir-complex 
 
To a mixture of [Ir(cod)Cl]2 (520 mg, 0.774 mmol, 100 mol%), (S)-SEGPHOS (945 mg, 
1.55 mmol, 200 mol %), Cs2CO3 (1.010 g, 3.10 mmol, 400 mol %), 4-CN-3-NO2BzOH 
(595 mg, 3.10 mmol, 400 mol %) and allyl acetate (387 mg, 3.87 mmol, 500 mol %) in a 
sealed tube under a N2 atmosphere was added THF (15.5 mL, 0.05 M). The reaction 
mixture was stirred for 30 min at 70 °C and heated for 1.5 h at 80 °C, at which point the 
reaction mixture was allowed to cool to 25 ºC. The reaction mixture was filtered and the 
filter cake was washed with THF (100 mL). The filtrate was concentrated in vacuo and 
hexanes (350 mL) were added. The title compound was formed as a yellow precipitate, 
which was collected by filtration and dried under vacuum (1.52 g, 1.47 mmol, 95% 
yield). 
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Allyl 4-methylbenzenesulfonate (3.18) 
The following procedure is a modification of the prior report127, which allowed the title 
compound to prepared in higher yield. To a suspension of sodium hydride (60% in 
mineral oil, 2.5 g, 65 mmol) and ether (65 mL) under an atmosphere of argon was added 
allyl alcohol (2.9 mL, 43 mmol) at ambient temperature. After gas evolution ceased the 
reaction mixture was cooled to 0 °C. p-Toluenesulfonyl chloride (8.1 g, 43 mmol) was 
dissolved in ether (100 mL) and resulting solution was added dropwise to reaction 
mixture. After the addition was complete the reaction mixture was warmed to ambient 
temperature and allowed to stir for 1 h. The reaction mixture was added to an aqueous 
solution of ammonium chloride (100 mL). The resulting mixture was extracted with ether 
(3 x 50 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. 
The resulting oil was washed with hexanes (2 x 20 mL) and concentrated under reduced 
pressure to give allyl 4-methylbenzenesulfonate (9.0 g, 42 mmol, 98% yield) as a clear 
oil. The data for the compound was consistent with reported values.127 
Rf (SiO2, hexanes/EtOAc = 9 : 1) = 0.6. 
1H NMR (400 MHz, CDCl3): δ 7.75 (d, J = 8.3 Hz, 2H), 7.31 (d, J = 7.9 Hz, 2H), 5.78 
(ddt, J = 17.1 Hz, 10.4 Hz, 5.9 Hz, 1H), 5.31–5.19 (m, 2H), 4.49 (ddd, J = 5.9 Hz, 1.5 
Hz, 1.2 Hz, 2H), 2.41 (s, 3H) ppm. 
13C NMR (100 MHz, CDCl3): δ 144.89, 133.07, 130.19, 129.86, 127.83, 120.21, 70.81, 
21.58 ppm. 
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2-Oxoethyl 4-methylbenzenesulfonate (3.4) 
The following procedure is a modification of the prior report128, which allowed the title 
compound to prepared in higher yield A solution of allyl 4–methylbenzenesulfonate (3.1 
g, 15 mmol) in dichloromethane (140 mL) at –78 C was sparged with ozone until the 
reaction mixture was pale blue. Ozone was removed and the reaction was sparged with 
argon for 5 min. Dimethyl sulfide (10.0 mL, 142 mmol) was added at –78 C and 
reaction was allowed to warm to ambient temperature with stirring for 12 h. The reaction 
mixture was concentrated under reduced pressure and purified (SiO2, 30% to 70% ethyl 
acetate/hexanes, gradient elution) to give 2–oxoethyl 4–methylbenzenesulfonate (2.25 g, 
8.20 mmol, 72 % yield) as a light yellow oil. Due to the rapid decomposition of the title 
compound, it was stored as a 0.2 M solution in toluene at –20 °C. The data for the title 
compound was consistent with reported values.128  
Rf (SiO2, hexanes/EtOAc = 1 : 2) = 0.2. 
1H NMR (400 MHz, CDCl3): δ 9.60 (s, 1H), 7.82–7.79 (m, 2H), 7.38–7.35 (m, 2H), 4.50 
(s, 2H), 2.45 (s, 3H) ppm.  
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S,Z)-2-Hydroxyhexa-3,5-dienyl 4-methylbenzenesulfonate (3.19) 
To a solution of [Rh(COD)2]BARF (155 mg, 0.13 mmol), (S)-MeO-BIPHEP (72 mg, 
0.13 mmol), 3-nitrobenzoic acid (39 mg, 0.20 mmol), and Na2SO4 (1.85 g, 13.1 mmol) in 
1,2-dichloroethane (11 mL) and toluene (11 mL) under an atmosphere of hydrogen and 
acetylene gas (approximately 1:1 by volume) was added a solution of 2-oxoethyl 4-
methylbenzenesulfonate (700 mg, 3.27 mmol) in 1,2-dichloroethane (3.5 mL) and toluene 
(3.5 mL). The resulting mixture was stirred at ambient temperature for 16 h. The crude 
reaction mixture was filtered, concentrated under reduced pressure, and purified (SiO2, 
30% ethyl acetate/hexanes) to give (S,Z)-2-hydroxyhexa-3,5-dienyl 4-
methylbenzenesulfonate (729 mg, 2.71 mmol, 83% yield) as a colorless oil. The resulting 
compound was not stable as a neat oil at –20 ºC. The stereochemical assignment was 
inferred based on analogy with the literature precedent.52 
Rf (SiO2, hexanes/EtOAc = 2 : 1) = 0.5. 
[α]24
D= +106 (c = 0.65, CHCl3, 85% ee ). 
1H NMR (400 MHz, CDCl3): δ 7.73 (d, J = 8.3 Hz, 2H), 7.28 (d, J = 8.0 Hz, 2H), 6.49–
6.39 (m, 1H), 6.02 (t, J = 11.1 Hz, 1H), 5.26–5.12 (m, 3H), 4.75 (s, 1H), 3.90 (dd, J = 8.0 
Hz, 5.7 Hz, 2H), 3.18 (s, 1H), 2.37 (s, 3H) ppm. 
13C NMR (100 MHz, CDCl3): δ 145.1, 133.0, 132.5, 131.2 (3), 129.9 (2), 127.9, 120.7, 
72.9, 66.0, 21.6 ppm. 
FTIR (Neat): λ−1 = 1354, 1172, 1095 cm−1. 
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HRMS (CI): Calcd. for C13H16O4S (M): 268.0769, found 268.0765. 
HPLC (Chiralcel OD–H column, 3% i-PrOH/hexanes, 1 mL/min, 230 nm), tminor = 11.1 
min, tmajor = 13.3 min; ee = 85%. 
 
 
(S,Z)–2–Methoxyhexa–3,5–dienyl 4–methylbenzenesulfonate (3.20) 
To a solution of (S,Z)-2-hydroxyhexa-3,5-dienyl 4-methylbenzenesulfonate (330 mg, 
1.23 mmol) in dichloromethane (25 mL) at ambient temperature under an atmosphere of 
argon was added trimethyloxonium tetrafluoroborate (455 mg, 3.08 mmol) and 1,8-
bis(dimethylamino)naphthalene (791 mg, 3.69 mmol). The resulting mixture was stirred 
for 2 h at ambient temperature. The crude reaction mixture was filtered, concentrated 
under reduced pressure, and purified (SiO2, 10% ethyl acetate/hexanes) to give (S,Z)-2-
methoxyhexa-3,5-dienyl 4-methylbenzenesulfonate (330 mg, 1.17, 95% yield) as a clear 
oil. 
Rf (SiO2, hexanes/EtOAc = 2 : 1) = 0.8. 
[α]26D= +78 (c = 1.0, CHCl3, 85% ee). 
1H NMR (400 MHz, CDCl3): δ 7.89–7.30 (m, 2H), 7.46–7.30 (m, 2H), 6.54 (dt, J = 16.8 
Hz, 10.5 Hz, 1H), 6.23 (t, J = 11.3 Hz, 1H), 5.30–5.26 (m, 2H), 5.16 (t, J = 10.0 Hz, 1H), 
4.33 (dt, J = 9.0 Hz, 5.7 Hz, 1H), 4.00–3.98 (m, 2H), 3.24 (s, 3H), 2.44 (s, 3H) ppm. 
13C NMR (100 MHz, CDCl3): δ 144.8, 134.9, 132.9, 131.0, 129.8 (3), 127.9 (2), 126.2, 
121.0, 74.6, 56.5, 21.6 ppm. 
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FTIR (Neat): λ−1 = 1359, 1188, 1174, 1096 cm−1. 
HRMS (CI): Calcd. for C14H18O4S (M): 282.0926, found 282.0924. 
 
 
(R,Z)-3-Methoxyhepta-4,6-dienenitrile (3.21) 
To a solution of 3.20 (299 mg, 1.06 mmol), 18-crown-6 (280 mg, 1.06 mmol), 
tetrabutylammonium iodide (80 mg, 0.21 mmol) in dimethylsulfoxide (0.5 ml) was added 
potassium cyanide (300 mg, 3.18 mmol) and stirred at 45 oC for 90 min.  The crude 
reaction mixture was added to ethyl acetate (50 mL) and washed with brine (2 x 100 mL).  
The organic extract was dried over sodium sulfate, filtered, concentrated under reduced 
pressure and purified (SiO2, 10% ether/hexanes) to give 3.21 (103 mg, 71%yield) as a 
light yellow oil.   
[α]25D= 7.5 (c = 0.9, CHCl3). 
 1H NMR (400 MHz; CDCl3)  δ  6.60-6.51 (m, 1H), 6.28-6.22 (m, 1H), 5.33-5.28 (m, 1H), 
5.26-5.22 (m, 2H), 4.33 (dtd, J = 9.2 Hz, 6.0 Hz, 1.0 Hz, 1H), 3.25 (s, 3H), 2.51 (dd, J = 
6.0 Hz, 1.4 Hz, 2H).  
13C NMR (100 MHz; CDCl3)  δ  134.9,  130.8,  128.3,  121.4,  117.2,  72.0,  56.7,  24.7.     
FTIR (Neat): λ−1 = 2230, 1359, 1188, 1174, 1096 cm−1. 
HRMS calcd. for C8H12NO (M+H): 138.0919, found 138.0925. 
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(R,Z)-3-Methoxyhepta-4,6-dienamide (3.22) 
To 3.21 (120 mg, 0.876 mmol) and hydrido(dimethylphosphinous acid)[hydrogen 
bis(dimethylphosphinito)]platinum114 (1.9 mg, 0.0044 mmol) under an atmosphere of 
argon was added a solution of ethanol (2 mL) and water (1 mL).  The resulting mixture 
was stirred at 80 oC for 15 h.  The crude reaction mixture was extracted with 
dichloromethane (3 x 20 mL).  The organic extracts were combined, concentrated under 
reduced pressure, and purified (SiO2, 2% ethanol/ethyl acetate) to give 3.22 (99 mg, 74% 
yield) as a clear oil.   
[α]25D= 9.5 (c = 0.40, CHCl3). 
1H NMR (400 MHz; CDCl3):  δ  6.68-6.58 (m, 1H), 6.40 (s, 1H), 6.17 (t, J= 11.2 Hz, 1H), 
6.11 (s, 1H), 5.28-5.17 (m, 3H), 4.51-4.45 (m, 1H), 3.26 (s, 3H), 2.48-2.29 (m, 2H).   
13C NMR (100 MHz; CDCl3):   δ   173.5,   133.3,   131.4,   130.5,   120.5,   73.6,   56.5,   42.5.    
IR(neat): λ−1 3135, 2928, 1673, 1397, 1217, 1093, 999, 915, 748, 665.  
HRMS calcd. for C8H14NO2 (M+H): 156.1025, found 156.1026  
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(R,E)-3-Methoxyhepta-4,6-dienamide  (3.23) 
To a solution of 3.22 (134 mg, 0.876 mmol) in dichloromethane (1.6 mL) under an 
atmosphere of argon was added PdCl2(MeCN)2 (10 mg, 0.087 mmol), the resulting 
mixture was stirred for 18 h at ambient temperature.  The crude reaction mixture was 
concentrated under reduced pressure and purified (SiO2, 5% isopropanol/chloroform) to 
give 3.23 (75 mg, 56%, E/Z = 9:1) as a clear oil 
[α]27D= -50.3 (c = 0.35, CHCl3). 
1H NMR  (400 MHz; CDCl3):  δ  6.37-6.22 (m, 3H), 5.65 (s, 1H), 5.55 (dd, J = 14.8 Hz, 
7.9 Hz, 1H), 5.25 (dd, J = 16.5 Hz, 2.1 Hz, 1H), 5.16-5.13 (m, 1H), 4.03-3.98 (m, 1H), 
3.30 (s, 3H), 2.47-2.43 (m, 2H).   
13C NMR (100 MHz; CDCl3):   δ   173.5,   136.0,   134.1,   132.0, 118.8, 78.7, 56.6, 42.5.  
IR(neat): λ−1 3338, 3197, 1662, 1401, 1089, 1003, 955, 906. 
MS calcd. for C8H14NO2 (M+H): 156.1, found 156.1 
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(S,E)–2–Methoxyhexa–3,5–dienyl 4–methylbenzenesulfonate (3.3) 
To a solution of (S,Z)-2-methoxyhexa-3,5-dienyl 4-methylbenzenesulfonate (512 mg, 
1.82 mmol) in dichloromethane (3.6 mL) under an atmosphere of argon was added 
PdCl2(MeCN)2 (55 mg, 0.36 mmol), the resulting mixture was stirred for 5 days at 
ambient temperature. The crude reaction mixture was diluted with diethyl ether (30 mol), 
filtered, concentrated under reduced pressure, and purified (SiO2, 10–30% ether/hexanes, 
gradient elution) to give (S,E)-2-methoxyhexa-3,5-dienyl 4-methylbenzenesulfonate 3.3 
(398 mg, 1.41 mmol, 78% yield) as a light yellow oil.  
Rf (SiO2, hexanes/EtOAc = 2 : 1) = 0.8. 
[α]25D= +118 (c = 1.50, CHCl3, 85% ee). 
1H NMR (400 MHz, CDCl3): δ 7.79–7.77 (m, 2H), 7.42–7.32 (m, 2H) 6.30–6.23 (m, 
2H), 5.43 (dd, J = 14.0 Hz, 7.6 Hz, 1H), 5.29–5.22 (m, 1H), 5.17–5.14 (m, 1H), 4.01–-
3.95 (m, 2H), 3.88–3.79 (m, 1H), 3.25 (s, 3H), 2.44 (s, 3H) ppm. 
13C NMR (100 MHz, CDCl3): δ 145.1, 135.9, 135.6, 133.1, 130.0 (2), 128.4, 128.1 (2), 
119.2, 79.3, 71.6, 56.9, 21.8 ppm. 
FTIR (Neat): λ−1 =  1359, 1189, 1175 cm−1. 
HRMS (CI): Calcd. for C14H19O4S (M+H+): 283.1001, found 283.1004. 
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(R,E)-3-Methoxyhepta-4,6-dienoic acid (1.64) 
To a solution of (S,E)-2-methoxyhexa-3,5-dienyl 4-methylbenzenesulfonate (340 mg, 
1.38 mmol), [18]-crown-6 (360 mg, 1.40 mmol), tetrabutylammonium iodide (100 mg, 
0.28 mmol) in dimethyl sulfoxide (1.3 mL) was added potassium cyanide (270 mg, 4.14 
mmol) and stirred at 45 °C for 2 h. The crude reaction mixture was added to ether (10 
mL) and then water (30 mL) was added. The resulting mixture was extracted with ether 
(3 x 30 mL). The organic extracts were combined and filtered through a plug of Celite. 
The filtrate was concentrated under reduced pressure and diluted with ethanol (6 mL). 
Then 30% hydrogen peroxide (6 mL) and lithium hydroxide hydrate (283 mg, 11.9 
mmol) were added at ambient temperature. The resulting solution was stirred for 24 h. 
Brine (10 mL) was added and the reaction mixture was washed with ether (2 x 20 mL) 
and the aqueous layer was neutralized with citric acid (2.5 g, 12 mmol). The resulting 
mixture was extracted with ether (3 x 30 mL), the combined organic extracts were 
washed with brine (10 mL), dried over sodium sulfate, filtered, and concentrated under 
reduced pressure to give acid 1.64 (135 mg, 0.12 mmol, 72% yield). To corroborate the 
assignment of absolute stereochemistry, the optical rotation was compared to a known 
compound.32 
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1H NMR (400 MHz, CDCl3): δ 6.38–6.24 (m, 2H), 5.55 (dd, J = 14.5 Hz, 8.0 Hz, 1H), 
5.26 (dd, J = 15.9 Hz, 1.9 Hz, 1H) 5.15 (dd, J = 9.7 Hz, 1.9 Hz, 1H), 4.10–4.05 (m, 1H), 
3.30 (s, 3H), 2.68–2.51 (m, 2H) ppm. 
13C NMR (100 MHz, CDCl3): δ 176.2, 136.0, 134.4, 131.8, 118.9, 78.3, 56.7, 41.0 ppm 
[α]26D= +6.5 (c = 0.61, CHCl3, 85% ee) 
Lit. [α]26D= +7.8 (c = 0.61, CHCl3, 98% ee)32 
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(S)-2-methoxybutane-1,4-diol (1.9R) 
Acid 1.64R (40 mg, 0.25 mmol), methanol (5 mL), and benzene (15 mL) were combined 
under an atmosphere of nitrogen, cooled to 0 °C. 4 tms was added, and the cooling bath 
was removed. After 1 h at ambient temperature the reaction mixture was concentrated 
under reduced pressure. Dichloromethane (20 mL) was added and reaction vessel was 
cooled to -78 °C. Ozone was bubbled into the solution until a blue color persisted. The 
cooling bath was removed and stream of nitrogen was used to concentrate the mixture to 
dryness. The resulting residue was dissolved in tetrahydrofuran (10 mL) under an 
atmosphere of nitrogen and  cooled with an ice bath. Lithium aluminum hydride (2.5 mL, 
2.5 mmol, 1 M in tetrahydrofuran) was added, the cooling bath was removed and the 
resulting mixture was stirred at ambient temperature for 16 h. The reaction vessel was 
cooled with an ice bath, water (0.1 mL) was added, followed by NaOH (0.3 mL, 15% 
solution) and water (0.4 mL), the resulting mixture was stirred vigorously.  Magnesium 
sulfate (5 g) was added to the reaction mixture, filtered, concentrated under reduced 
pressure and resulting residue was purified via column chromatography (SiO2, 
hexanes/ethyl acetate, 30%-100% gradient elution) to furnish diol 1.9R (20 mg, 0.17 
mmol, 65% yield). The data collected for the compound was consistent with the known 
values:19 
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1H NMR (400 MHz, CDCl3): δ 3.79 (m, 3H), 3.58 (dd, J = 4.5, 11.4 H, 1H), 3.48 (m, 
1H), 3.42 (s, 3H), 2.4 (br s, 2H), 1.86-1.81 (m, 2 H) ppm. 
13C NMR (100 MHz, CDCl3): δ 80.1, 63.3, 59.7, 57.1, 33.4 ppm 
 
 
(2R,2'R)-(S)-2-methoxybutane-1,4-diyl bis(3,3,3-trifluoro-2-methoxy-2-
phenylpropanoate) (3.25) 
The following procedure is a modification of the prior report127, which allowed the title 
compound to prepared in higher yield Diol 1.9R (20 mg, 0.17 mmol), dichloromethane (5 
mL), (R)-(+)-α-methoxy-α-trifluoromethylphenylacetic acid (MTPA) (312 mg, 1.33 
mmol), 4-dimethylamino pyridine (2 mg, 0.02 mmol) were combined under an 
atmosphere of nitrogen. The reaction vessel was cooled with an ice batch, DCC (275 mg, 
1.33 mmol) was added and the cooling bath was removed. Dichloromethane (10 mL) was 
added, the resulting mixture was filtered, concentrated under reduced pressure and 
resulting residue was purified via column chromatography (SiO2, hexanes/ethyl acetate, 
10%-30% gradient elution) to furnish bis(Mosher ester) 3.25 (20 mg, 0.17 mmol, 65% 
yield). The data collected for the compound was consistent with the known values:19 
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1H NMR (400 MHz, CDCl3): δ 7.5 (m, 4H), 7.39 (m, 6H), 4.32-4.49 (m, 3H), 4.13 (dd, J 
= 11.5, 5.6 Hz, 1H), 3.54 (s, 3H), 3.53 (s, 3H), 3.40 (m, 1H), 3.29 (s, 3H), 1.70-1.88 (m, 
2H) ppm. 
13C NMR (100 MHz, CDCl3): δ 166.4, 166.3, 132.1, 132.0, 129.5, 128.4, 128.3, 127.2, 
127.2, 124.4, 124.3, 122.1, 122.0, 84.8, 84.6, 84.5, 84.4, 75.0, 65.9, 62.3, 55.8, 55.3, 30.6 
ppm 
 
 
 
(Z)-3-Bromo-2-methylprop-2-ene-1-ol (3.15) 
The following procedure is a modification of the prior report, which allowed the title 
compound to prepared in higher yield. A solution of MeMgBr (52 mL, 160 mmol, 220 
mol %, 3 M in Et2O) was added dropwise to a stirred suspension of freshly distilled 
propargylalcohol (4.00 g, 71.4 mmol, 100 mol %) and CuI (1.36 g, 7.14 mmol, 10 mol 
%) in THF (70 mL, 1 M) at –10°C. After addition the cooling bath was removed and the 
dark suspension was stirred for a further 16 h at 25 °C. The suspension was cooled to –78 
°C and trimethylborate (9.7 mL, 8.9 g, 86 mmol, 120 mol %) was added. The reaction 
mixture was stirred for an additional 30 min at 25 °C after the cooling bath was removed. 
The reaction mixture was transferred to a separatory funnel containing HCl (aq.) (100 
mL, 2 M). The organic layer was washed and separated and the aqueous layer was 
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extracted with Et2O (3 x 50 mL). The combined organic extracts were concentrated under 
reduced pressure to roughly half their initial volume. The organic layer was transferred to 
a separatory funnel and was extracted with NaOH (aq.) (4 x 25 mL, 8 M). The combined 
aqueous layers were washed with Et2O (2 x 25 mL), then acidified with aq. HCl (approx. 
140 mL, 6 M) so that color change (from yellow to colorless) occurred. The acidic 
aqueous layer was then extracted with Et2O (6 x 40 mL) and the combined organic 
extracts were dried (Na2SO4), filtered and concentrated under reduced pressure. The 
crude residue (4.1 g) was dissolved in MeOH (82 mL, 0.5 M) and a solution of CuBr2 
(28.1 g, 126 mmol, 300 mol %) in water (82 mL) was added. The dark solution was 
stirred under reflux for 22 h. Brine (80 mL) was added at 25 °C and the aqueous layer 
was extracted with Et2O (6 x 80 mL). The combined organic extracts were dried 
(Na2SO4), filtered and concentrated under reduced pressure. The residue was purified by 
column chromatography (SiO2, 10–50% DCM/hexanes) to furnish the title compound 
3.15 as a light yellow oil (3.74 g, 24.8 mmol) in 21% yield.  
.Rf = 0.34 (SiO2, DCM). 
1H NMR (400 MHz, CDCl3): δ 5.98 (s, 1H), 4.29 (s, 2H), 1.97 (s, 1H), 1.89 (s, 3H) ppm. 
13C NMR (100 MHz, CDCl3): δ 140.5, 101.9, 63.6, 20.1 ppm. 
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(Z,3S,4S)-1-Bromo-2,4-dimethyl-3-hydroxyhexa-1,5-diene (3.14) 
(S)-Ir-complex (103 mg, 0.099 mmol, 5 mol %), vinylbromide 3.15 (300 mg, 1.99 mmol, 
100 mol %), and Na2CO3 (105 mg, 0.994 mmol, 50 mol %) were suspended in THF (1.0 
mL, 2 M) at 25 °C in a resealable pressure tube (13 x 100 mm). -Methyl allyl acetate 
(454 mg, 3.97 mmol, 200 mol %) and degassed water (180 mg, 9.94 mmol, 500 mol %) 
were added and the mixture was stirred under an atmosphere of argon at 70 °C for 6 d. 
The reaction mixture was concentrated under reduced pressure and the residue was 
chromatographically purified (SiO2, 5–10% EtOAc /hexanes) to furnish the title 
compound 3.14 (267 mg, 1.30 mmol, dr = 12:1, anti:syn, 94% ee) in 66% yield as pale 
yellow oil. The stereochemical assignment was inferred based on analogy with the 
literature precedent.79 
Rf = 0.38 (SiO2, hexanes/EtOAc = 5 : 1). 
 [α]26D= +178 (c = 0.37, CHCl3 96% ee). 
1H NMR (400 MHz, CDCl3): δ 6.07 (qd, J = 1.5 Hz, 0.5 Hz, 1H), 5.80 (ddd, J = 17.1 Hz, 
10.3 Hz, 8.6 Hz, 1H), 5.20 (ddd, J = 17.1 Hz, 1.8 Hz, 0.9 Hz, 1H), 5.19 (ddd, J = 10.3 
Hz, 1.8 Hz, 0.5 Hz, 1H), 4.49 (d, J = 9.0 Hz, 1H), 2.40–2.31 (m, 1H), 1.79 (d, J = 1.5 Hz, 
3H), 1.55 (s, 1H), 0.97 (d, J = 6.9 Hz, 3H) ppm. 
13C NMR (100 MHz, CDCl3): δ 140.9, 140.6, 117.1, 103.4, 74.1, 42.8, 17.2, 15.9 ppm. 
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FTIR (ATR): 3423 (m), 3077 (w), 2970 (m), 2920 (m), 2161 (w), 1637 (m), 1436 (m), 
1375 (m), 1292 (m), 1008 (vs), 915 (s), 725 (s) cm−1. 
HRMS (CI): Calcd. for C8H14OBr (MH): 205.0228; Found: 205.0225. 
GC: (Cyclosil-B: Initial temperature: 50 °C (3 min hold), final temperature: 200 °C; rate: 
10 K/min): (Z)-anti-diastereoisomer: tmajor = 13.4 min, tminor = 13.5 min 
 (Z)-syn-diastereoisomer: tmajor = 13.6 min; (E)-diastereoisomer: t = 14.1 min  
 ee = 94%, dr = 12:1 
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(3R,4S,Z)-1-Bromo-2,4-dimethylhexa-1,5-dien-3-yl 4-nitrobenzoate (3.29) 
Diisopropyl azodicarboxylate (0.23 mL, 1.2 mmol, 220 mol %) was added dropwise to a 
solution of compound 3.14 (110 mg, 0.54 mmol, 100 mol %), PPh3 (281 mg, 1.07 mmol, 
200 mol %), ethyldiisopropylamine (0.18 mL, 1.1 mmol, 200 mol %) and 4-nitrobenzoic 
acid (179 mg, 1.07 mmol, 200 mol %) in THF (35 mL, 0.015 M) at 0 ºC under an 
atmosphere of argon. The reaction mixture was stirred at 0 ºC for 3 h. The crude reaction 
mixture was concentrated under reduced pressure and the residue was purified 
chromatographically (SiO2, 10% EtOAc/hexanes) to furnish 3.29 (150 mg, 0.42 mmol) in 
79% yield as a colorless solid.   
Rf = 0.43 (SiO2, hexanes/EtOAc = 5 : 1). 
MP:  49–50 °C (rac), 62–63 °C. 
[α]26
D= +139 (c = 1.03, CHCl3 96% ee). 
1H NMR (400 MHz, CDCl3): δ 8.33–8.29 (m, 2H), 8.25–8.22 (m, 2H), 6.16–6.13 (m, 
1H), 5.89 (d, J = 8.8 Hz, 1H), 5.78 (ddd, J = 17.1 Hz, 10.3 Hz, 8.1 Hz, 1H), 5.14 (dt, J = 
17.1 Hz, 1.2 Hz, 1H), 5.08 (ddd, J = 10.3 Hz, 1.5 Hz, 0.5 Hz, 1H), 2.88–2.79 (m, 1H), 
1.80 (d, J = 1.5 Hz, 3H), 1.19 (d, J = 6.7 Hz, 3H) ppm. 
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13C NMR (100 MHz, CDCl3): δ 163.6, 150.6, 137.8, 137.4, 135.4, 130.7, 123.7, 116.1, 
105.4, 78.6, 40.5, 18.4, 16.5 ppm. 
FTIR (ATR): 3111 (w), 3080 (w), 2975 (m), 2922 (m), 2854 (w), 1727 (s), 1527 (s), 
1319 (m), 1270 (vs), 1101 (s), 952 (m), 719 (s) cm−1. 
HRMS (CI): Calcd. for C15H17NO4Br (MH+): 354.0341; Found: 354.0343. 
 
 
 
(Z,3R,4S)-1-Bromo-2,4-dimethyl-3-hydroxyhexa-1,5-diene (3.30) 
Ester 3.29 (3.77 g, 10.6 mmol, 100 mol %) was dissolved in a mixture of THF, MeOH 
and  water  (71  mL,  0.15  M,  5:1:1  volume  ratios,  respectively)  at  25  °C.  Then  LiOH•H2O 
(3.57 g, 85.1 mmol, 800 mol %) was added and the reaction mixture was stirred at 25 °C 
for 2 h. The reaction mixture was transferred to a separatory funnel and the organic layer 
was washed with brine (70 mL). The aqueous layer was extracted with diethyl ether (3 x 
70 mL), and the combined organic layers were dried (Na2SO4), filtered, and evaporated 
under reduced pressure. The residue was purified by column chromatography (SiO2, 10–
20% EtOAc/hexanes) to furnish the title compound 3.30 (2.15 g, 10.5 mmol) in 99% 
yield as a light yellow oil. 
Rf = 0.38 (SiO2, hexanes/EtOAc = 5 : 1). 
[α]28
D= +30.9 (c = 1.25 , CHCl3 96% ee). 
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1H NMR (400 MHz, CDCl3): δ 5.97–5.95 (m, 1H), 5.71 (ddd, J = 17.2 Hz, 10.3 Hz, 7.9 
Hz, 1H), 5.06 (ddd, J = 17.2 Hz, 1.7 Hz, 1.2 Hz, 1H), 5.01 (ddd, J = 10.4 Hz, 1.8 Hz, 0.9 
Hz, 1H), 4.56 (d, J = 8.4 Hz, 1H), 2.52–2.42 (m, 1H), 1.85 (s, 1H), 1.79 (d, J = 1.5 Hz, 
3H), 1.16 (d, J = 6.7 Hz, 3H) ppm. 
13C NMR (100 MHz, CDCl3): δ 142.0, 139.4, 115.1, 102.4, 74.9, 41.9, 17.7, 16.2 ppm. 
FTIR (ATR): 3371 (m), 3076 (w), 2975 (m), 2922 (m), 1641 (m), 1436 (m), 1374 (m), 
1292 (m), 1008 (vs), 915 (s), 716 (s) cm−1. 
GC: (Cyclosil-B: Initial temperature: 50 °C (3 min hold), final temperature: 200 °C; rate: 
10 K/min): (Z)-anti-diastereoisomer: tmajor = 13.5 min,  
 (Z)-syn-diastereoisomer: tmajor = 13.8 min; tminor = 13.7 min 
 ee = 93%, dr = 17 : 1  
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(3R,4S,Z)-1-Bromo-2,4-dimethylhexa-1,5-dien-3-yloxy)(tert-
butyl)dimethylsilane (3.12) 
To a stirred solution of compound 3.30 (40 mg, 0.195 mmol) and 2,6-lutidine (48 L, 
0.39 mmol) in dichloromethane (2 mL) at 0 oC under an atmosphere of argon was added 
TBS-OTf (31.5 L, 0.195 mmol).  After 1 h the crude mixture was concentrated under 
reduced pressure and purified (SiO2, 10% ether/hexanes) to give 3.12 (58 mg, 95% 
yield).  
Rf (SiO2, hexanes : ethyl acetate = 9 : 1) = 0.9.   
[α]28
D= +30.9 (c = 1.25 , CHCl3 96% ee). 
1H NMR (400 MHz, CDCl3): δ 5.87 (qd, J = 1.5 Hz, J = 0.4 Hz, 1H), 5.68 (ddd, J = 17.2 
Hz, J = 10.3 Hz, J = 8.2 Hz, 1H), 4.99 (ddd, J = 17.2 Hz, J = 1.9 Hz, J = 1.1 Hz, 1H), 
4.93 (ddd, J = 10.3 Hz, J = 1.9 Hz, J = 0.7 Hz, 1H), 4.45 (d, J =  8.8  Hz,  1H),  2.31−2.40  
(m, 1H), 1.73 (d, 1.5 Hz, 3H), 1.09 (d, J = 6.7 Hz, 3H), 0.90 (s, 9H), 0.10 (s, 3H), 0.02 (s, 
3H).   
13C NMR (100 MHz, CDCl3): δ 142.65, 139.73, 114.29, 101.43, 75.67, 43.18, 25.79, 
18.11,  17.41,  17.00,  −4.82,  −5.00.     
IR (neat): λ−1 = 3078, 2956, 2929, 2857, 1641, 1462, 1252, 1067, 913, 837.   
HRMS calcd. for C14H28BrOSi (M+H): 319.1093; Found: 319.1104 
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Bromo-2,5-dimethoxy-3-nitrobenzene 
Dimethylsulfate (3.05 g, 34.2 mmol, 200 mol %) was added at 25 °C to a stirred 
suspension of K2CO3 (5.02 g, 36.3 mmol, 300 mol %) and bromomethoxynitrophenol 
(3.00 g, 12.1 mmol, 100 mol %) in acetone (60 mL, 0.2 M). After stirring the mixture at 
reflux for 16 h, the solvent was removed under reduced pressure. Flash column 
chromatography (SiO2, 10–20% EtOAc/hexanes) furnished the title compound 1-bromo-
2,5-dimethoxy-3-nitrobenzene as a yellow solid (3.02 g, 11.5 mmol, 95% yield). 
Rf = 0.45 (SiO2, hexanes/EtOAc = 5 : 1). 
MP: 100-101°C. (Lit.: 98–98.5 °C)129 
1H NMR (400 MHz, CDCl3): δ 7.34 (d, J = 3.1 Hz, 1H), 7.28 (d, J = 3.1 Hz, 1H), 3.96 (s, 
3H), 3.83 (s, 3H) ppm. 
13C NMR (100 MHz, CDCl3): δ 155.5, 145.0, 144.4, 123.8, 120.1, 109.2, 62.7, 56.2 ppm. 
FTIR (ATR): 3102 (w), 2946 (w), 2840 (w), 1524 (s), 1475 (m), 1341 (m), 1229 (m), 
1042 (m) cm−1. 
HRMS (CI): Calcd. for C8H8NO4Br (M): 260.9637; Found: 260.9635.  
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2,5-Dimethoxy-1-nitro-3-vinylbenzene (3.16) 
1-Bromo-2,5-dimethoxy-3-nitrobenzene (131 mg, 0.500 mmol, 100 mol %), 
triphenylphosphine (10.5 mg, 0.040 mmol, 8 mol %), PdCl2(PPh3)2 (7 mg, 0.01 mmol, 2 
mol %), Cs2CO3 (489 mg, 1.50 mmol, 300 mol %), and potassium vinyltrifluoroborate 
(67 mg, 0.50 mmol, 100 mol %) were added to a resealable pressure tube (13 x 100 mm). 
THF (2.1 mL, 2 M) and H2O (0.2 mL) were added in oxygen free conditions and the 
mixture was stirred under argon at 85 °C for 2 d.  Saturated NH4Cl solution (2 mL) was 
added, the layers were separated and the aqueous layer was extracted with DCM (3 x 2 
mL). The combined organic phases were dried (MgSO4), the mixture filtered and the 
solvent removed under reduced pressure. Flash column chromatography (SiO2, 10–20% 
EtOAc/hexanes) furnished 2,5-dimethoxy-1-nitro-3-vinylbenzene 3.16 (96 mg, 0.46 
mmol, 92% yield) as a yellow solid. 
Rf = 0.39 (SiO2, hexanes/EtOAc = 5 : 1). 
MP: 54–55 °C.  
1H NMR (400 MHz, CDCl3): δ 7.26 (d, J = 3.2 Hz, 1H), 7.24 (d, J = 3.2 Hz, 1H), 6.97 
(dd, J = 17.7 Hz, 11.1 Hz, 1H), 5.82 (dd, J = 17.7 Hz, 0.9 Hz, 1H), 5.47 (dd, J = 11.1 Hz, 
1.1 Hz, 1H), 3.85 (s, 3H), 3.84 (s, 3H) ppm. 
13C NMR (100 MHz, CDCl3): δ 155.1, 144.6, 144.6, 134.9, 129.9, 117.8, 116.9, 108.6, 
63.1, 56.0 ppm. 
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FTIR (ATR): 3090 (w), 2941 (w), 2837 (w), 1528 (s), 1477 (m), 1414 (m), 1352 (m), 
1230 (m), 1071 (w), 994 (s) cm−1. 
HRMS (CI): Calcd. for C10H11NO4 (M): 209.0688; Found: 209.0692. 
 
 
 
(3S,4R,Z)-6-Bromo-4-(tert-butyldimethylsilyloxy)-3,5-dimethylhex-5-ene-1,2-diol 
(3.31diol) 
To a solution of 3.12 (80 mg, 0.25 mmol), N-methylmorpholine-N-oxide (58 mg, 0.50 
mmol), and water (0.01 ml), 0.5 mmol) in dichloromethane (2 mL) was added osmium 
tetraoxide (3.4 mg, 0.012 mmol).  The resulting mixture was stirred at ambient 
temperature for 2 h until the complete conversion of starting material was observed by 
TLC.  NaHSO3 (200 mg) was added and the reaction mixture was decanted.  The crude 
reaction mixture was concentrated and purified (SiO2, 50% ethyl acetate/hexanes) to give 
3.31diol (80 mg, 90% yield) as white solid.   
Rf (SiO2, hexanes : ethyl acetate = 1 : 1) = 0.46.   
mp  =  68−69°C  (rac),  77−78°C  (93%  ee).   
[α]25D=  −24 (c = 1.0, CHCl3). 
1H NMR (400 MHz, CDCl3): (major diastereomer, dr =  5  :  1)  δ  =  6.00  (s, 1H), 4.88 (d, J 
=  5.3  Hz,  1H),  3.60−3.68  (m,  1H),  3.52  (dd,  J = 11.0 Hz, J = 6.5 Hz, 1H), 2.30 (s, br, 2 
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OH),  2.00−2.09  (m,  1H),  1.88  (s,  3H),  0.91  (s,  9H),  0.90  (d,  J = 7.2 Hz, 3H), 0.14 (s, 3H), 
0.05 (s, 3H).   
13C NMR (100 MHz, CDCl3):   δ   =   142.31,   102.35,   74.46,   73.76,   64.68,   41.01,   25.73,  
18.88,  17.99,  11.64,  −4.87,  −5.00.   
IR (neat): λ−1 3383, 2955, 2928, 2857, 1462, 1252, 1041, 870, 837.   
HRMS calcd. for C14H30BrOSi (M+H): 353.1148; Found: 353.1149.  
[α]25D=  −34.0  (c = 1.00, CHCl3). 
 
  
 
((3R,4S,Z)-1-Bromo-4-(2,2-dimethyl-1,3-dioxolan-4-yl)-2-methylpent-1-en-3-
yloxy)(tert-butyl)dimethylsilane  (3.31) 
To a solution of 3.31diol (565 mg, 1.60 mmol) and 2,2-dimethoxypropane (5.7 mL, 16.0 
mmol) in dichloromethane (10 mL) under an atmosphere of argon was added pyridinium 
p-toluenesulfonate (40 mg, 0.16 mmol) at ambient temperature.  The mixture was stirred 
for 1 h, concentrated onto silica gel under reduced pressure, and purified (SiO2, 10% 
ether/hexanes) to give 3.31 (590 mg, 94% yield) as clear oil.  :   
Rf (SiO2, hexanes : ethyl acetate = 5 : 1) = 0.54.  
[α]25D=  −14.4 (c = 1.08, CHCl3). 
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1H NMR (400 MHz, CDCl3): major diastereomer, dr =  5  :  1  (NMR)  δ  =5.90  (qd, J = 1.5 
Hz, J = 1.0 Hz, 1H), 4.70 (dd, J = 5.6 Hz, J = 0.8 Hz, 1H), 4.00 (dd, J = 7.9 Hz, J = 6.3 
Hz, 1H), 3.92 (td, J = 7.2 Hz, J = 6.3 Hz, 1H), 3.64 (dd, J = 7.8 Hz, J = 7.5 Hz, 1H), 1.97 
(qdd, J = 6.9 Hz, J = 6.8 Hz, J = 5.7 Hz, 1H), 1.79 (d, J = 1.5 Hz, 3H), 1.41 (d, J = 0.5 
Hz, 3H), 1.33 (d, J = 0.5 Hz, 3H), 0.88 (d, J = 6.8 Hz, 3H), 0.91 (s, 9H), 0.11 (s, 3H), 
0.01 (s, 3H).   
13C NMR (100 MHz, CDCl3):   δ  = 143.72, 108.40, 100.51, 76.17, 72.77, 67.17, 41.30, 
26.54,  25.84,  25.42,  18.80,  18.13,  10.02,  −4.90,  −5.15.     
IR (neat): λ−1 2983, 2955, 2929, 2857, 1472, 1369, 1252, 1213, 1161, 1121, 1047, 859, 
839, 775.   
HRMS calcd. for C17H32BrO3Si (M-H): 391.1304; Found: 391.1304.   
 
 
 
tert-Butyl[(2S,3R,Z)-7-(2,5-dimethoxy-3-nitrophenyl)-2-(2,2-dimethyl-1,3-
dioxolan-4-yl)-4-methylhept-4-en-3-yloxy]dimethylsilane  (3.32) 
To a solution of 3.31 (400 mg, 1.02 mol), PdCl2(dppf).CH2Cl2 (41 mg, 0.05 mmol),  
cesium carbonate (0.98 g, 2.85 mmol), and water (0.4 ml) in dimethyl acetamide (6 mL) 
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under an atmosphere of argon was added a solution of 3.16 (3 ml, 1.52 mmol, 0.5 M in 
tetrahydrofuran).  The resulting black solution was stirred at 50 oC for 48 h.  The reaction 
mixture was added to brine (60 mL) and extracted with ether (3 x 20 mL).  The organic 
extracts were combined, dried over sodium sulfate, filtered, concentrated under reduced 
pressure and purified purified (SiO2, 50% to 100% dichloromethane/hexanes, gradient 
elution) to give 3.32 (291 mg, 55% yield) as yellow oil 
Rf (SiO2, hexanes : ethyl acetate = 5 : 1) = 0.26.   
[α]25D=  −18.2 (c = 0.45, CHCl3). 
1H NMR (400 MHz, CDCl3):  δ  =  7.17  (d, J = 3.2 Hz, 1H), 6.99 (d, J = 3.2 Hz, 1H), 5.18 
(ddt, J = 8.0 Hz, J = 6.5 Hz, J = 1.3 Hz, 1H), 4.70 (d, J = 2.6 Hz, 1H), 3.85 (s, 3H), 3.82–
3.98 (m, 2H), 3.81 (s, 3H), 3.51 (t, J = 7.3 Hz, 1H), 2.70 (t, J = 7.8 Hz, 2H), 2.40–2.50 
(m, 1H), 2.17–2.27 (m, 1H), 1.72 (d, J = 0.9 Hz, 3H), 1.57–1.67 (m, 1H), 1.33 (s, 6H), 
0.90 (s, 9H), 0.81 (d, J =  6.9  Hz,  3H),  0.04  (s,  3H),  −0.06  (s,  3H).     
13C NMR (100 MHz, CDCl3):   δ   =154.96,   145.57,   144.06,   139.67,   139.40,   124.02,  
121.65, 108.49, 106.66, 76.68, 70.28, 67.96, 62.71, 55.81, 44.16, 29.90, 28.11, 26.64, 
25.87,  25.61,  20.22,  18.20,  9.76,  −4.95,  −5.25.     
IR (neat): λ−1  2954, 2930, 2856, 1619, 1536, 1473, 1426, 1368, 1234, 1181, 1053, 1004, 
838, 774.   
HRMS calcd. for C27H46NO7Si (M+H): 524.3044; Found: 524.3035.  
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(Z,3R,4S)-1-Bromo-3-(4-methoxybenzyloxy)-2,4-dimethylhexa-1,5-diene (3.37) 
NaH (807 mg, 20.2 mmol, 60% in mineral oil, 300 mol %) was added portion wise to a 
solution of alcohol 3.30 (1.38 g, 6.73 mmol, 100 mol %) at 0 °C. p-Methoxybenzyl 
chloride (1.58 g, 10.1 mmol, 150 mol %) was added as a solution in THF–DMSO (34 
mL, 0.2 M, 5:1, volume ratio, respectively). The cooling bath was removed and the 
reaction mixture was allowed to stir 2 h. A saturated solution of NaHCO3 (aq) (30 mL) 
was carefully added and the reaction mixture transferred to a separatory funnel. The 
aqueous layer was extracted with diethyl ether (3 x 30 mL), the combined organic 
extracts were dried (Na2SO4), filtered and the solvent was removed under reduced 
pressure. The residue was purified by column chromatography (SiO2, 0–5% 
EtOAc/hexanes) to furnish the title compound 3.37 (1.75 g, 5.38 mmol) in 80% yield as a 
light yellow oil. 
Rf = 0.57 (SiO2, hexanes/EtOAc = 5 : 1). 
[α]26
D= +32 (c = 1.3, CHCl3 94% ee). 
1H NMR (400 MHz, CDCl3): δ 7.29–7.24 (m, 2H), 6.89–6.85 (m, 2H), 6.13 (qd, J = 1.4 
Hz, 0.5 Hz, 1H), 5.63 (dddd, J = 17.2 Hz, 10.2 Hz, 8.4 Hz, 0.5 Hz, 1H), 5.03–4.98 (m, 
1H), 4.93 (ddt, J = 10.3 Hz, 1.8 Hz, 0.8 Hz, 1H), 4.41 (d, J = 11.3 Hz, 1H), 4.22 (d, J = 
9.4 Hz, 1H), 4.21 (d, J = 11.3 Hz, 1H), 3.83 (s, 3H), 2.43 (tq, J = 8.5 Hz, 6.6 Hz, 1H), 
1.75 (dd, J = 1.5 Hz, 0.6 Hz, 3H), 1.13 (d, J = 6.6 Hz, 3H) ppm. 
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13C NMR (100 MHz, CDCl3): δ 159.1, 139.9, 139.3, 130.4, 129.6, 114.6, 113.6, 104.7, 
81.5, 70.3, 55.2, 41.2, 17.4, 17.4 ppm. 
FTIR (ATR): 3072 (w), 2959 (m), 2929 (m), 2835 (w), 1641 (m), 1513 (s), 1246 (vs), 
1172 (m), 1109 (s), 1064 (s) cm−1. 
HRMS (CI): Calcd. for C16H20BrO2 (M−H+): 323.0647; Found: 323.0651. 
 
 
 
 (3S,4R,5Z)-6-Bromo-4-(4-methoxybenzyloxy)-3,5-dimethylhex-5-ene-1,2-diol (3.38) 
NMO (144 mg, 1.23 mmol, 200 mol %) was added to a solution of olefin 3.37 (200 mg, 
0.615 mmol, 100 mol %) and osmium tetroxide (3 mg, 0.01 mmol, 2 mol %) in DCM 
(6.0 mL, 0.1 M) at 25 °C. Water (22 mg, 1.2 mmol, 200 mol %) was added and the 
solution was allowed to stir for 4 h at 25 °C. The reaction mixture was concentrated 
under reduced pressure and the residue was purified by column chromatography (SiO2, 
30–50% EtOAc/hexanes) to furnish the title compound 3.38 (214 mg, 0.595 mmol) in 
97% yield as a highly viscous colorless oil. 
Rf = 0.24 (SiO2, hexanes/EtOAc = 1 : 1). 
[α]25D= +26 (c = 0.80, 94% ee CHCl3). 
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1H NMR (400 MHz, CDCl3): major diastereoisomer, dr =  4:1   (NMR)  δ  7.28–7.25 (m, 
2H), 6.92–6.87 (m, 2H), 6.19 (s, br, 1H), 4.60 (d, J = 5.3 Hz, 1H), 4.45 (d, J = 11.4 Hz, 
1H), 4.19 (d, J = 11.3 Hz, 1H), 3.81 (s, 3H), 3.68–3.60 (m, 2H), 3.52–3.46 (m, 1H), 2.89 
(s, br, 2H), 2.11–2.03 (m, 1H), 1.90–1.88 (m, 3H), 0.99 (d, J = 7.1 Hz, 3H) ppm. 
13C NMR (100 MHz, CDCl3):   δ   159.4,   140.7,   129.7,   129.5,   113.9,   104.4,   79.2,   74.3,  
70.8, 64.7, 55.2, 39.2, 18.9, 11.7 ppm. 
FTIR (ATR): 3404 (m), 3069 (w), 2922 (m), 2882 (m), 2836 (w), 1612 (m), 1513 (m), 
1246 (s), 1033 (s) cm−1. 
HRMS (CI): Calcd. for C16H22BrO4 (M−H+): 357.0701; Found: 357.0699. 
 
 
 
4-[(2R,3R,4Z)-5-Bromo-3-(4-methoxybenzyloxy)-4-methylpent-4-en-2-yl]-2,2-dime-
thyl-1,3-dioxolane (3.39) 
2,2-Dimethoxypropane (812 mg, 7.79 mmol, 1000 mol %) was added to a solution of diol 
3.38 (280 mg, 0.779 mmol, 100 mol %) in DCM (8.0 mL, 0.1 M) at 25 °C. Then p-
Toluenesulfonic acid  (10 mg, 0.04 mmol, 5 mol %) was added and the solution was 
stirred at 25 °C under nitrogen for 17 h. After completion of the reaction the solvent was 
removed under reduced pressure and the residue was purified by column chromatography 
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(SiO2, 10–20% EtOAc/hexanes) to furnish the title compound 3.39 (308 mg, 0.771 mmol, 
99% yield) as a viscous colorless oil. 
Rf = 0.54 (SiO2, hexanes/EtOAc = 5 : 1). 
 [α]26D=  −1.4  (c  =  1.38,  CHCl3 94% ee). 
1H NMR (400 MHz, CDCl3): major diastereoisomer, dr = 3 : 1 (NMR) δ 7.27–7.25 (m, 
2H), 6.89–6.86 (m, 2H), 6.13 (qd, J = 1.4 Hz, 0.7 Hz, 1H), 4.39 (d, J = 11.2 Hz, 1H), 
4.31 (dd, J = 7.2 Hz, 0.7 Hz, 1H), 4.22 (d, J = 11.3 Hz, 1H), 4.01–3.91 (m, 2H), 3.80 (s, 
3H), 3.69–3.60 (m, 1H), 2.14 (dqd, J = 7.2 Hz, 6.8 Hz, 5.8 Hz, 1H), 1.82 (d, J = 1.5 Hz, 
3H), 1.40 (s, 3H), 1.32 (s, 3H), 0.96 (d, J = 6.8 Hz, 3H) ppm. 
13C NMR (100 MHz, CDCl3):   δ  159.1,   140.9,  130.3,  129.5,  113.6,  108.2,  103.9,  79.5,  
76.3, 70.6, 66.3, 55.2, 38.8, 26.4, 25.3, 18.4, 10.2 ppm. 
FTIR (ATR): 3064 (w), 2982 (m), 2934 (m), 2857 (w), 1612 (m), 1513 (s), 1369 (m), 
1246 (s), 1036 (vs) cm−1. 
HRMS (CI): Calcd. for C19H26BrO4 (M−H+): 397.1014; Found: 397.1018. 
 
 
2-(2,5-dimethoxy-3-nitrophenethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3.40) 
To a stirred solution of [Ir(cod)Cl]2 (88 mg, 0.13 mmol, 2.5 mol %), 1,2-
bis(diphenylphosphino)ethane (171 mg, 0.274 mmol, 5.2 mol %), toluene (4.5 mL), 1,2-
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dichloroethane (0.5 mL) under argon at 25 °C was added 4,4,5,5-tetramethyl-1,3,2-
dioxaborolane (0.89 mL, 13 mmol, 250 mol %) followed by 2,5-dimethoxy-1-nitro-3-
vinylbenzene (1.1 g, 5.2 mmol, 100 mol %). The resulting solution was stirred for 14 h. 
The reaction mixture was added to ether (50 mL) and methanol (3 mL) was added slowly. 
After gas evolution ceased, brine (10 mL) was added and the organic layer was washed, 
dried (Na2SO4), filtered, concentrated, and purified via column chromatography (SiO2, 
20-100% dichloromethane/hexanes, gradient elution) to give 1.5 g the title compound 
3.40  (1.56 g, 4.63 mmol, 88 % yield) as a yellow solid. 
Rf = 0.2 (SiO2, hexanes/DCM = 1 : 1). 
MP: 36–37 °C. 
1H NMR (400 MHz, CDCl3): δ  7.14  (d,  J = 3.2 Hz, 1H), 7.04 (d, J = 3.2 Hz, 1H), 3.84 (s, 
3H), 3.79 (s, 3H), 2.78 (t, J = 8.1 Hz, 2H), 1.22 (s, 12H), 1.12 (t, J = 8.1 Hz, 2H) ppm. 
13C NMR (100 MHz, CDCl3, C attached to quadropole B not observed): δ 156.8, 147.1, 
145.8, 143.6, 122.6, 108.5, 85.1, 64.5, 57.7, 26.6, 25.8 ppm. 
FTIR (ATR): λ−1  2977, 1530, 1369, 1319, 1229, 1141, 1050 cm−1. 
HRMS (ESI): Calcd. for C16H24NBO6 (M+Na+): 360.1594, found 360.1592. 
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Potassium trifluoroborate salt (3.41) 
A mixture of [Ir(cod)Cl]2 (192 mg, 0.287 mmol), 1,2-bis(diphenylphosphino)ethane (358 
mg, 0.574 mmol), toluene (5 mL), and dichloroethane was sparged with argon. 4,4,5,5-
Tetramethyl-1,3,2-dioxaborolane (2.4 mL, 36 mmol) was added to the mixture followed 
by nitro styrene 3.16 (2.5 g, 11.9 mmol) dissolved in toluene (18 mL). The resulting 
mixture was stirred for 2 h, and added a solution of diethyl ether (50 mL), methanol (5 
mL) and water (5 mL). After gas evolution ceased, brine (10 mL) was added and the 
organic layer was washed, dried (Na2SO4), filtered, concentrated, and purified via column 
chromatography (SiO2, 50-100% dichloromethane/hexanes, gradient elution) to give 3.5 
g of the intermediate pinacol ester as a yellow oil. The residue was diluted with 
tetrahydrofuran (10 mL) and cooled to 0 C. Potassium hydrogen fluoride was added 
followed by water (2 mL), the resulting mixture was stirred overnight at ambient 
temperature. The reaction mixture was concentrated to dryness under reduced pressure, to 
give an off white solid, which was suspended in hot acetone and filtered. The filtrate was 
concentrated in the minimal amount of hot acetone, added to a solution of diethyl ether 
and filtered to provide the title compound (3.41) as a yellow powder (2.81 g, 10.0 mmol, 
84% yield) 
MP: 189-190 °C. 
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1H NMR (400  MHz;;  acetone):  δ  7.09  (d,  J = 3.2, 1H), 7.06 (d, J = 3.2, 1H), 3.81 (s, 3H), 
3.79 (s, 3H), 2.67-2.62 (m, 2H), 0.57-0.48 (m, 2H) ppm. 
13C NMR (100 MHz, CDCl3, C attached to quadropole B not observed): δ 156.2, 146.4, 
145.7, 145.2, 121.1 106.3, 63.1, 53.3, 26.2 ppm. 
19F NMR -141.8 ppm. 
FTIR (ATR): ): λ−1  3555, 1525, 1340, 1318, 1267, 1223, 1074, 1050, 1024 cm−1. 
MS (ESI): Calcd. for C10H12BF3KNO4 (M-K+): 278, found 278. 
 
 
 
4-[(2R,3R,4Z)-7-(2,5-Dimethoxy-3-nitrophenyl)-3-[(4-methoxybenzyloxy)-4-methyl-
hept-4-en-2-yl]-2,2-dimethyl-1,3-dioxolane (3.34 3.34) 
Vinyl bromide 3.39 (110 mg, 0.275 mmol, 100 mol %) and pinacol ester 3.40 (139 mg, 
0.413 mmol, 150 mol %) were added to a resealable pressure tube (13 x 100 mm) and 
dissolved in THF (1.05 mL, 0.26 M). Degassed aqueous NaOH solution (0.1 mL, 0.825 
mmol, 300 mol %, 3 M) was added and after additional degassing of the reaction mixture, 
Pd(dppf) Cl2 ∙  DCM  (23  mg,  0.028  mmol,  10  mol  %)  was  added.  The  mixture  was  stirred  
under argon at 50°C for 25 h.  The black reaction mixture was diluted with DCM (3 mL) 
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and aqueous saturated NaHCO3 solution (3 mL). The layers were separated and the 
aqueous layer was extracted with DCM (3 x 3 mL), the combined organic layers were 
dried (MgSO4), filtered and the solvent was removed under reduced pressure. Flash 
column chromatography (SiO2, 10–20% EtOAc/hexanes) furnished the title compound 
3.34 (109 mg, 0.206 mmol, 75% yield) as a yellow oil. 
Rf = 0.32 (SiO2, hexanes/EtOAc = 5 : 1). 
[α]27
D= +17.5 (c = 1.55, CHCl3 92% ee). 
1H NMR (400 MHz, CDCl3): major diastereoisomer, dr = 5 : 1, δ 7.21–7.19 (m, 2H), 
7.15 (d, J = 3.2 Hz, 1H), 6.93 (d, J = 3.1 Hz, 1H), 6.86–6.84 (m, 2H), 5.43 (t, J = 7.2 Hz, 
1H), 4.30 (d, J = 11.3 Hz, 1H), 4.11 (d, J = 5.6 Hz, 1H), 4.05 (d, J = 11.2 Hz, 1H), 4.04–
3.95 (m, 1H), 3.86–3.83 (m, 1H), 3.83 (s, 3H), 3.79 (s, 3H), 3.77 (s, 3H), 3.58 (t,  J = 7.9 
Hz, 1H), 2.78–2.64 (m, 2H), 2.46–2.36 (m, 1H), 2.30–2.20 (m, 1H), 1.91 (dqd, J = 6.9 
Hz, 5.9 Hz, 6.7 Hz, 1H) 1.73 (d, J = 0.7 Hz, 3H), 1.35 (s, 3H), 1.30 (s, 3H), 0.92 (d, J = 
6.9 Hz, 3H) ppm. 
13C NMR (100 MHz, CDCl3): δ 158.9, 154.8, 145.4, 143.9, 139.0, 135.8, 130.6, 129.0, 
127.9, 121.6, 113.6, 108.0, 106.6, 77.5, 76.6, 70.0, 66.5, 62.6, 55.7, 55.1, 40.5, 30.0, 28.0, 
26.4, 25.3, 19.5, 10.0 ppm. 
FTIR (ATR): 2982 (m), 2936 (m), 1613 (m), 1531 (s), 1456 (s), 1368 (m), 1235 (s), 
1052 (vs) cm−1. 
HRMS (CI): Calcd. for C29H40NO8 (MH+): 530.2754; Found: 530.2745. 
  
 138 
 
(2R,3R,4Z)-7-(2,5-Dimethoxy-3-nitrophenyl)-3-(4-methoxybenzyloxy)-2,4-dimethyl-
hept-4-enal (3.35) 
Acetonide 3.34 (1.52 g, 2.87 mmol, 100 mol %) was dissolved in EtOAc (78 mL, 0.04 
M). This solution was added to a suspension of H5IO6 (1.31 g, 5.74 mmol, 200 mol %) in 
EtOAc (78 mL, 0.04 M) at 25 °C. The reaction mixture was stirred for 40 min (color 
change) at 25 °C, then Na2S2O3 (one spatula) was added and the resulting mixture was 
stirred for a further 5 min at 25 ºC. The suspension was filtered through a plug of 
Celite/SiO2 = 4:1 and the solvent was removed under reduced pressure (to furnish 
aldehyde 3.35 (1.30 g, 2.84 mmol, 99% yield) as a yellow oil. (Note: Aldehyde 3.35 is 
highly unstable and epimerizes easily at elevated temperatures and/or catalytic amounts 
of acid) 
Rf = 0.26 (SiO2, hexanes/EtOAc = 5 : 1). 
[α]26
D= +16 (c = 0.83, CHCl3 95% ee). 
1H NMR (400 MHz, CDCl3): δ 9.56 (d, J = 2.1 Hz, 1H), 7.21–7.18 (m, 2H), 7.16 (d, J = 
3.1 Hz, 1H), 6.94 (d, J = 3.2 Hz, 1H), 6.88–6.85 (m, 2H), 5.53 (t, J = 7.2 Hz, 1H), 4.34 
(d, J = 11.3 Hz, 1H), 4.29 (d, J = 8.4 Hz, 1H), 4.06 (d, J = 11.3 Hz, 1H), 3.84 (s, 3H), 
3.79 (s, 3H), 3.78 (s, 3H), 2.74–2.64 (m, 3H), 2.41–2.32 (m, 1H), 2.30–2.22 (m, 1H), 
1.73 (d, J = 1.0 Hz, 3H), 1.14 (d, J = 6.8 Hz, 3H) ppm. 
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13C NMR (100 MHz, CDCl3): δ 203.1, 159.2, 154.0, 145.5, 143.0, 138.9, 133.6, 130.1, 
129.0, 129.3, 121.6, 113.7, 106.9, 75.8, 69.4, 62.7, 55.8, 55.2, 49.6, 30.1, 28.2, 18.5, 10.7 
ppm. 
FTIR (ATR): 2939 (m), 2838 (m), 1723 (m), 1531 (s), 1514 (s), 1368 (m), 1236 (s), 
1053 (s) cm−1. 
HRMS (CI): Calcd. for C25H31NO7 (M+): 457.2101; Found: 457.2094. 
 
 
 
(3E,6R,7S,8R,9Z)-12-(2,5-dimethoxy-3-nitrophenyl)-8-(4-methoxybenzyloxy)-7,9-di-
methyldodeca-1,3,9-trien-6-ol (3.36) 
A solution of Me2AlCl in hexanes (5.7 mL, 5.7 mmol, 250 mol %, 1.0 M) was added 
dropwise (over glass wall) at –78 °C to a stirred solution of aldehyde 3.35 (1.05 g, 2.29 
mmol, 100 mol %) in DCM (11.5 mL, 0.2 M). After 10 min penta-1,3-dienyltrimethyl 
silane122 (964 mg, 6.87 mmol, 300 mol %) was added dropwise (over glass wall) at –78 
°C and the dark orange solution was stirred for a further 5 h at this temperature. 
Phosphate buffer (pH = 7) was added (15 mL) followed by a concentrated citric acid 
solution (20 mL). The layers were separated and the aqueous layer was extracted with 
diethyl ether (3 x 30 mL). The solvent was removed under reduced pressure after drying 
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over Na2SO4 and filtration. Flash column chromatography (SiO2, 10–20% 
EtOAc/hexanes) furnished the title compound 3.36 (635 mg, 1.209 mmol, 53% yield, >20 
: 1 dr) as a yellow oil. . The stereochemical assignment was inferred based on analogy 
with the literature precedent.113 
Rf = 0.46 (SiO2, hexanes/EtOAc = 2 : 1). 
[α]25
D= +95.4 (c = 1.00, CHCl3 92% ee). 
1H NMR (400 MHz, CDCl3): δ 7.21–7.19 (m, 2H), 7.15 (d, J = 3.2 Hz, 1H), 6.93 (d, J = 
3.2 Hz, 1H), 6.88–6.85 (m, 2H), 6.27 (dt, J = 17.0 Hz, 10.4 Hz, 1H), 6.05 (dd, J = 15.0 
Hz, 10.4 Hz, 1H), 5.67 (dt, J = 15.2 Hz, 7.4 Hz, 1H), 5.45 (t, J = 7.2 Hz, 1H), 5.07 (dd, J 
= 17.0 Hz, 1.1 Hz, 1H), 4.96 (dd, J = 10.3 Hz, 1.5 Hz, 1H), 4.32 (d, J = 11.3 Hz, 1H), 
4.26 (d, J = 5.4 Hz, 1H), 4.04 (d, J = 11.3 Hz, 1H), 3.84 (s, 3H), 3.80 (s, 3H), 3.78 (s, 
3H), 3.55 (ddt, J = 7.4 Hz, 5.4 Hz, 5.3 Hz, 1H), 2.76–2.68 (m, 2H), 2.64 (d, J = 5.2 Hz, 
1H), 2.41 (sext, J = 7.7 Hz, 1H), 2.30–2.22 (m, 1H), 2.18–2.12 (m, 2H), 1.82–1.74 (m, 
1H), 1.76 (d, J = 1.0 Hz, 3H), 0.98 (d, J = 7.0 Hz, 3H) ppm. 
13C NMR (100 MHz, CDCl3): δ 159.2, 154.9, 145.4, 144.0, 138.9, 136.8, 135.2, 133.4, 
131.2, 130.0, 129.4, 128.7, 121.6, 115.5 113.7, 106.7, 77.7, 73.4, 69.0, 62.6, 55.7, 55.1, 
41.7, 37.6, 30.1, 28.2, 19.7, 12.0 ppm. 
FTIR (ATR): 3476 (OH, br), 3083 (w), 2939 (m), 2837 (m), 1613 (m), 1531 (vs), 1514 
(s), 1236 (s), 1053 (s) cm−1. 
HRMS (CI): Calcd. for C30H39NO7 (M+): 525.2727; Found: 525.2717. 
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(3E,6S,7S,8R,9Z)-12-(2,5-dimethoxy-3-[(3R,4E)-3-methoxyhepta-4,6-dienamido]phe-
nyl)-8-(4-methoxybenzyloxy)-7,9-dimethyldodeca-1,3,9-trien-6-yl 1-[(cyclohex-1-
ene)amido]cyclopropane-1-carboxylate (3.55) 
Sulfur (156 mg, 4.88 mmol, 3500 mol %) and NaBH4 (105 mg, 2.78 mmol, 2000 mol %) 
were added at 25 °C to a stirred solution of nitroarene 3.36 (100 mg, 0.139 mmol, 100 
mol %) in THF (14 mL, 0.01 M). This solution was stirred under inert conditions for a 
further 1 h at 50 °C. After cooling to 25 °C saturated NaHCO3 solution (15 mL) was 
slowly added, the layers separated and the aqueous layer was extracted with chloroform 
(3 x 15 mL). The combined organic layers were washed with brine (15 mL), dried 
(MgSO4) and filtered. Then the solvent was removed in vacuo and the crude solid residue 
was used in the next step.  
Freshly distilled ethyldiisopropylamine (898 mg, 6.95 mmol, 5000 mol %) was added to 
a solution of solid residue in toluene (14 mL, 0.01 M) at 25 °C. This solution was added 
at 25 °C to a stirred solution of acid 1.64 (109 mg, 0.698 mmol, 500 mol %) and BOPCl 
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(212 mg, 0.834 mmol, 600 mol%) in THF (23 mL, 0.03 M with respect to acid 1.64). 
After addition of powdered molecular sieves (4 Å, 2 spatulas) the reaction mixture was 
stirred for further 21 h at 25 °C under inert conditions. Saturated NaHCO3 solution (45 
mL) was added, the layers separated and the aqueous layer was extracted with chloroform 
(3 x 45 mL). The combined organic layers were dried (MgSO4), filtered and then the 
solvent was removed in vacuo. Flash column chromatography (SiO2, 
toluene/EtOAc/hexanes = 3 : 1 : 1) furnished bis(diene) 3.55 (79 mg, 0.096 mmol) in 
69% yield as a yellow oil. 
Rf = 0.10 (SiO2, toluene/EtOAc/hexanes = 3 : 1 : 1). 
[α]26
D= +34.1 (c = 1.00, CHCl3 90% ee). 
1H NMR (400 MHz, CDCl3): δ 8.94 (s, 1H), 7.92 (d, J = 3.0 Hz, 1H), 7.21–7.19 (m, 2H), 
6.85–6.83 (m, 2H), 6.57–6.55 (m, 1H), 6.43 (d, J = 3.0 Hz, 1H), 6.33 (dt, J = 16.4 Hz, 
10.4 Hz, 1H), 6.30 (dd, J = 21.2 Hz, 10.8 Hz, 1H), 6.24 (dt, J = 17.0 Hz, 10.2 Hz, 1H), 
6.17 (s, 1H), 5.98 (dd, J = 15.2 Hz, 10.3 Hz, 1H), 5.56 (ddd, J = 20.3 Hz, 14.3 Hz, 8.0 
Hz, 1H), 5.55–5.48 (m, 2H), 5.28 (d, J = 16.7 Hz, 1H), 5.17 (d, J = 9.6 Hz, 1H), 5.06 (d, 
J = 17.0 Hz, 1H), 4.96 (d, J = 10.1 Hz, 1H), 4.80 (ddd, J = 8.9 Hz, 4.8 Hz, 3.0 Hz, 1H), 
4.28 (d, J = 11.3 Hz, 1H), 4.07 (td, J = 7.9 Hz, 3.9 Hz, 1H), 4.01 (d, J = 11.3 Hz, 1H), 
3.91 (d, J = 8.1 Hz, 1H), 3.79 (s, 3H), 3.75 (s, 3H), 3.68 (s, 3H), 3.37 (s, 3H), 2.69–2.60 
(m, 4H), 2.43–2.35 (m, 1H), 2.30–2.05 (m, 8H), 1.76 (s, 4H), 1.67–1.60 (m, 2H), 1.59–
1.54 (m, 2H), 1.50–1.47 (m, 2H), 1.14–1.10 (m, 2H), 0.98 (d, J = 6.8 Hz, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ = 171.7, 169.2, 168.8, 159.0, 156.0, 140.8, 136.9, 135.7, 
134.7, 134.4, 134.3 133.8, 133.5 133.3, 132.4, 131.3, 131.0, 130.1, 129.8, 129.2, 118.9, 
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115.6, 113.7, 110.6, 103.3, 78.7, 77.5, 75.1, 69.6, 61.2, 56.4, 55.5, 55.2, 44.2, 39.2, 33.9, 
33.0, 30.1, 28.6, 25.4, 24.2, 22.1, 21.5, 18.8, 17.2, 11.0 ppm. 
FTIR (ATR): 3311 (w, br), 2936 (m), 2245 (w), 1724 (m), 1667 (m), 1529 (m), 1513 (s), 
1420 (m), 1171 (s), 1083 (s) cm−1. 
HRMS (CI): Calcd. for C49H65N2O9 (M+H+): 825.4690; Found: 825.4695. 
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Cytotrienin A Core (3.56) 
Indinylidene Grubbs-I derivative124 (18 mg, 0.02 mmol, 20 mol %) was added to a 
solution of bisdiene 3.55 (79 mg, 0.096 mmol, 100 mol %) in DCM (60 mL, 1.6 mM) at 
25 °C. The solution was then stirred at 40 °C under inert conditions in the dark. After 16 
h additional ruthenium precatalyst (9 mg, 0.01 mmol, 10 mol %) was added, the mixture 
was sparged with argon, and stirred for 3 h at 40 °C. The solvent was removed under 
reduced pressure.  The residue was purified by column chromatography (SiO2, 30–50% 
EtOAc/hexanes) furnished the Cytotrienin A Core 3.56 (33 mg, 0.041 mmol) 43% yield 
as a yellow oil. 
Rf = 0.22 (SiO2, EtOAc/hexanes = 1 : 1). 
[α]27
D= +51 (c = 1.00, CHCl3 90% ee). 
1H NMR (500 MHz, CDCl3): δ 8.19 (s, 1H), 7.84 (d, J = 3.1 Hz, 1H), 7.19–7.17 (m, 2H), 
6.85–6.83 (m, 2H), 6.59–6.56 (m, 1H), 6.38–6.31 (m, 1H), 6.33 (d, J = 3.1 Hz, 1H), 6.11 
(s, 1H), 6.03–5.98 (m, 2H), 5.55 (dd, J = 15.6 Hz, 5.5 Hz, 1H), 5.49–5.46 (m, 2H),  4.81 
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(td, J = 6.9 Hz, 3.0 Hz, 1H), 4.31 (d, J = 11.2 Hz, 1H), 4.15–4.12 (m, 1H), 4.00 (d, J = 
5.5 Hz, 1H), 3.97 (d, J = 11.2 Hz, 1H), 3.80 (s, 3H), 3.69 (s, 3H), 3.66 (s, 3H), 3.44 (s, 
3H), 2.85–2.80 (m, 1H), 2.75–2.70 (m, 1H), 2.50–2.44 (m, 1H), 2.39–2.33 (m, 1H), 2.24–
2.10 (m, 8H), 1.89–1.85 (m, 1H), 1.78 (d, J = 1.1 Hz, 3H), 1.66–1.63 (m, 3H), 1.59–1.57 
(m, 3H), 1.30–1.20 (m, 3H), 0.98 (d, J = 6.9 Hz, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ 171.1, 169.3, 168.2, 158.9, 155.7, 140.6, 134.8, 134.2, 
133.9, 133.5, 133.2, 133.0, 132.2, 131.0, 129.5, 129.3, 129.3, 129.2, 129.1, 113.7, 110.5, 
103.1, 77.9, 75.3, 74.8, 70.1, 61.0, 56.9, 55.4, 55.3 43.6, 39.7, 33.9, 32.5, 31.2, 28.8, 25.4, 
24.2, 22.1, 21.5, 19.3, 17.3, 17.1, 10.6 ppm. 
FTIR (ATR): 3346 (w, br), 2934 (m), 1724 (m), 1667 (m), 1613 (m), 1514 (s), 1465 (m), 
1247 (m), 1173 (s) cm−1. 
HRMS (ESI): Calcd. for C47H60N2O9Na (M+Na+): 819.4197; Found: 819.4187. 
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3.6 Spectra relevant to chapter 3 
 
 
Figure 3.1 1H NMR spectrum of compound 3.19 
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Figure 3.2 13C NMR spectrum of compound 3.19 
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Figure 3.3 Chiral HPLC data for compound 3.19  
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Figure 3.4 13C NMR spectrum of compound 3.20 
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Figure 3.5 13C NMR spectrum of compound 3.20    
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Figure 3.6 1H NMR spectrum of compound 3.21  
 152 
 
Figure 3.7 13C NMR spectrum of compound 3.21  
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Figure 3.8 1H NMR spectrum of compound 3.22  
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Figure 3.9 13C NMR spectrum of compound 3.22 
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Figure 3.10 1H NMR spectrum of compound 3.23 
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Figure 3.11 13C NMR spectrum of compound 3.23 
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Figure 3.12 1H NMR spectrum of compound 3.3 
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Figure 3.13 13C NMR spectrum of compound 3.3 
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Figure 3.14 1H NMR spectrum of compound 3.14 
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Figure 3.15 13C NMR spectrum of compound 3.14 
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Figure 3.16 Racemic GC data for compound 3.14 
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Figure 3.17 Chiral GC data for compound 3.14 
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Figure 3.18 1H NMR spectrum of compound 3.29 
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Figure 3.19 13C NMR spectrum of compound 3.29 
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Figure 3.20 1H NMR spectrum of compound 3.30 
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Figure 3.21 13C NMR spectrum of compound 3.30 
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Figure 3.22 Chiral GC data for compound 3.30 
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Figure 3.23 1H NMR spectrum of compound 3.12  
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Figure 3.24 13C NMR spectrum of compound 3.12 
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Figure 3.25 1H NMR spectrum of compound 3.16 
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Figure 3.26  13C NMR spectrum of compound 3.16 
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Figure 3.27 1H NMR spectrum of compound 3.31diol 
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Figure 3.28 13C NMR spectrum of compound 3.31diol 
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Figure 3.29 1H NMR spectrum of compound 3.31 
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Figure 3.30 13C NMR spectrum of compound 3.31 
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Figure 3.31 1H NMR spectrum of compound 3.32 
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Figure 3.32 13C NMR spectrum of compound 3.32 
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Figure 3.33  1H NMR spectrum of compound 3.34 
  
 179 
 
 
Figure 3.34 13C NMR spectrum of compound 3.34 
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Figure 3.35 1H NMR spectrum of compound 3.35 
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Figure 3.36 13C NMR spectrum of compound 3.35 
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Figure 3.37 1H NMR spectrum of compound 3.36 
 
  
 183 
 
Figure 3.38 13C NMR spectrum of compound 3.36 
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Figure 3.39 1H NMR spectrum of compound 3.37 
 185 
 
Figure 3.40 13C NMR spectrum of compound 3.37 
 186 
 
Figure 3.41 1H NMR spectrum of compound 3.38 
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Figure 3.42 13C NMR spectrum of compound 3.38 
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Figure 3.43 1H NMR spectrum of compound 3.39 
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Figure 3.44 13C NMR spectrum of compound 3.39 
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Figure 3.45 1H NMR spectrum of compound 3.40 
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Figure 3.46 13C NMR spectrum of compound 3.40 
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Figure 3.47 1H NMR spectrum of compound 3.41 
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Figure 3.48 13C NMR spectrum of compound 3.41 
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Figure 3.49 19F NMR spectrum of compound 3.41  
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Figure 3.50 1H NMR spectrum of cytotrienin A bis(diene) 3.55 
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Figure 3.51 13C NMR spectrum of cytotrienin A bis(diene) 3.55 
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Figure 3.52  1H NMR spectrum of cytotrienin A core 3.56 
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Figure 3.53 13C NMR spectrum of cytotrienin A core 3.56 
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4 SYNTHESIS OF TRIENOMYCIN A AND F 
4.1 Initial efforts toward trienomycin A  
After our synthetic studies on the C17-benzene ansamycins resulted in a synthesis 
of the cytotrienin A core 3.56, we recognized two areas in need of improvement. It would 
be ideal130 to use a syn-crotylation in the stereotriad construction, thus avoiding a 
Mitsunobu inversion to correct the C13 stereocenter after the C-C bond formation 
event.131 To this end, the second generation C17-benzene ansamycin synthesis would 
employ an enantioselective ruthenium-catalyzed alcohol CH-syn-crotylation89 for that 
purpose. The other modification would be in the endgame strategy. During our studies 
towards cytotrienin A (1.6a) we were able to construct all of the C-C bonds in the target 
natural product, but were unable to achieve the final deprotection. At the onset of the 
second generation route we also chose to change the target to trienomycin A (1.1a). This 
would allow us to evaluate the generality of our route toward the other members of this 
class of natural products and pursue a new protecting group strategy. 
 Our retrosynthetic analysis of trienomycin A (1.1a) would employ strategies and 
fragments from our previous routes that were effective. The pivotal bond disconnections 
were envisioned at the C11 side chain, a diene-diene RCM, and at the C1 amide 
providing two major fragments: alcohol 4.1 and acid 1.64 (Scheme 4.1). Since we did not 
know, which protecting group strategy would be required in the final steps of our route, 
we initially planned to install silyl ethers at the C13 and C22 hydroxyl groups. The 
stereotriad of fragment 4.1 could be constructed from adduct 4.2, through a 
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diastereoselective hydroboration to set the C11 stereochemistry, a Suzuki cross-coupling 
to diene 4.3 and a Fleming-Tamao oxidation.89 Further disconnection of adduct 4.2 
through a Suzuki reaction at C15-C16 would require access to nitro styrene 4.4 and vinyl 
bromide 4.5. Again, using a Suzuki disconnection nitro styrene 4.4 would be assembled 
from potassium ethenyltrifluoroborate salt 4.6 and aryl bromide 4.7. The keystone of this 
approach would be implementation of an enantioselective ruthenium-catalyzed alcohol 
CH-syn-crotylation, which we envisioned would construct alcohol 4.5 from vinyl 
bromide 3.15 and silyldiene 4.8. 
 
Scheme 4.1 Initial retrosynthesis for trienomycin A (1.1a) 
We first explored the coupling of vinyl bromide 3.15 with silyldiene 4.8 under 
conditions previously described for enantioselective ruthenium-catalyzed alcohol 
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CH-syn-crotylation (Scheme 4.2).89 Krische and co-workers previously demonstrated that 
the coupling of nerol 4.9 and silyldiene 4.8 to furnish alcohol 4.10 in moderate yield and 
in high selectivity. However, upon treatment of a mixture of bromide 3.15 with silyldiene 
4.8 under syn-selective reaction conditions the coupling product 4.5 was not observed. 
This lack of reactivity required us to pursue an alternate route to intermediate 4.2. 
 
Scheme 4.2 Unsuccessful application of ruthenium-catalyzed crotylation 
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4.1.1 REVISED ROUTE FOR INTERMEDIATE 4.2 
Undeterred by our initial failure, we revised our route to intermediate 4.2 by 
reordering the steps to access alcohol 4.11 (Scheme 4.3). With alcohol 4.11 we could 
determine if removing the bromide at C15 would permit the syn-crotylation to occur. Our 
initial investigation focused on developing a route to access 4.11 without a protecting 
group, at the C13 hydroxyl group. 
 
Scheme 4.3  Revised retrosynthesis of intermediate 4.2 
Bromination of nitro arene 4.12 followed by exposure to sulfuric acid and sodium 
nitrite furnished commercially available bromoarene 4.7 (Scheme 4.4). Suzuki 
cross-coupling of bromoarene 4.7 with potassium vinyltrifluoroborate 4.6 delivered nitro 
styrene 4.4 in 90% yield. With this route large quantities of nitro styrene 4.4 were 
accessible. Reaction of nitro styrene 4.4 with chlorotriisopropylsilane furnished TIPS 
ether 4.13 in 95% yield. Unfortunately, the one-pot hydroboration Suzuki cross-coupling 
of nitro sytrene 4.13 and vinyl bromide 3.15 or vinyl iodide 4.14 was a fruitless endeavor. 
Furthermore, model studies to hydroborate/cross-couple nitro sytrene 4.13 with simple 
alkenyl halides were not sucessful. We attributed the poor reactivity to the lability of the 
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TIPS ether under the reaction conditions, and subsequently considered other protecting 
groups for the phenolic hydroxyl group. 
 
Scheme 4.4 Efforts toward alcohol 4.11 
 Since it seemed that a C13 protecting group was necessary and that the C22 TIPS 
protection was ineffective in any cross-coupling, we revised our protecting group 
strategy. Using orthogonal protecting groups we would be able to investigate the 
cross-coupling and selectively deprotect the C13 hydroxyl to access our target 
intermediate. To that end, phenol 4.4 was treated with chloromethyl methyl ether to 
furnish MOM ether 4.15 (Scheme 4.5). Exposure of vinyl iodide 4.14 to 
tert-butyldimethylchlorosilane provided TBS ether 4.16. With both coupling partners in 
hand we would be able explore their union. 
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Scheme 4.5  Synthesis of intermediates 4.15 and 4.16 
We revisited the possibility of a direct coupling of nitro styrene 4.15 and vinyl 
iodide 4.14 at the beginning of our exploration of the Suzuki coupling (Scheme 4.6). 
Unfortunately, the desired coupling product was not detected. We changed our focus 
toward the cross-coupling of nitro styrene 4.15 and TBS ether 4.16. Using catalytic 
Pd(dppf)Cl2 allowed the desired adduct 4.17 to be isolated in 32% yield. Exploration of 
other catalyst/ligand systems led to the discovery that Pd(OAc)2 and Ru-Phos would 
deliver adduct 4.17 in 90% yield. Deprotection of the TBS ether with TBAF afforded the 
target alcohol 4.18 in 88% yield. 
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Scheme 4.6  Revised route to alcohol 4.18 
With alcohol 4.18 in hand, we set out to install the C12-C13 stereocenters using 
an enantioselective ruthenium-catalyzed alcohol CH-syn-crotylation. Exposure of 
alcohol 4.18 to silyldiene 4.8, catalytic RuHCl(CO)(PPh3)3, and a phosphine ligand 
furnished the alcohol 4.19 (Scheme 4.7). Unfortunately the reaction produced a mixture 
of products: including syn-anti diastereomers and products of Z to E isomerization (entry 
1). This was an unexpected result, as none of the prior examples of this transformation 
had such low diastereoselectivity. The alkene isomerization likely occurred from the 
intermediate aldehyde generated in the course of the reaction (Figure 2.6). An adjustment 
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of reaction solvent and chiral ligand furnished alcohol 4.19 in modest yield and 
selectivity (entry 4). The mixture of isomers was carried forward in the synthesis so that 
we could determine the viability of the current route to intermediate 4.1. 
 
Scheme 4.7 Application of ruthenium-catalyzed syn-crotylation 
 With alcohol 4.19 in hand, we set out to construct the C11-C13 stereotriad by 
utilizing a one-pot diastereoselective hydroboration Suzuki cross-coupling. To facilitate 
this transformation we chose to protect the C11 hydroxyl group of alcohol 4.19 as a 
MOM ether (Scheme 4.8). This would also play a role in our endgame strategy, as 
bis(MOM) protection might allow a single step deprotection in the final step under mild 
acidic conditions. Although we intended to hydroborate across the C11-C10 bond, NMR 
experiments indicated that the C14-C15 bond underwent hydroboration first. We were 
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unable to overcome this difference in chemoselectivity, consequently a revision of the 
route was required. 
 
Scheme 4.8 Unsuccessful diastereoselective hydroboration 
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4.2 Revised route for fragment 4.1 
Returning to a chelation strategy to set the C11 stereocenter, we sought to obtain 
4.1 through a chelation controlled addition of 3.44 to aldehyde 4.20 (Scheme 4.9). At this 
junction we were unsure, which protecting group on the C13 hydroxyl group would be 
optimal, or which group could be cleaved at the final stages of the synthesis. Several 
groups would need to be explored in the chelation controlled addition and subsequently 
tested in a model system to ensure cleavage would be possible. To that end, aldehyde 
4.20 would be accessed from alcohol 4.21, which in turn could be constructed from 
alcohol 4.18 and silyldiene 4.8. 
 
Scheme 4.9 Revised route to alcohol 4.1 
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 To begin our investigation of protecting groups at the C13 hydroxyl, we first 
effected a proto-desilylation of alcohol 4.19 with TBAF to furnish alcohol 4.21 
(Scheme 4.10). From alcohol 4.21 we were able to gain access to the protected aldehydes 
in three steps using a protection, dihydroxylation, oxidative cleavage sequence. We 
investigated how changes at the C13 position would affect yield and selectivity in the 
chelation controlled addition with allyltrimethylsilane. Our first choice was to evaluate an 
acid sensitive ether group, subsequently MOM ether 4.22 was isolated in modest yield 
and poor selectivity. Next we explored a silyl protecting group, and TES ether 4.23 was 
isolated in both low yield and selectivity. Our top two options for hydroxyl protecting 
group, with regards to ease of deprotection in the final steps, were unsuitable for the 
allylation reaction. Revisiting the PMB group we found that PMB ether 4.24 was isolated 
in both modest yield and high selectivity. Given our inability to deprotect the PMB ether 
in cytotrienin A, we were reluctant to forge ahead in the synthesis with a PMB ether in 
the C13 position. 
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Scheme 4.10 Investigation of the C13 protecting group 
Before committing to the PMB ether, we needed some assurance that it could be 
deprotected later in the synthesis by testing cleavage conditions on a similar system. 
After inspection of the chemical literature, we became aware of the difficulties associated 
with cleavage of PMB ethers in the presence of 1,3 dienes.132 Thus we investigated a 
model system and found that treatment of intermediate 3.54 with an excess of magnesium 
dibromide diethyl ether complex and dimethyl sulfide furnished alcohol 3.54a in 
50% yield (Scheme 4.11).133 With this result we were confident that a late stage PMB 
ether deprotection would be possible. 
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Scheme 4.11 Model system for cleavage of the C13 PMB ether 
 At this stage, we were using two separate steps for crotylation and 
proto-desilylation to access alcohol 4.21. In order to further streamline our synthetic route 
we sought to employ the one-pot crotylation-desilylation protocol (Table 4.1).89 Our 
initial investigation of the transformation of alcohol 4.18 under standard conditions 
afforded alcohol 4.21 in low selectivity and 48% yield (entry 1). An increase of the 
reaction time resulted in lower selectivity and yield (entry 2). Increasing the 
catalyst/ligand loading improved selectivity and the yield (entry 3-4). As observed in the 
previous experiments further increases in the reaction time did not provide additional 
benefits (entry 5). Due to the high cost of the ligand we continued to investigate 
conditions at 5 mol% catalyst/ligand loading. By changing the solvent and reaction time 
the desired product was isolated in high selectivity and modest yield (entry 7-9).   
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Table 4.1 Optimization of ruthenium-catalyzed syn-crotylation 
With a reliable method for the preparation of alcohol 4.21, three steps remained to 
install the stereotriad and diene. Protection of the C13 alcohol as PMB ether 4.25 
followed by oxidative cleavage of the terminal olefin using a modification of the 
Johnson-Lemieux protocol134 provided the aldehyde 4.26 in only seven steps from phenol 
4.7 (Scheme 4.12). Aldehyde 4.26 was exposed to (E)-trimethyl-2,4-pentadienylsilane 
3.44 in the presence of Me2AlCl to generate stereotriad 4.27 via chelation-controlled 
pentadienylation.113 Importantly, a short reaction time was necessary to obtain the 
stereotriad as a single isomer and in high yield. 
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Scheme 4.12 Synthesis of alcohol 4.27 
4.3 Final strategy for trienomycin A and F 
With a route in place to access alcohol 4.27, we were able to elaborate the side 
chain at C11 with a three step protocol. Accordingly, acylation of the C11 hydroxyl 
group of 4.27 with the symmetrical anhydride of FMOC-D-alanine to provide ester 4.28 
(Scheme 4.13). By introducing different acyl moieties at C11, compound 4.28 serves a 
common intermediate in the syntheses of trienomycin A and F and potentially other 
triene-containing C17-benzene ansamycins. Treatment of compound 4.28 with 
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piperidine, followed by the indicated acids permitted formation of amides 4.29a and 
4.29f. 
 
Scheme 4.13 Elaboration of the C11 side chain 
With fragment 4.29a in hand its union to acid fragment 1.64R (Scheme 4.14) was 
explored. As discussed in sections 2.2.2 and 3.2.2.3, there was an ambiguity in the 
literature regarding, which stereochemistry would be obtained from a chiral ligand 
modified catalyst. This led to the construction of acid 1.64R, which was used in several 
valuable experiments that ultimately culminated in the successful deprotection strategy. 
Attempted reduction of the nitro group of 4.29a with NaBH2S3121 provided a complex 
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mixture of compounds. One plausible explanation for this might be epimerization of the 
C28 methyl group under the reaction conditions. Browsing the chemical literature 
revealed an alternative reduction protocol employing mild conditions at room 
temperature.135 Accordingly, exposure of nitro arene 4.29a to an excess of zinc dust and 
ammonium formate provided an unstable aniline 4.30a, which was immediately coupled 
with acid 1.64R to furnish bis(diene) 4.31a in 65% yield over two steps. 
 
Scheme 4.14 Synthesis of bis(diene) 4.31a 
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With bis(diene) 4.31a in hand, the macrocyclization and ether deprotection were 
all that remained to complete the synthesis. Exposure of bis(diene) 4.31a to the 
indenylidene analogue of the first generation Grubbs’ metathesis catalyst124 provided 
macrocycle 4.32 in 10% yield as a mixture of compounds, with several other RCM 
products detected by LC/MS (Scheme 4.15). Nevertheless, the small amount of 
macrocycle 4.32 was subjected to conditions to deprotect the MOM and PMB ethers. 
Exposure of macrocycle 4.32 to conditions that had worked on a model system 
(Scheme 4.11) resulted only in decomposition. On a related system Smith and Wan 
reported conditions for a late stage deprotection of a MOM ether in their synthesis of 
thiazinotrienomycin E (Scheme 1.14).30 Fortunately, we were able to employ those acidic 
conditions to cleave the MOM ether and furnish alcohol 4.33. Unfortunately, subsequent 
experiments to deprotect the PMB ether were not successful. It appeared that the C13 
PMB ether could not be cleaved after the macrocyclization, and thus we would again 
revise the route to circumvent this issue. 
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Scheme 4.15 Initial macrocyclization and deprotection 
Since we were unable to cleave the C13 PMB ether at the end of the synthetic 
sequence, we intended to liberate the protecting group before cyclization and carryout the 
previously established plan. Exposure of the bis(diene) 4.31a to an excess of magnesium 
dibromide diethyl ether complex and methyl sulfide furnished two products in low yield: 
diol 4.34 and alcohol 4.35 (Scheme 4.16). It would be advantageous for the diene-diene 
RCM to be successful on diol 4.34 because it would allow the natural product to be 
formed directly without any additional protecting group manipulations. The minor 
 218 
product, alcohol 4.35 could also be subjected to the RCM, but this would require an 
additional step to remove the MOM ether. 
 
Scheme 4.16  Late stage deprotection of C11 PMB ether 
Diol 4.34 did not productively react in the diene-diene RCM with Grubbs I or 
Hoveyda-Grubbs I (Scheme 4.17). Only when the catalyst loading was increased above 
100 mol% was the starting material consumed. Fortunately, treatment of alcohol 4.35 
under RCM conditions did produce a mixture of compounds that was consistent with the 
desired triene 4.36. The desired triene macrocycle 4.36 was isolated in 10% yield or less 
despite changes in concentration, solvent, catalyst, and reaction temperature. The triene 
product required reverse phase HPLC to separate it from the myriad of products produced 
in the RCM. After deprotection and reverse-phase HPLC separation, none of the isolated 
products were consistent with the reported proton NMR spectra of trienomycin A (1.1a).  
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Scheme 4.17 Studies toward macrocyclization and deprotection 
We were able to trace this problem to an incorrectly established stereocenter at 
the C3 position (section 3.2.2.3) and corrected the problem by synthesizing acid 1.64 
with the correct chiral ligand. Despite the epi-C3 stereocenter, we were able to access the 
final product in low yield. To improve the yield of the final steps, we would revise the 
route again and attempt to access trienomycin A (1.1a) in higher yield. 
To selectively cleave the C13 PMB ether without affecting the diene moieties or 
MOM ether, we chose to deprotect intermediates 4.29a and 4.29f (Scheme 4.18). Based 
on the poor results obtained from PMB cleavage of bis(diene) 4.31a (Scheme 4.16), our 
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rationale was that it might be more likely to achieve a selective ether cleavage before the 
nitro reduction. On these substrates cleavage of the PMB ethers was often accompanied 
with decomposition. To address this issue, we turned to the chemical literature for insight 
and found that 1,3-dimethoxybenzene136 was known to act as a scavenger of reactive 
intermediates in various PMB ether deprotections. Fortunately, the use of 
1,3-dimethoxybenzene in our system allowed us to obtain 4.37a and 4.37f in good yields. 
Subsequent reduction of the C20 nitro moieties and acylation of the resulting anilines 
with acid 1.64 provided the bis(diene) 4.38a and 4.38f. 
 
Scheme 4.18 Synthesis of bis(diene) 4.38a and 4.38f 
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Finally, diene-diene RCM to form the triene was explored using Grubbs’ first 
generation catalysts and the Grubbs-Hoveyda-I catalyst. Ring-closing metathesis of 4.38a 
and 4.38f occurred to form a complex mixture of macrocylic products. The indenylidene 
analogue of the first generation Grubbs’ metathesis catalyst,124 again was more selective 
for triene formation (Scheme 4.19). In addition to the low yield for the RCM, the 
subsequent MOM ether cleavage also required HPLC separation to furnish purified 
natural products in low yield. To circumvent the low yield and poor recovery observed in 
prior RCM experiments (Scheme 4.17), the RCM reactions were monitored by LC/MS, 
and the mixture of macrocycles was used directly in the next reaction. The crude mixture 
was treated with HCl to cleave the MOM ether, and one final reverse phase HPLC 
purification was performed, thus enabling the 16 step (LLS) total syntheses of 
trienomycin A and F. This sequence is 14 steps (LLS) shorter than the prior syntheses of 
trienomycin A and F, and eight steps (LLS) shorter than any prior synthesis of a 
triene-containing C17-benzene ansamycin. 
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Scheme 4.19 Synthesis of trienomycin A and F 
4.4 Conclusions 
By applying C-C bond forming hydrogenation methods, concise syntheses of 
C17-benzene ansamycins trienomycin A and F were completed. Throughout our 
synthetic efforts, several key challenges had to be overcome. First, the synthetic route 
necessitated the expansion of substrate scope for use of this methodology. During the 
course of our work we found some substrates that contain -chiral centers or (Z)-olefins 
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might be unsuitable for the hydrogenation methodology. Second, scalability is possible 
but the high cost and loadings of chiral ligands were a hindrance during scale up. As the 
cost of chiral ligands comes down and more efficient catalyst systems are developed 
these methodologies will find greater use. 
The success of the final strategy hinged upon three critical observations: (1) the 
importance of a scavenger in the PMB cleavage, (2) the protocol developed for the RCM, 
and (3) the Mosher ester study that indicated the C3 stereocenter was incorrectly set. 
With these advances the synthesis came to a successful end. Although we were able to 
fruitfully employ the diene-diene RCM, it proved to be highly substrate specific and 
analogue synthesis should be approached with caution.  
In summary, with the exception of eribulin, a truncated derivative of 
halichondrin,137,138,139 all FDA approved polyketides are prepared through fermentation or 
semi-synthesis, as current synthetic methods cannot concisely address the preparation of 
such complex structures. Accordingly, the Krische laboratory has devised a suite of 
catalytic methods for polyketide construction wherein the addition or exchange of 
hydrogen is accompanied by C-C bond formation.48,84,85 As illustrated by the present total 
syntheses of trienomycin A and F,140 application of this technology has availed the most 
concise route to any member of this polyketide natural product family.  
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4.5 Experimental  
General Methods 
All reactions were run under an atmosphere of argon under anhydrous conditions unless 
otherwise indicated. Dichloromethane (DCM), 1,2-dichloroethane (DCE), 
tetrahydrofuran (THF), and toluene (PhMe) were obtained from a Pure-Solv MD-5 
Solvent Purification System (Innovative Technology, inc). Anhydrous solvents were 
transferred using oven-dried syringes. All other commercial reagents were used directly 
without further purification. Analytical thin-layer chromatography (TLC) was carried out 
using 0.2-mm commercial silica gel plates (DC-Fertigplatten Kieselgel 60 F254). 
Visualization of the chromatograms was accomplished using UV light and vanillin, 
anisaldehyde, permanganate, or cerium molybdate stain with heating. Preparative column 
chromatography using silica gel was performed according to the method of Still.  Infrared 
spectra were recorded on a Nicolet 380 FTIR. Analytical high performance liquid 
chromatography (HPLC) spectra were obtained using an Agilent Technologies 1200 
series HPLC. Analytical Gas Chromatography (GC) spectra were obtained using an 
Agilent Technologies 7890A GC system. High-resolution mass spectra (HRMS) were 
obtained on a Waters Micromass Autospec or a Varian FTICR as m/z (relative intensity). 
Accurate masses are reported for the molecular ion (M+1, M or M–1) or a suitable 
fragment ion. Melting points were obtained on a Stuart® melting point apparatus SMP3. 
Proton nuclear magnetic resonance spectra (1H NMR) were recorded with a Varian 
spectrometer (400 MHz or 500 MHz) and reported in parts per million (ppm) referenced 
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to the residual protio solvent signal as an internal standard. Coupling constants are 
reported in hertz (Hz). Carbon nuclear magnetic resonance spectra (13C NMR) were 
recorded with a Varian spectrometer (100 MHz or 125 MHz) and reported in parts per 
million (ppm) referenced to the residual solvent signal as an internal standard. Optical 
rotations were measured on an ATAGO AP-300 automatic polarimeter at a path length of 
1 dm. 
 
 
 
3-nitro-5-vinylphenol 
A solution of potassium carbonate (38 g, 280 mmol), water (100 mL) was added to a 
solution of 3-bromo-5-nitrophenol (20 g, 92 mmol), triphenylphosphine (0.72 g, 2.8 
mmol), potassium vinyltrifluoroborate (12.3 g, 92 mmol), PdCl2(PPh3)2 (0.64 g, 0.92 
mmol), tetrahydrofuran (200 mL, 0.5 M) under an atmosphere of argon. The reaction 
vessel was sealed with a screw cap and heated at 100 C for 16 h. The resulting solution 
was cooled to ambient temperature, added to a separatory funnel containing saturated 
solution of NH4Cl (100 mL) and brine (200 mL). The resulting mixture was extracted 
with ethyl acetate (3 x 75 mL). The combined organic extracts were dried over sodium 
sulfate, filtered, concentrated under reduced pressure, and purified via column 
chromatography (SiO2, 10% to 30% ethyl acetate/hexanes, gradient elution) to give the 
title compound 4.4 (13.7 g, 82.8 mmol, 90% yield) as a yellow solid. 
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Rf (SiO2, hexanes/EtOAc = 2 : 1) = 0.3. 
1H NMR (400 MHz; acetone-d6):   δ  9.37 (brs, 1H), 7.80 (s, 1H), 7.56 (s, 1H), 7.34 (s, 
1H), 6.82 (dd, J = 17.6, 10.9, 1H), 5.97 (d, J = 17.6, 1H), 5.42 (d, J = 10.9, 1H) ppm. 
13C NMR (100 MHz, acetone-d6):   δ   159.1,   150.5,   141.2,   136.0,   119.9,   117.3,   112.9,  
110.0 ppm. 
FTIR (Neat): λ−1 = 3429, 3093, 1618, 1512, 1477, 1344, 1277, 1208, 1159 cm−1. 
MS (CI): Calcd. for C8H8NO3 (M+H): 166; Found: 166. 
MP: 64-65 C. 
 
 
  
triisopropyl(3-nitro-5-vinylphenoxy)silane (4.13) 
Triisopropylsilyl chloride (4.3 mL, 20 mmol) was added at 25 C to a mixture of phenol 
4.4 (3.0g, 18 mmol), imidazole (3.1g, 45 mmol), and dichloromethane (30 mL). The 
resulting mixture was stirred at ambient temperature for 16 h, filtered, concentrated under 
reduced pressure, and purified via column chromatography (SiO2, 10% ethyl 
acetate/hexanes) to give the title compound 4.13 (5.57 g, 17.1 mmol, 95% yield) as a 
yellow oil 
1H NMR (400 MHz, CDCl3): δ  7.85   (s,  1H),  7.65   (s,  1H),  7.11   (s,  1H),  6.77   (dd, J = 
17.5, 10.9, 1H), 5.85 (d, J = 17.5, 1H), 5.39 (d, J = 10.9, 1H), 1.31 (m, 3H), 1.12 (s, 18H) 
ppm. 
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13C NMR (100 MHz, CDCl3):  δ  157.1, 140.2, 135.1, 123.8, 114.0, 113.9, 18.1, 12.9 ppm. 
FTIR (Neat): λ−1 = 3429, 3093, 1618, 1512, 1477, 1344, 1277, 1208, 1159 cm−1. 
HRMS (CI): Calcd. for C17H28NO3Si (M+H): 322.1838; Found: 322.1839. 
 
 
 
1-(methoxymethoxy)-3-nitro-5-vinylbenzene (4.15) 
A solution of chloromethyl methyl ether (81 mL, 170 mmol, 2.1 M toluene) was added at 
ambient temperature to a solution of 3-nitro-5-vinylphenol 4.4  (14.0 g, 84.8 mmol) and 
diethyl ether (30 mL). The resulting solution was cooled to 0 C and 
diisopropylethylamine (22 mL, 130 mmol) was added slowly, warmed to ambient 
temperature and stirred 14 h. The resulting mixture was added to a separatory funnel 
containing NaHCO3 (100 mL) and organic layer was separated. The aqueous layer was 
extracted with ether (2 x 30 mL), the organic extracts were combined, dried over 
magnesium sulfate, filtered, and concentrated under reduced pressure. The crude reside 
was purified via column chromatography (SiO2, 6% to 33% ethyl acetate/hexanes, 
gradient elution) to give the title compound 4.15 (17.5 g, 84.0 mmol, 99% yield) as a 
yellow oil. 
Rf (SiO2, hexanes/EtOAc = 9 : 1) = 0.54. 
 228 
1H NMR (400 MHz, CDCl3): δ  7.85   (s,  1H),  7.72   (s,  1H),  7.31   (s,  1H),  6.67   (dd, J = 
17.5, 10.9, 1H), 5.83 (d, J = 17.5, 1H), 5.39 (d, J = 10.9, 1H), 5.21 (s, 2H), 3.46 (s, 3H) 
ppm. 
13C NMR (100 MHz, CDCl3):  δ  157.8,  149.3,  140.1,  134.7,  120.1,  117.2,  114.3,  110.0,  
94.5, 56.3 ppm. 
FTIR (Neat): λ−1 =2958, 1617, 1515, 1347, 1270, 1149 cm−1. 
MS (CI): Calcd. for C10H12NO4 (M+H): 210; Found: 210. 
 
 
(Z)-3-iodo-2-methylprop-2-en-1-ol (4.14) 
According to a literature procedure:141 propargyl alcohol (5.2 mL, 90 mmol) was added 
to a solution of copper iodide (1.7 g, 9.0 mmol) and tetrahydrofuran (90 mL, 1.0 M) 
under N2, at 20 C. A solution of methylmagnesium bromide (66 mL, 200 mmol, 3 M 
diethyl ether) was added slowly. After the addition was complete the reaction vessel was 
warmed to 10 C and the solution was stirred for 30 min. A solution of Iodine (22.9 g, 
90.0 mmol), diethyl ether (20 mL), and tetrahydrafuran (20 mL) was added to the 
reaction mixture and the cooling bath was removed. The resulting mixture was added to a 
separatory funnel containing saturated NH4Cl (100 mL) and brine (100 mL), extracted 
with diethyl ether (3 x 50 mL). The combined organic extracts were dried with 
magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was 
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purified by column chromatography (SiO2, 10–50% DCM/hexanes, gradient elution) to 
furnish the title compound (13.5 g, 68.2 mmol, 75% yield) as a light yellow oil. The 
spectral data for the title compound were consistent with reported values.2 
1H NMR (400 MHz, CDCl3): δ 5.96 (s, 1H), 4.22 (s, 2H), 1.95 (s, 3H) ppm. 
13C NMR (100 MHz, CDCl3):  δ  145.8,  74.7,  67.8,  21.4  ppm. 
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(Z)-tert-butyl(3-iodo-2-methylallyloxy)dimethylsilane (4.16) 
tert-Butyldimethylsilyl chloride was added (11.3 g, 75.0 mmol) to a solution of (Z)-3-
iodo-2-methylprop-2-en-1-ol (13.5 g, 68.2 mmol), imidazole (5.11 g, 75.0 mmol), and 
dichloromethane (120 mL, 0.57 M)  under an atmosphere of N2 at 0 C. The cooling bath 
was removed and the reaction was stirred for 16 h at ambient temperature. The resulting 
mixture was filtered, concentrated, and purified via column chromatography (SiO2, 
18:1:1 to 9:1:1 hexanes-dichloromethane-ethyl acetate, gradient elution) to furnish the 
title compound 4.16 (20.3 g, 65.0 mmol, 95% yield) as a light yellow oil. The spectral 
data for the title compound were consistent with reported values.142 
1H NMR (400 MHz, CDCl3): δ 5.85 (s, 1H), 4.24 (s, 2H), 1.90 (s, 3H) 0.91 (s, 9H), 0.09 
(s, 6H) ppm. 
13C NMR (100 MHz, CDCl3):  δ  146.5,  72.3,  68.5,  25.7,  21.3,  18.8,  -5.4 ppm. 
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 (Z)-tert-butyl(5-(3-(methoxymethoxy)-5-nitrophenyl)-2-methylpent-2-
enyloxy)dimethylsilane (4.17) 
1-(methoxymethoxy)-3-nitro-5-vinylbenzene  4.15 (4.0g, 19 mmol), tetrahydrofuran (50 
mL), and 9-borabicyclo[3.3.1]nonane (3.0 g, 24 mmol) were combined under N2 and 
stirred at ambient temperature overnight. The resulting solution was cooled to 0 C and 
solution of caesium carbonate (31 g, 96 mmol) and water (30 mL) was added, followed 
by a solution of Pd(OAc)2 (180 mg, 0.80 mmol), 2-Dicyclohexylphosphino-2′,6′-
diisopropoxybiphenyl (450 mg, 0.96 mmol), and tetrahydrofuran (50 mL). To the 
resulting mixture a solution of (Z)-tert-butyl(3-iodo-2-methylallyloxy)dimethylsilane 3 
(5.0 g, 16 mmol) and tetrahydrofuran (30 mL, 0.12 M). The cooling bath was removed 
and reaction mixture was stirred for 14 h. The reaction mixture was added to a separatory 
funnel containing NH4Cl (100 mL), water (200 ml), and extracted with ethyl acetate (3 x 
100 mL). The combined organic extracts were dried with sodium sulfate, filtered, 
concentrated under reduced pressure, and purified via column chromatography (SiO2, 
18:1:1 to 9:1:1 hexanes-dichloromethane-ethyl acetate, gradient elution) to give the title 
compound 4.17 (5.6g, 14 mmol, 90% yield) as a dark brown oil. 
Rf (SiO2, hexanes/EtOAc = 5 : 1) = 0.54. 
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1H NMR (400 MHz, CDCl3): δ  7.72   (s,   1H),  7.70   (s,  1H),  7.15   (s,  1H),  5.25-5.12 (m, 
3H), 4.04 (s, 2H), 3.49 (s, 3H), 2.70 (t, J = 7.7, 2H), 2.37 (q, J = 7.4, 2H), 1.73 (s, 3H), 
0.88 (s, 9H), 0.04 (s, 6H) ppm. 
13C NMR (100 MHz, CDCl3):   δ  157.7,   145.0,  136.6,  124.4,  122.9,  116.9,  108.8,  94.6,  
61.8, 56.3, 36.0, 29.0, 26.0, 21.2, 18.4, -5.2 ppm. 
FTIR (Neat): λ−1 = 2928, 2855, 1748, 1532, 1450, 1349, 1268, 1251, 1216, 1149, 1076, 
1018 cm−1. 
MS (CI) Calcd. for C20H33NO5Si (M-): 395; Found: 395. 
 
 
 
(Z)-5-(3-(methoxymethoxy)-5-nitrophenyl)-2-methylpent-2-en-1-ol (4.18) 
Tetra-n-butylammonium fluoride (31 mL, 31 mmol, 1 M tetrahydrofuran) was added to a  
solution of (Z)-tert-butyl(5-(3-(methoxymethoxy)-5-nitrophenyl)-2-methylpent-2-
enyloxy)dimethylsilane (11.0 g, 27.8 mmol) and tetrahydrofuran (150 ml, 0.15 M) under 
N2 at 0 C, the cooling bath was removed and the reaction mixture was stirred for 1.5 h. 
NH4Cl (100 mL) and Brine (150 mL) were added to the reaction mixture. The resulting 
mixture was extracted with diethyl ether (3 x 100 mL), the organic extracts were 
combined, dried with magnesium sulfate, filtered, and concentrated under reduced 
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pressure. The crude residue was purified via column chromatography (SiO2, 10% to 30% 
ethyl acetate/hexanes, gradient elution) to give the title compound 4.18 (6.90 g, 24.5 
mmol, 88% yield) as a light brown solid. 
Rf (SiO2, hexanes/EtOAc = 3 : 1) = 0.2. 
1H NMR (400 MHz, CDCl3): δ  7.72  (t, J = 2.2, 1H), 7.69 (s, 1H), 7.16 (s, 1H), 5.30 (t, J 
= 7.3, 1H), 5.22 (s, 2H), 4.04 (s, 2H), 3.49 (s, 3H), 2.73 (t, J = 7.5, 2H), 2.41 (q, J = 7.4, 
2H), 1.79 (s, 3H) ppm. 
13C NMR (100 MHz, CDCl3):  δ  157.5,  149.1,  144.8,  136.1,  126.2,  122.8,  116.9,  108.9,  
94.5, 61.4, 56.4, 35.9, 28.8, 21.3 ppm. 
FTIR (Neat): λ−1 = 3332, 2968, 2937, 1738, 1582, 1536, 1454, 1344, 1267, 1151, 1086, 
1002 cm−1. 
MS (CI): Calcd. for C14H19NO5 (M-): 281; Found: 281. 
MP: 35-36 C. 
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(3R,4R,Z)-2-(dimethyl(phenyl)silyl)-8-(3-(methoxymethoxy)-5-nitrophenyl)-3,5-
dimethylocta-1,5-dien-4-ol (4.19) 
In a screw cap vial ethyl acetate (1.0 mL, 2.1M) and 2-(dimethyl(phenyl)silyl)-1,3-
butadiene143 (1.0 g, 5.3 mmol) were added to (Z)-5-(3-(methoxymethoxy)-5-nitrophenyl)-
2-methylpent-2-en-1-ol 4 (600 mg, 2.1 mmol), (R)-(+)-5,5′−Βis[di(3,5-xylyl)phosphino]-
4,4′-bi-1,3-benzodioxole (77 mg, 0.107 mmol), and RuHCl(CO)(PPh3)3144 (102 mg, 
0.107) under and atmosphere of argon. The reaction vessel was sealed with a screw cap 
and heated at 95 C for 16 h.. After cooling to ambient temperature, the resulting mixture 
concentrated under reduced pressure, and purified via column chromatography (SiO2, 5% 
to 15% ethyl acetate/hexanes, gradient elution) to give the title compound 4.19 (550 mg, 
1.1 mmol, 55% combined yield) with a diastereomeric ratio of 12:1 (syn:anti) and a 7:1 
(Z:E) mixture of alkene isomers as a yellow oil. . The stereochemical assignment was 
inferred based on analogy with the literature precedent.89 
Rf (SiO2, hexanes/EtOAc = 4 : 1) = 0.55. 
[α]24
D= 38 (c = 1.10, CHCl3). 
1H NMR (400 MHz, CDCl3): δ 7.72 (t, J = 2.2, 1H), 7.67 (s, 1H), 7.50-7.48 (m, 2H), 
7.35-7.29 (m, 3H), 7.15 (s, 1H), 5.81 (d, J = 1.3, 1H), 5.61 (d, J = 2.2, 1H), 5.22 (s, 2H), 
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5.11-5.08 (m, 1H), 4.30 (d, J = 6.6, 1H), 3.49 (s, 3H), 2.72-2.59 (m, 2H), 2.57-2.47 (m, 
1H), 2.31-2.19 (m, 3H), 1.53 (s, 3H), 1.03 (d, J = 6.9, 3H), 0.39 (s, 6H) ppm. 
13C NMR (100 MHz, CDCl3):  δ  157.6, 153.3, 149.2, 145.1, 137.9, 137.6, 134.1, 129.3, 
127.9, 127.3, 125.9, 122.8, 117.0, 109.0, 94.6, 72.5, 56.5, 41.8, 35.9, 28.9, 19.5, 
16.6, -2.3, -2.5 ppm. 
FTIR (Neat): λ−1 = 3468, 2958, 1530, 1451, 1349, 1268, 1149, 1011 cm−1. 
MS (CI) Calcd. for C26H35NO5Si: 469; Found: 469. 
 
 
 
(3S,4R,Z)-8-(3-(methoxymethoxy)-5-nitrophenyl)-3,5-dimethylocta-1,5-dien-4-ol 
(4.21) 
In a screw cap vial ethyl acetate (1.0 mL, 2.1M) and 2-(dimethyl(phenyl)silyl)-1,3-
butadiene143 (1.2 g, 6.3 mmol) were added to (Z)-5-(3-(methoxymethoxy)-5-nitrophenyl)-
2-methylpent-2-en-1-ol 4 (600 mg, 2.1 mmol), (R)-(+)-5,5′−Βis[di(3,5-xylyl)phosphino]-
4,4′-bi-1,3-benzodioxole (108 mg, 0.150 mmol), and RuHCl(CO)(PPh3)3144 (142 mg, 
0.150) under and atmosphere of argon. The reaction vessel was sealed with a screw cap 
and heated at 95 C for 16 h. After cooling to ambient temperature, dimethyl sulfoxide (1 
mL) and tetra-n-butylammonium fluoride (6.3 mL, 6.3 mmol, 1 M in tetrahydrofuran) 
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were added. The reaction vessel was sealed with a screw cap and heated at 80 C for 3 h. 
After cooling to ambient temperature, the resulting mixture was added to a separatory 
funnel containing NH4Cl (20mL) and extracted with ethyl acetate (3 x 10 mL). The 
combined organic extracts were dried with sodium sulfate, filtered, concentrated under 
reduced pressure, and purified via column chromatography (SiO2, 5% to 25% ethyl 
acetate/hexanes, gradient elution) to give the title compound 4.21 (460 mg, 1.3 mmol, 
64% combined yield) with a diastereomeric ratio of 9:1 (syn:anti) and a 7:1 (Z:E) mixture 
of alkene isomers as a yellow oil. The stereochemical assignment was inferred based on 
analogy with the literature precedent.89 
Rf (SiO2, hexanes/EtOAc = 4 : 1) = 0.25. 
[α]24
D= 158 (c = 1.50, CHCl3). 
1H NMR (400 MHz, CDCl3): δ  7.71  (s,  1H),  7.69  (s,  1H),  7.16  (s,  1H),  5.56  (ddd, J = 
17.4, 10.2, 7.4, 1H), 5.23 (d, J = 13.7, 3H), 5.02 (d, J = 17.2, 1H), 4.95 (d, J = 10.4, 1H), 
4.17 (d, J = 8.8, 1H), 3.49 (s, 3H), 2.72 (q, J = 6.9, 3H), 2.44-2.33 (m, 3H), 1.69 (s, 3H), 
1.11 (d, J = 6.6, 3H) ppm. 
13C NMR (100 MHz, CDCl3):  δ  157.7,  149.2,  144.9,  140.0,  137.3,  126.9,  122.8,  117.0,  
114.7, 109.0, 94.6, 73.7, 56.5, 41.8, 35.9, 28.7, 18.2, 16.3 ppm. 
FTIR (Neat): λ−1 = 3468, 2958, 1530, 1451, 1349, 1268, 1149, 1011 cm−1. 
MS (CI) Calcd. for C18H25NO5: 335; Found: 335. 
HPLC (Chiralcel OJ–H, OJ–H, OJ–H column, 10-30% i-PrOH/hexanes, gradient elution 
0-15 min, 0.5 mL/min, 280 nm):  tminor = 33.96 min, tmajor = 34.75 min; ee = 90%. 
 
 237 
  
 238 
 
1-((5R,6S,Z)-5-(4-methoxybenzyloxy)-4,6-dimethylocta-3,7-dienyl)-3-
(methoxymethoxy)-5-nitrobenzene (4.24) 
Sodium hydride (720 mg, 18 mmol) was added to a mixture of (3S,4R,Z)-8-(3-
(methoxymethoxy)-5-nitrophenyl)-3,5-dimethylocta-1,5-dien-4-ol 6 (1.2 g, 3.6 mmol), 
dimethyl sulfoxide (5 mL), tetrahydrofuran (20 mL, 0.14 M), tetra-n-butylammonium 
iodide (130 mg, 0.35 mmol), and 4-methoxybenzyl chloride (1.7 g, 11 mmol) under an 
atmosphere of nitrogen. The cooling bath was removed and the mixture was stirred for 3 
h. The reaction mixture was added to NH4Cl (50 mL), extracted with ethyl acetate (3 x 25 
mL), the combined organic extracts were washed with brine (10 mL), and concentrated 
onto SiO2 under reduced pressure. The crude reside was purified via column 
chromatography (SiO2, 5% to 20% ethyl acetate/hexanes, gradient elution) to give the 
title compound 4.24 (1.4 g, 3.1 mmol, 87% yield) as a yellow oil.  
Rf = (SiO2, hexanes/EtOAc = 9 : 1) = 0.5. 
[α]24
D= 21 (c = 1.0, CHCl3). 
 
1H NMR (400 MHz, CDCl3):  δ  7.71  (t, J = 2.2, 1H), 7.68 (t, J = 1.7, 1H), 7.22-7.20 (m, 
2H), 7.13 (t, J = 1.8, 1H), 6.88-6.86 (m, 2H), 5.52 (ddd, J = 17.3, 10.3, 7.6, 1H), 5.43 (t, J 
= 7.1, 1H), 5.20 (s, 2H), 4.99 (d, J = 17.2, 1H), 4.90 (d, J = 11.2, 1H), 4.32 (d, J = 11.5, 
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1H), 4.03 (d, J = 11.5, 1H), 3.80 (s, 3H), 3.48 (s, 3H), 2.76-2.63 (m, 2H), 2.45-2.23 (m, 
4H), 1.67 (s, 3H), 1.13 (d, J = 6.6, 3H) ppm. 
13C NMR (125 MHz, CDCl3):  δ  159.1,  157.6,  149.1,  144.9,  140.0,  135.0,  130.8,  129.2,  
128.8, 123.0, 116.8, 114.2, 113.7, 108.6, 94.5, 79.9, 69.4, 56.3, 55.2, 40.6, 36.0, 28.9, 
18.1, 17.0 ppm. 
FTIR (Neat): λ−1 = 2958, 1612, 1584, 1530, 1512, 1452, 1349, 1246, 1149, 1077, 1030, 
1013 cm−1. 
HRMS (CI): Calc for C26H33NO6 (M): 455.2308; Found 455.2308. 
 
 
 
2R,3R,Z)-3-(4-methoxybenzyloxy)-7-(3-(methoxymethoxy)-5-nitrophenyl)-2,4-
dimethylhept-4-enal (4.26 ) 
1-((5R,6S,Z)-5-(4-methoxybenzyloxy)-4,6-dimethylocta-3,7-dienyl)-3-
(methoxymethoxy)-5-nitrobenzene (405 mg, 0.89 mmol), dioxane (15 mL, 0.06 M), and 
water (5 mL) were combined and vigorously stirred at ambient temperature. 2,6Lutidine 
(0.20 mL, 1.8 mmol), and osmium tetratoxide (1.8 mL, 0.036 mmol, 0.02 M tert-butanol) 
were added, followed by sodium periodate (570 mg, 2.7 mmol). The resulting mixture 
was vigorously stirred at ambient temperature for 17.5 h, filtered, extracted with 
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dichloromethane (3 x 20 mL), and the combined organic extracts were concentrated 
under reduced pressure (water bath under 20C). The crude reside was purified via 
column chromatography (SiO2, 1:1 dichloromethane/hexanes) to give the title compound 
4.26 (310 mg, 0.69 mmol, 77% yield) as a yellow oil. 
Rf (SiO2, hexanes/EtOAc = 4: 1) = 0.5. 
[α]23
D= 28 (c = 1.0, CHCl3). 
1H NMR (400 MHz; acetone-d6):  δ  9.53  (s,  1H),  7.74  (t, J = 1.6, 1H), 7.68 (t, J = 2.2, 
1H), 7.32 (t, J = 1.7, 1H), 7.20 (d, J = 8.8, 2H), 6.88 (d, J = 8.7, 2H), 5.59 (t, J = 7.1, 1H), 
5.29 (s, 3H), 4.45 (d, J = 8.0, 1H), 4.27 (d, J = 11.4, 1H), 4.07 (d, J = 11.4, 1H), 3.77 (s, 
3H), 3.44 (s, 3H), 2.67-2.62 (m, 1H), 2.53 (dd, J = 15.1, 7.8, 1H), 2.38 (q, J = 9.4, 1H), 
1.71 (s, 3H), 1.07 (d, J = 6.8, 3H) ppm. 
13C NMR (100 MHz, acetone-d6): δ   203.0, 160.0, 158.5, 149.8, 146.0, 134.5, 131.2, 
130.6, 129.8, 123.9, 117.3, 114.2, 108.9, 95.2, 76.6, 69.9, 56.2, 55.3, 50.3, 36.0, 29.5, 
18.6, 10.6 ppm. 
FTIR (Neat): λ−1 = 2936, 1723, 1530, 1513, 1452, 1302, 1246, 1149, 1079, 1029, 1013 
cm−1. 
MS (CI): Calcd. for C25H30NO7 (M-H): 456; Found: 456. 
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(3E,6S,7S,8R,9Z)-8-(4-methoxybenzyloxy)-12-(3-(methoxymethoxy)-5-nitrophenyl)-
7,9-dimethyldodeca-1,3,9-trien-6-ol (4.27) 
Dimethyl aluminium chloride (2.1 mL, 2.1 mmol, 1 M hexanes) was added to a solution 
of intermediate 4.26 (380 mg, 0.83 mmol) in dichloromethane (12 mL, 0.07 M) under an 
atmosphere of N2 at 78 C. After 2 min (E)-trimethyl(penta-2,4-dien-1-yl)silane (174 
mg, 1.25 mmol) was added to the orange solution. The resulting mixture was stirred for 5 
min at 78 C. Methanol (1 mL) was added to the reaction mixture, followed by a 10% 
citric acid solution (5 mL) and a 10% dipotassium phosphate solution (10 mL). The 
reaction mixture was warmed to ambient temperature, added to a separatory funnel, and 
extracted with chloroform (2 x 25 mL). The combined organic extracts were dried with 
sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was 
purified via column chromatography (SiO2, 1:1:8 to 1:1:3 dichloromethane/diethyl 
ether/hexanes, gradient elution) to give the title compound 4.27 (340 mg, 0.65 mmol, 
78% yield) with a diastereomeric ratio of >20:1 as a light yellow oil. The stereochemical 
assignment was inferred based on analogy with the literature precedent.113  
Rf (SiO2, hexanes/EtOAc = 4 : 1) = 0.4. 
[α]23
D= 34.6 (c = 1.00, CHCl3). 
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1H NMR (600 MHz, CDCl3): δ  7.71  (t, J = 2.2, 1H), 7.68 (t, J = 1.6, 1H), 7.19 (d, J = 
8.6, 2H), 7.14 (t, J = 1.8, 1H), 6.87 (d, J = 8.6, 2H), 6.29 (dt, J = 16.9, 10.3, 1H), 6.05 
(dd, J = 15.3, 10.4, 1H), 5.66 (dt, J = 15.0, 7.4, 1H), 5.44 (t, J = 7.2, 1H), 5.20 (s, 2H), 
5.08 (d, J = 16.9, 1H), 4.97 (d, J = 10.3, 1H), 4.32 (d, J = 11.4, 1H), 4.26 (d, J = 5.3, 1H), 
4.02 (d, J = 11.4, 1H), 3.79 (s, 3H), 3.54 (quintet, J = 5.8, 1H), 3.47 (s, 3H), 2.77-2.67 
(m, 3H), 2.42 (dq, J = 15.1, 7.6, 1H), 2.33-2.28 (m, 1H), 2.16 (t, J = 6.7, 2H), 1.76 (s, 
4H), 0.97 (d, J = 7.0, 3H) ppm. 
13C NMR (150 MHz, CDCl3):  δ  159.3,  157.6,  149.1,  144.7,  136.9,  135.7,  135.5,  131.2,  
130.0, 129.4, 128.2, 122.9, 116.8, 115.6, 113.8, 108.7, 94.5, 77.6, 73.5 70.0, 56.3, 55.2, 
41.8, 37.9, 35.9, 29.0, 19.9, 12.2 ppm. 
FTIR (Neat): λ−1 = 3450, 2936, 1530, 1513, 1452, 1349, 1302, 1246, 1149, 1079, 1029, 
1010 cm−1. 
HRMS (CI): Calcd. for C30H39NO7 (M): 525.2727; Found: 525.2730. 
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(R)-(3E,6S,7S,8R,9Z)-8-((4-methoxybenzyl)oxy)-12-(3-(methoxymethoxy)-5-
nitrophenyl)-7,9-dimethyldodeca-1,3,9-trien-6-yl 2-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)propanoate (4.28) 
Fmoc-D-alanine hydrate (1.55g, 4.71 mmol), molecular sieves (1.0 g), and 
dichloromethane (50 mL) were combined under N2 stirred vigorously at ambient 
temperature for 1 h and cooled to 0 C. N,N'-Dicyclohexylcarbodiimide (486 mg, 2.36 
mmol) was added to the reaction mixture, the cooling bath was removed, and the mixture 
was vigorously stirred for 1 h at ambient temperature. The resulting mixture was filtered, 
the filter cake was rinsed with dichloromethane (3 x 20 mL) and the filtrate was 
concentrated under reduced pressure. Tetrahydrofuran (10 mL) was added to the white 
residue, the reaction vessel was cooled to 78 C. A solution of (3E,6S,7S,8R,9Z)-8-(4-
methoxybenzyloxy)-12-(3-(methoxymethoxy)-5-nitrophenyl)-7,9-dimethyldodeca-1,3,9-
trien-6-ol 4.27 (413 mg, 0.785 mmol),, tetrahydrofuran (10 mL), and 4-
dimethylaminopyridine (96 mg, 0.79 mmol) was added to the reaction mixture. The 
resulting solution was stirred for 3 h at 78 C. Phosphate buffer solution (3 mL, pH =7) 
was added and cooling bath was removed. The reaction mixture was added to a 
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separatory funnel containing NaHCO3 (15 mL) and extracted with CHCl3 (3 x 50 mL). 
The combined organic extracts were dried with sodium sulfate, filtered, and concentrated 
under reduced pressure. The crude residue was purified via column chromatography 
(SiO2, 1:1:8 to 1:1:3 dichloromethane/diethyl ether/hexanes, gradient elution) to give the 
title compound 4.28 (590 mg, 0.72 mmol, 92% yield) as a light yellow oil. 
Rf (SiO2, Hexanes/DCM/Ethyl   Ether = 3 : 1 : 1) = 0.2. 
[α]22
D=  74 (c = 1.0, CHCl3). 
1H NMR (400 MHz, CDCl3): δ  7.76-7.73 (m, 4H), 7.60 (t, J = 8.3, 1H), 7.39 (t, J = 7.4, 
1H), 7.30 (t, J = 7.4, 2H), 7.21 (d, J = 8.3, 2H), 7.17 (s, 1H), 6.87 (d, J = 8.5, 2H), 6.27 
(dt, J = 17.0, 10.1, 1H), 6.04 (dd, J = 14.9, 10.6, 1H), 5.59-5.51 (m, 3H), 5.16 (s, 2H), 
5.10 (d, J = 17.0, 1H), 5.01 (d, J = 10.2, 1H), 4.99-4.81 (m, 1H), 4.43-4.34 (m, 3H), 4.27 
(d, J = 11.2, 1H), 4.21 (t, J = 7.0, 1H), 4.05-4.00 (m, 2H), 3.77 (s, 3H), 3.45 (s, 3H), 2.79-
2.69 (m, 2H), 2.52-2.42 (m, 1H), 2.35-2.25 (m, 2H), 2.12 (dd, J = 12.8, 6.4, 1H), 1.83 (s, 
3H), 1.38 (d, J = 7.0, 3H), 1.07 (d, J = 6.8, 3H) ppm. 
13C NMR (100 MHz, CDCl3):  δ  172.6,  159.0,  155.5,  149.0,  144.6,  143.9,  143.7,  141.2,  
136.5, 135.3, 133.9, 130.5, 129.3, 129.1, 128.6, 127.6, 127.0, 125.0, 125.0, 124.9,  122.8, 
119.8, 116.6, 116.1, 113.6, 108.6, 94.4, 77.3, 75.2, 69.7, 66.8, 56.2, 55.1, 49.7, 47.1, 39.8, 
35.8, 33.5, 29.0, 18.9, 18.6, 11.1 ppm. 
FTIR (Neat): λ−1 = 2936, 1720, 1612, 1584, 1530, 1513, 1450, 1348, 1302, 1246, 1180, 
1150, 1076, 1031, 1010 cm−1. 
MS (ESI): Calcd. for C48H54N2O10 (M+ Na+): 841.4; Found: 841.4.  
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(R)-((3E,6S,7S,8R,9Z)-8-(4-methoxybenzyloxy)-12-(3-(methoxymethoxy)-5-
nitrophenyl)-7,9-dimethyldodeca-1,3,9-trien-6-yl) 2-
(cyclohexanecarboxamido)propanoate (4.29a) 
Compound 4.28 (300 mg, 0.37 mmol) and tetrahydrofuran (10 mL) were combined under 
N2, the reaction vessel was cooled to 0 C, piperidine (5 mL) was added. The reaction 
vessel was warmed to ambient temperature and stirred for 30 min. The resulting mixture 
was concentrated under reduced pressure and azeotroped with toluene (3 x 10 mL). 
Under an atmosphere of N2, dichloromethane (5 mL), hydroxybenzotriazole hydrate (170 
mg, 1.11 mmol), cyclohexanecarboxylic acid (187 mg, 1.47 mmol, N-ethyl-N′-(3-
dimethylaminopropyl)carbodiimide hydrochloride (226 mg, 1.10 mmol), and 
ethyldiisopropylamine (0.1 mL) were added to the white residue at 0 C. The cooling 
bath was removed and the mixture was stirred for 14 h. The reaction mixture was added 
to a separatory funnel containing NaHCO3 (10 mL), the organic layer was separated, and 
the aqueous layer was extracted with dichloromethane (10 mL). The combined organic 
were concentrated and purified via column chromatography (SiO2, 1:1:18 to 1:1:3 
 246 
dichloromethane/ethyl acetate/hexanes, gradient elution) to give the title compound 4.29a 
(198 mg, 0.28 mmol, 77% yield) as a light yellow oil. 
Rf (SiO2, dichloromethane:ethyl acetate: hexanes = 1: 2: 2) = 0.80. 
[α]23
D=  41 (c = 1.0, CHCl3). 
1H NMR (400 MHz, CDCl3): δ  7.70 (t, J = 1.9, 2H), 7.17 (d, J = 8.6, 2H), 7.14 (s, 1H), 
6.85 (d, J = 8.6, 2H), 6.22 (dt, J = 16.9, 10.3, 1H), 5.99 (dd, J = 15.6, 9.5, 2H), 5.49 (dt, J 
= 15.8, 7.4, 2H), 5.19 (s, 2H), 5.07 (d, J = 17.0, 1H), 4.97 (d, J = 10.2, 1H), 4.88 (ddd, J 
= 9.0, 5.7, 3.1, 1H), 4.50 (quintet, J = 7.2, 1H), 4.23 (d, J = 11.2, 1H), 3.96 (t, J = 9.5, 
2H), 3.79 (s, 3H), 3.47 (s, 3H), 2.72 (t, J = 7.0, 2H), 2.49-2.39 (m, 1H), 2.33-2.18 (m, 
3H), 2.10-2.02 (m, 2H), 1.82 (m, 3H), 1.77 (s, 3H), 1.74 (m, 1H), 1.68-1.63 (m, 2H), 1.40 
(dt, J = 12.1, 6.0, 3H), 1.29 (d, J = 7.1, 3H), 1.25-1.18 (m, 2H), 1.01 (d, J = 6.8, 3H) ppm. 
13C NMR (125 MHz, CDCl3):  δ  175.5, 173.0, 159.2, 157.7, 149.3, 144.8, 136.6, 135.4, 
134.1, 130.7, 129.5, 129.3, 128.7, 123.1, 116.9, 116.3, 113.8, 108.9, 94.7, 75.3, 69.9, 
56.4, 55.4, 48.0, 45.4, 39.9, 36.1, 33.7, 29.7, 29.6, 29.2, 26.1, 25.8, 25.8, 25.7, 19.1, 19.0, 
11.2 ppm. 
FTIR (Neat): λ−1 = 2930, 2854, 1737, 1616, 1584, 1531, 1514, 1449, 1349, 1250, 1214, 
1150, 1031, 1005 cm−1. 
MS (ESI): Calcd. for C40H54N2O9 (M+ Na+): 729.4; Found:729.5. 
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(R)-(3E,6S,7R,8R,9Z)-8-hydroxy-12-(3-(methoxymethoxy)-5-nitrophenyl)-7,9-
dimethyldodeca-1,3,9-trien-6-yl 2-(cyclohexanecarboxamido)propanoate (4.37a) 
Compound 4.29a (250 mg, 0.35 mmol), dichloromethane (20 mL), 1,3-
dimethoxybenzene (240 mg, 1.77 mmol), and dimethyl sulfide (650 mg. 10.6 mmol), 
were combined under N2, cooled to 0C, and freshly prepared magnesium bromide 
diethyl etherate  (457 mg, 1.77 mmol) was added The cooling bath was removed, and the 
resulting mixture was stirred for 6 h at ambient temperature. NH4Cl (10 mL) and ethyl 
acetate (20 mL) were added to the reaction mixture. The organic layer was separated, 
washed with brine (5 mL), dried with sodium sulfate, filtered, and concentrated under 
reduced pressure. The crude residue was purified via column chromatography (SiO2, 
1:1:8 to 1:1:3 dichloromethane/ethyl acetate/hexanes, gradient elution) to give the title 
compound 4.37a (107 mg, 0.30 mmol, 85% yield) as a light yellow oil. 
Rf = (SiO2, dichloromethane:ethyl acetate: hexanes = 1: 2: 2) = 0.60. 
[α]23
D=  23 (c = 1.0, CHCl3). 
 
1H NMR (600 MHz, CDCl3): δ  7.71  (s,  1H),  7.17  (t, J = 1.8, 1H), 6.23 (dt, J = 16.9, 10.3, 
1H), 6.04 (dd, J = 15.2, 10.5, 1H), 5.91 (d, J = 6.8, 1H), 5.54 (ddd, J = 15.0, 8.5, 6.2, 1H), 
 248 
5.25-5.23 (m, 1H), 5.22 (s, 2H), 5.08 (d, J = 16.9, 1H), 4.98 (d, J = 10.7, 1H), 4.90 (ddd, 
J = 8.8, 7.5, 3.1, 1H), 4.45 (d, J = 5.4, 1H), 4.42 (t, J = 7.1, 1H), 3.49 (s, 3H), 2.72 (t, J = 
7.6, 2H), 2.45 (dq, J = 14.9, 7.4, 1H), 2.39-2.26 (m, 3H), 2.09 (tt, J = 11.7, 3.5, 1H), 1.87-
1.82 (m, 3H), 1.76 (s, 3H), 1.66-1.64 (m, 2H), 1.43-1.37 (m, 2H), 1.32 (d, J = 7.2, 3H), 
1.28-1.20 (m, 5H), 0.97 (d, J = 6.9, 3H) ppm. 
13C NMR (150 MHz, CDCl3):  δ  176.1,  173.4,  157.7,  149.3,  145.1,  138.2,  136.7,  134.3,  
139.4, 125.6, 122.9, 117.0, 116.3, 109.0, 94.7, 75.6, 70.2, 56.5, 48.4, 45.3, 41.4, 36.0, 
34.7, 29.7, 29.6, 29.1, 25.8, 25.8, 25.7, 19.9, 18.3, 10.6 ppm. 
FTIR (Neat): λ−1 = 3396, 2931, 1734, 1654, 1531, 1450, 1350, 1270, 1214, 1150, 1031, 
1005 cm−1. 
MS (ESI): Calcd. for C32H46N2O8 (M+ Na+): 609.3; Found:609.3. 
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R)-(3E,6S,7R,8R,9Z)-8-hydroxy-12-(3-((R,E)-3-methoxyhepta-4,6-dienamido)-5-
(methoxymethoxy)phenyl)-7,9-dimethyldodeca-1,3,9-trien-6-yl 2-
(cyclohexanecarboxamido)propanoate (4.38a) 
Zinc (1.5 g, 23 mmol) was added in three portions to solution of  (R)-(3E,6S,7R,8R,9Z)-8-
hydroxy-12-(3-(methoxymethoxy)-5-nitrophenyl)-7,9-dimethyldodeca-1,3,9-trien-6-yl 2-
(cyclohexanecarboxamido)propanoate  (160 mg, 0.22 mmol), tetrahydrofuran (10 mL. 
0.011 M), water (5 mL), methanol (5 mL), and ammonium formate (710 mg, 11 mmol) 
under argon at 0 C. The cooling bath was removed and resulting mixture was vigorously 
stirred at ambient temperature for 14 h. The resulting slurry was decanted into a 
separatory funnel containing brine (20 mL) and extracted with toluene (3 x 20 mL). The 
organic extracts were combined, dried over sodium sulfate, filtered, and concentrated 
under reduced pressure (water bath under 30C). The crude residue was dissolved with 
dichloromethane (5 mL) under an atmosphere of N2, and combined with 
hydroxybenzotriazole hydrate (41 mg, 0.37 mmol) acid 1.64(40 mg, 0.27 mmol), and 
ethyldiisopropylamine (0.06 mL, 0.45 mmol). N-ethyl-N′-(3-
dimethylaminopropyl)carbodiimide hydrochloride (56 mg, 0.30mmol) was added and the 
solution was stirred at ambient temperature for 18 h. Dichloromethane (10 mL) and 
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NaHCO3 (5 mL) were added, the organic layer was separated, concentrated under 
reduced pressure, and purified via column chromatography (SiO2, 1:1:1 
dichloromethane/ethyl acetate/hexanes) to give the title compound 4.38a (49 mg, 0.071 
mmol, 51% yield) as a light yellow oil. The stereochemical assignment was comfirmed 
by converting the title compound to the known natural product. 
Rf (SiO2, dichloromethane:ethyl ether: Hexanes: Ethyl Acetate = 3: 3: 3: 1) = 0.4. 
[α]26
D= 11 (c = 0.95, CHCl3). 
1H NMR (400 MHz; CDCl3):   δ   8.67   (s,   1H),   7.27   (s,   1H),   6.91   (s,   1H),   6.60   (s,   1H),  
6.38-6.16 (m, 6H), 6.03 (dd, J = 15.1, 10.5, 1H), 5.61-5.49 (m, 4H), 5.32-5.23 (m, 3H), 
5.17-5.12 (m, 4H), 5.08 (d, J = 16.7, 1H), 4.98 (d, J = 10.2, 1H), 4.90 (ddd, J = 8.8, 7.5, 
3.1, 2H), 4.52 (quintet, J = 7.2, 1H), 4.36 (d, J = 5.2, 1H), 4.15-4.13 (m, 1H), 3.47 (s, 
3H), 3.33 (s, 3H), 2.67-2.49 (m, 5H), 2.38-2.26 (m, 3H), 2.17-2.08 (m, 3H), 1.87-1.84 
(m, 3H), 1.78 (s, 3H), 1.30 (d, J = 7.1, 3H), 1.28-1.21 (m, 3H), 0.97 (d, J = 6.9, 3H) ppm. 
13C NMR (100 MHz, CDCl3):  δ  175.9,  173.4,  169.0,  157.7,  144.0,  139.5,  137.4,  136.7,  
135.9, 134.2, 134.0, 132.0, 129.4, 126.5, 118.6, 116.2, 113.3, 112.1, 106.0, 94.6, 78.7, 
75.8, 69.8, 56.6, 56.2, 48.1, 45.3, 44.0, 42.8, 41.6, 36.1, 34.5, 29.7, 29.6, 25.8, 25.7, 25.7, 
19.5, 18.9, 10.5 ppm. 
FTIR (Neat): λ−1 = 3310, 2930, 1737, 1652, 1604, 1541, 1448, 1374, 1299, 1204, 1146 
cm−1. 
HRMS (ESI): Calcd. for C40H58N2O8 (M+ Na+): 717.40854; Found:717.40808. 
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(+)-trienomycin A (1.1a) 
A solution of compound 4.38a (7.0 mg, 0.011 mmol) in dichloromethane (11 mL, 0.001 
M) was sparged with argon. Bis(tricyclohexylphosphine)-3-phenyl-1H-inden-1-
ylideneruthenium(II) dichloride (3.9 mg, 4.2 mol) was added and the reaction mixture 
was sparged with argon for 10 min. The resulting mixture was heated at 40 C for 14 h, 
cooled to ambient temperature and filtered through a plug of silica gel, eluted with 1:1 
ethyl acetate/dichloromethane (50 mL) and discarded fraction, eluted 4:1 ethyl 
acetate/dichloromethane, collected fraction and concentrated under reduced pressure. The 
crude residue was dissolved in tetrahydrofuran (3 mL), 3N HCl (3 mL) was added at 
ambient temperature, and the resulting mixture was allowed to stand for 24 h. The 
reaction mixture was added dropwise to a solution of 50% NaHCO3 (10 mL), extracted 
with chloroform (3 x 15 mL), dried with sodium sulfate, filtered, and concentrated under 
reduced pressure. The crude residue was purified by reverse-phase HPLC (Agilent 
Eclipse  5  μm  XDB-C18, 9.4 x 250 mm, 63% Methanol in water with 0.1% TFA over 30 
min, 2.5 mL/min, RT = 16.1 min.) to give (+)-trienomycin A (1.1a) ( 1.4 mg, .0022 
mmol, 21% yield) as a white powder. The spectral data obtained for (+)-trienomycin A 
were consistent with reported values.145  
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Rf (SiO2, chloroform/methanol = 9 : 1) = 0.1. 
[α]25
D=  78  (c = 0.014, methanol). 
1H NMR (500 MHz, CD3OD): δ  6.96  (s,  1H),  6.43  (s,  1H),  6.38  (s,  1H),  6.14-6.07 (m, 
4H), 5.62-5.55 (m, 2H), 5.21 (s, 1H), 4.62 (s, 1H), 4.27 (q, J = 7.3, 1H), 4.06-4.02 (m, 
1H), 2.72 (dd, J = 12.0, 4.2, 1H), 2.56-2.48 (m, 2H), 2.45-2.37 (m, 2H), 2.31-2.19 (m, 
4H), 1.95-1.91 (m, 2H), 1.79-1.76 (m, 2H), 1.74 (s, 3H), 1.75-1.68 (m, 2H), 1.47-1.39 
(m, 2H), 1.36 (d, J = 7.3, 3H), 1.31-1.17 (m, 4H), 0.90 (d, J = 6.8, 3H) ppm. 
13C NMR (125 MHz, CD3OD):  δ  179.2,  173.7,  170.9,  158.7,  144.9,  139.8,  135.3,  135.0,  
134.7, 132.5, 131.0, 130.6, 125.9, 113.4, 112.8, 107.1, 81.6, 76.4, 69.7, 56.6, 50.0, 45.9, 
44.8, 40.3, 374, 33.7, 30.6, 30.5, 26.9, 26.7, 26.7, 20.8, 17.2, 10.1 ppm. 
FTIR (Neat): λ−1 = 3310, 2930, 1737, 1652, 1604, 1541, 1448, 1374, 1299, 1204, 1146 
cm−1. 
HRMS (ESI): Calcd. for C36H50N2O7 (M+Na+): 645.35102; Found:645.35162. 
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(R)-(3E,6S,7S,8R,9Z)-8-((4-methoxybenzyl)oxy)-12-(3-(methoxymethoxy)-5-
nitrophenyl)-7,9-dimethyldodeca-1,3,9-trien-6-yl 2-((E)-2-methylbut-2-
enamido)propanoate (4.29f) 
Compound 4.28 (300 mg, 0.37 mmol) and tetrahydrofuran (10 mL) were combined under 
N2. The reaction vessel was cooled to 0 C and piperidine (5 mL) was added. The 
reaction vessel was warmed to ambient temperature and stirred for 30 min. The resulting 
mixture was concentrated under reduced pressure and azeotroped with toluene (3 x 10 
mL). Under an atmosphere of N2, dichloromethane (5 mL), hydroxybenzotriazole hydrate 
(170 mg, 1.11 mmol), tiglic acid (147 mg, 1.47 mmol, N-ethyl-N′-(3-
dimethylaminopropyl)carbodiimide hydrochloride (226 mg, 1.10 mmol), and 
ethyldiisopropylamine (0.1 mL) were added to the white residue at 0 C. The cooling 
bath was removed and the mixture was stirred for 14 h. The reaction mixture was added 
to a separatory funnel containing NaHCO3 (10 mL), the organic layer was separated, and 
the aqueous layer was extracted with dichloromethane (10 mL). The combined organic 
were concentrated and purified via column chromatography (SiO2, 1:1:6 to 1:1:3 
dichloromethane/diethyl ether/hexanes, gradient elution) to give the title compound 4.29f 
(199 mg, 0.33 mmol, 88% yield) as a light yellow oil. 
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Rf = (SiO2, dichloromethane:ethyl acetate: hexanes = 1: 2: 2) = 0.80. 
 [α]23D= +48 (c = 0.95, CHCl3) 
1H NMR (400 MHz, CDCl3):  δ  7.69-7.67 (m, 2H), 7.16 (d, J = 8.7, 2H), 7.13 (t, J = 1.9, 
1H), 6.83 (d, J = 8.7, 2H), 6.46-6.40 (m, 1H), 6.28 (d, J = 7.3, 1H), 6.21 (dt, J = 16.9, 
10.4, 1H), 5.99 (dd, J = 15.2, 10.5, 1H), 5.52-5.45 (m, 2H), 5.17 (s, 2H), 5.05 (d, J = 
16.8, 1H), 4.96 (d, J = 10.3, 1H), 4.87 (ddd, J = 9.0, 5.8, 3.1, 1H), 4.54 (quintet, J = 7.2, 
1H), 4.22 (d, J = 11.2, 1H), 3.97-3.93 (m, 2H), 3.76 (s, 3H), 3.45 (s, 3H), 2.73-2.69 (m, 
2H), 2.43 (dq, J = 15.2, 7.6, 1H), 2.31-2.17 (m, 3H), 2.08-2.03 (m, 1H), 1.81 (s, 3H), 1.76 
(s, 3H), 1.72 (dd, J = 7.0, 1.0, 3H), 1.32 (d, J = 7.1, 3H), 1.01 (d, J = 6.9, 3H) ppm. 
13C NMR (125 MHz, CDCl3):  δ  172.9,  168.5,  159.1,  157.6,  149.2,  144.7,  136.5,  135.3,  
134.0, 131.3, 130.6, 129.4, 129.2, 128.7, 123.0, 116.8, 116.2, 113.7, 108.7, 94.5, 77.2, 
75.2, 69.7, 56.3, 55.3, 48.3, 39.7, 36.0, 33.5, 29.1, 18.9, 18.7, 13.9, 12.3, 11.2 ppm. 
FTIR (Neat): λ−1 =2938, 2857,1780, 1736, 1665, 1612, 1532, 1514, 1444, 1373, 1349, 
1271, 1244. 1174, 1150, 1032, 1010 cm−1. 
HRMS (ESI): Calcd. for C38H50N2O9 (M+ Na+): 701.34085; Found: 701.33997. 
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(R)-(3E,6S,7R,8R,9Z)-8-hydroxy-12-(3-(methoxymethoxy)-5-nitrophenyl)-7,9-
dimethyldodeca-1,3,9-trien-6-yl 2-((E)-2-methylbut-2-enamido)propanoate (4.37f) 
Freshly prepared magnesium bromide diethyl etherate (260 mg, 3.0 mmol), 
dichloromethane (40 mL), 1,3-dimethoxybenzene (200 mg, 1.5 mmol), and dimethyl 
sulfide (600 mg. 8.9 mmol), were combined under N2 and cooled to 0 C. A solution of 
compound 4.29f (200 mg, 0.30 mmol) and dichloromethane (10 mL) was added, the 
cooling bath was removed the resulting mixture was stirred for 1.5 h at ambient 
temperature. The reaction vessel was cooled 78 C, and tetrahydrofuran (20 mL) was 
added followed by 50% NaHCO3 (10 mL). The resulting mixture was warmed to ambient 
temperature, and extracted with chloroform (3 x 30 mL). The organic extracts were 
combined, dried with sodium sulfate, filtered, and concentrated under reduced pressure. 
The crude residue was purified via column chromatography (SiO2, 1:1:2 to 1:2:2 
dichloromethane/ethyl acetate/hexanes, gradient elution) to give the title compound 4.37f 
(115 mg, 0.21 mmol, 70% yield) as a light yellow oil. 
Rf = (SiO2, dichloromethane:ethyl acetate: hexanes = 1: 2: 2) = 0.50.  
[α]24
D= 30 (c = 1.0, CHCl3). 
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1H NMR (500 MHz, CDCl3): δ  7.70  (s,  2H),  7.16  (s,  1H),  6.46  (q, J = 6.9, 1H), 6.27-6.18 
(m, 2H), 6.27-6.18 (m, 2H), 6.04 (dd, J = 15.0, 10.5, 1H), 5.54 (dt, J = 14.8, 7.4, 1H), 
5.25-5.21 (m, 3H), 5.08 (d, J = 16.9, 1H), 4.97 (d, J = 10.1, 1H), 4.90 (td, J = 8.0, 2.6, 
1H), 4.49-4.42 (m, 2H), 3.50 (s, 3H), 2.71 (t, J = 7.6, 2H), 2.50-2.25 (m, 5H), 1.89-1.85 
(m, 1H), 1.82 (s, 3H), 1.76 (s, 3H), 1.73 (d, J = 7.0, 3H), 1.35 (d, J = 7.2, 3H), 0.96 (d, J 
= 6.8, 3H) ppm. 
13C NMR (125 MHz, CDCl3):  δ  173.4,  169.1, 157.6, 149.2, 145.1, 138.2, 136.6, 134.3, 
131.9, 131.1, 129.3, 125.5, 122.9, 116.9, 116.3, 108.9, 94.6, 75.5, 70.2, 56.4, 48.7, 41.3, 
35.9, 34.6, 29.0, 19.8, 18.3, 14.1, 12.3, 10.6 ppm. 
FTIR (Neat): λ−1 = 3359, 2929, 1723, 1661, 1528, 1451, 1350, 1288, cm−1. 
HRMS (ESI): Calcd. for C30H42N2O8 (M+ Na+): 581.28334; Found: 581.28427. 
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(R)-(3E,6S,7R,8R,9Z)-8-hydroxy-12-(3-((R,E)-3-methoxyhepta-4,6-dienamido)-5-
(methoxymethoxy)phenyl)-7,9-dimethyldodeca-1,3,9-trien-6-yl 2-((E)-2-methylbut-
2-enamido)propanoate (4.38f) 
Zinc (1.2 g, 18 mmol) was added to solution of (R)-(3E,6S,7R,8R,9Z)-8-hydroxy-12-(3-
(methoxymethoxy)-5-nitrophenyl)-7,9-dimethyldodeca-1,3,9-trien-6-yl 2-((E)-2-
methylbut-2-enamido)propanoate 4.37f  (100 mg, 0.18 mmol), tetrahydrofuran (10 mL), 
water (5 mL), methanol (5 mL), and ammonium formate (560 mg, 9.0 mmol) under argon 
at 0 C. The cooling bath was removed and the resulting mixture was vigorously stirred 
at ambient temperature for 14 h. The resulting slurry was decanted into a separaory 
funnel containing brine (20 mL) and extracted with toluene (3 x 20 mL). The organic 
extracts were combined, dried over sodium sulfate, filtered, and concentrated under 
reduced pressure (water bath under 30C). The crude residue was dissolved with 
dichloromethane (5 mL) under an atmosphere of N2, and combined with 
hydroxybenzotriazole hydrate (56 mg, 0.37 mmol), acid 1.64 (58 mg, 0.37 mmol), and 
ethyldiisopropylamine (0.1 mL, 0.72 mmol). N-ethyl-N′-(3-
dimethylaminopropyl)carbodiimide hydrochloride (226 mg, 1.10 mmol) was added and 
the solution was stirred at ambient temperature for 18 h. Dichloromethane (10 mL) and 
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NaHCO3 (5 mL) were added, the organic layer was separated, concentrated under 
reduced pressure, and purified via column chromatography (SiO2, 1:1:1 
dichloromethane/ethyl acetate/hexanes) to give the title compound 4.38f (69 mg, 0.10 
mmol, 58% yield) as a light yellow oil. The stereochemical assignment was comfirmed 
by converting the title compound to the known natural product. 
 
Rf (SiO2, hexanes/EtOAc/DCM = 1:1:1) = 0.34. 
[α]24
D= +16 (c = 0.90, CHCl3). 
1H NMR (500 MHz, CDCl3): 8.72 (s, 1H), 7.29 (t, J = 1.7, 1H), 6.91 (s, 1H), 6.59 (s, 
1H), 6.50 (q, J = 6.7, 1H), 6.43 (d, J = 7.1, 1H), 6.38-6.19 (m, 3H), 6.04 (dd, J = 15.1, 
10.5, 1H), 5.59-5.49 (m, 2H), 5.27-5.23 (m, 2H), 5.18-5.12 (m, 3H), 5.08 (d, J = 17.0, 
2H), 4.96 (d, J = 10.2, 1H), 4.92 (td, J = 8.2, 2.4, 1H), 4.59 (dt, J = 14.3, 7.1, 2H), 4.36 
(d, J = 5.1, 1H), 4.12 (td, J = 7.9, 4.2, 1H), 3.47 (s, 3H), 3.32 (s, 3H), 2.65-2.48 (m, 4H), 
2.40-2.24 (m, 3H), 2.24-2.17 (m, 2H), 1.84 (s, 3H), 1.77 (s, 3H), 1.75 (d, J = 7.0, 3H), 
1.34 (d, J = 7.1, 3H), 0.97 (d, J = 6.9, 3H) ppm. 
13C NMR (125 MHz, CDCl3):  δ  173.5,  169.0,  168.8,  157.7,  144.0,  139.6,  137.4,  136.7,  
136.0, 134.3, 133.9, 132.1, 131.2, 129.4, 126.4, 119.6, 116.2, 113.3, 112.1, 106.0, 94.6, 
78.8, 75.9, 69.8, 56.6, 56.2, 48.6, 44.0, 42.8, 41.6, 36.1, 34.5, 29.6, 19.5, 18.9, 14.1, 12.4, 
10.5 ppm. 
FTIR (Neat): λ−1 = 3332, 2970, 2935, 1736, 1663, 1616, 1557, 1437, 1378, 1207, 
1147cm−1. 
HRMS (ESI): Calcd. for C38H54N2O8 (M+Na+): 689.37724; Found: 689.37732.  
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(+)-trienomycin F (1.1f) 
A solution of 4.38f (7.0 mg, 0.011 mmol) in dichloromethane (11 mL, 0.001 M) was 
sparged with argon. Bis(tricyclohexylphosphine)-3-phenyl-1H-inden-1-
ylideneruthenium(II) dichloride (3.9 mg, 4.2 mol) was added and the reaction mixture 
was sparged with argon for 10 min. The resulting mixture was heated at 40 C for 14 h, 
cooled to ambient temperature and filtered through a plug of silica gel, eluted with 1:1 
ethyl acetate/dichloromethane (50 mL) and discarded the fraction, eluted 4:1 ethyl 
acetate/dichloromethane, collected fraction and concentrated under reduced pressure. The 
crude residue was dissolved in tetrahydrofuran (2 mL), 3N HCl (2 mL) was added at 
ambient temperature, and the resulting mixture was allowed to stand for 24 h. The 
reaction mixture was added dropwise to a solution of 50% NaHCO3 (10 mL), extracted 
with chloroform (3 x 15 mL), dried with sodium sulfate, filtered, and concentrated under 
reduced pressure. The crude residue was purified by reverse-phase HPLC (Agilent 
Eclipse  5  μm  XDB-C18, 9.4 x 250 mm, 60% Methanol in water with 0.1% TFA over 30 
min, 2.4 mL/min, RT = 16.3 min.) to give (+)-trienomycin F (1.6 mg, 0.0026 mmol, 24% 
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yield) as a white powder. The spectral data obtained for (+)-trienomycin F (1.1f) were 
consistent with reported values.25 
Rf (SiO2, CHCl3/MEOH =9 : 1) = 0.1. 
[α]24
D=  123 (c = 0.016, CHCl3). 
1H NMR (600 MHz; CDCl3):  δ  7.46  (t, J = 1.9, 1H), 7.43 (s, 1H), 6.92 (br s, 1H), 6.52 
(qd, J = 6.9, 1.3, 1H), 6.45 (s, 1H), 6.26-6.21 (m, 3H), 6.08-6.06 (m, 2H), 6.02-5.99 (m, 
1H), 5.59 (dd, J = 15.6, 6.4, 1H), 5.58-5.52 (m, 1H), 5.19-5.17 (m, 1H), 4.91 (ddd, J = 
9.4, 5.7, 2.3, 1H), 4.60 (br s, 1H), 4.45 (quintet, J = 7.0, 1H), 4.12-4.09 (m, 1H), 3.38 (s, 
3H), 2.73 (dd, J = 13.9, 3.7, 1H), 2.68-2.61 (m, 1H), 2.58 (dd, J = 13.9, 8.3, 1H), 2.51-
2.42 (m, 4H), 2.32 (ddd, J = 14.5, 8.7, 1.5, 1H), 2.19-2.13 (m, 1H), 1.99-1.93 (m, 1H), 
1.82 (t, J = 1.2, 3H), 1.78 (s, 3H), 1.74 (dd, J = 6.9, 0.9, 3H), 1.35 (d, J = 7.1, 3H), 0.90 
(d, J = 6.9, 3H) ppm. 
13C NMR (150  MHz,  CDCl3):  δ  172.9,  169.3,  168.5,  157.1,  144.0,  138.6,  138.3,  134.1,  
133.4, 133.3, 132.7, 130.6, 130.5, 129.4, 129.1, 124.5, 111.8, 110.8, 105.7, 78.5, 75.4, 
68.4, 56.8, 48.8, 43.5, 39.6, 36.2, 33.1, 29.6, 20.3, 17.8, 14.0, 12.1, 9.8 ppm. 
FTIR (Neat): λ−1 = 3310, 2930, 1737, 1652, 1604, 1541, 1448, 1374, 1299, 1204, 1146 
cm−1. 
HRMS (ESI): Calcd. for C34H46N2O7 (M-H)-: 593.32322; Found: 593.32344. 
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4.6 Spectra relevant to chapter 4 
 
Figure 4.1 1H NMR spectrum of compound 4.4 
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Figure 4.2 13C NMR spectrum of compound 4.4 
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Figure 4.3 1H NMR spectrum of compound 4.13  
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Figure 4.4 13C NMR spectrum of compound 4.13 
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Figure 4.5 1H NMR spectrum of compound 4.15  
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Figure 4.6 13C NMR spectrum of compound 4.15  
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Figure 4.7 1H NMR spectrum of compound 4.17 
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Figure 4.8 13C NMR spectrum of compound 4.17  
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Figure 4.9 1H NMR spectrum of compound 4.18  
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Figure 4.10 13C NMR spectrum of compound 4.18  
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Figure 4.11 1H NMR spectrum of compound 4.19 
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Figure 4.12 13C NMR spectrum of compound 4.19 
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Figure 4.13 1H NMR spectrum of compound 4.21  
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Figure 4.14 13C NMR spectrum of compound 4.21  
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Figure 4.15 HPLC data for compound 4.21  
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Figure 4.16 1H NMR spectrum of compound 4.24  
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Figure 4.17 13C NMR spectrum of compound 4.24  
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Figure 4.18 1H NMR spectrum of compound 4.26   
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Figure 4.19 13C NMR spectrum of compound 4.26   
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Figure 4.20 1H NMR spectrum of compound 4.27  
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Figure 4.21 13C NMR spectrum of compound 4.27 
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Figure 4.22 1H NMR spectrum of compound 4.28 
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Figure 4.23 13C NMR spectrum of compound 4.28 
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Figure 4.24 1H NMR spectrum of compound 4.29a  
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Figure 4.25 13C NMR spectrum of compound 4.29a  
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Figure 4.26 1H NMR spectrum of compound 4.37a  
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Figure 4.27 13C NMR spectrum of compound 4.37a  
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Figure 4.28 1H NMR spectrum of compound 4.38a  
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Figure 4.29 13C NMR spectrum of compound 4.38a  
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Figure 4.30 1H NMR spectrum of trienomycin A (1.1a)  
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Figure 4.31 13C NMR spectrum of trienomycin A (1.1a)  
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Figure 4.32  Comparison of 1H NMR spectra of natural145 and synthetic trienomycin A 
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No. Natural145 (δ) Synthetic  (δ) Δ  (δ) 
1 170.9 170.9 0.0 
2 44.8 44.8 0.0 
3 81.6 81.6 0.0 
4 132.5 132.5 0.0 
5 135.3 135.3 0.0 
6 131.0 131.0 0.0 
7 135.0 135.0 0.0 
8 134.7 134.7 0.0 
9 130.6 130.6 0.0 
10 33.7 33.7 0.0 
11 76.4 76.4 0.0 
12 40.4 40.3 0.1 
13 69.7 69.7 0.0 
14 139.8 139.8 0.0 
15 125.9 125.9 0.0 
16 30.9 30.9 0.0 
17 37.4 37.4 0.0 
18 140.2 140.2 0.0 
19 112.9 112.8 0.1 
20 145.0 145.0 0.0 
21 107.2 107.1 0.1 
22 158.7 158.7 0.0 
23 113.5 113.4 0.1 
24 10.1 10.1 0.0 
25 20.8 20.8 0.0 
26 56.7 56.7 0.0 
27 173.8 173.7 0.1 
28 50.0 50.0 0.0 
29 17.2 17.2 0.0 
30 179.2 179.2 0.0 
31 45.9 45.9 0.0 
32 30.6 30.6 0.0 
33 26.7 26.7 0.0 
34 26.9 26.9 0.0 
35 26.7 26.7 0.0 
36 30.5 30.5 0.0 
Table 4.2  Comparison of 13C NMR data of natural145 and synthetic trienomycin A  
 294 
 
 
Figure 4.33 1H NMR spectrum of compound 4.29f  
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Figure 4.34 13C NMR spectrum of compound 4.29f  
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Figure 4.35 1H NMR spectrum of compound 4.37f 
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Figure 4.36 13C NMR spectrum of compound 4.37f 
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Figure 4.37 1H NMR spectrum of compound 4.38f  
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Figure 4.38 13C NMR spectrum of compound 4.38f  
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Figure 4.39 1H NMR spectrum of trienomycin F (1.1f)  
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Figure 4.40 13C NMR spectrum of trienomycin F (1.1f)  
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Figure 4.41  Comparison of 1H NMR spectra of natural and synthetic trienomycin F    
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Natural  (δ) Synthetic  (δ) Δ  (δ) 
172.9 172.9 0.0 
169.3 169.3 0.0 
168.4 168.5 0.1 
157.1 157.1 0.0 
144.1 144.0 0.1 
138.6 138.6 0.0 
138.4 138.3 0.1 
134.1 134.1 0.0 
133.4 133.4 0.0 
133.3 133.3 0.0 
132.7 132.7 0.0 
130.6 130.6 0.0 
130.5 130.5 0.0 
129.3 129.4 0.1 
129.2 129.1 0.1 
124.5 124.5 0.0 
111.8 111.8 0.0 
110.8 110.8 0.0 
105.6 105.6 0.0 
78.5 78.5 0.0 
75.4 75.4 0.0 
68.3 68.4 0.1 
56.8 56.8 0.0 
48.8 48.8 0.0 
43.5 43.5 0.0 
39.6 39.6 0.0 
36.1 36.2 0.1 
33.1 33.1 0.0 
29.7 29.6 0.1 
20.3 20.3 0.0 
17.8 17.8 0.0 
14.0 14.0 0.0 
12.1 12.1 0.0 
9.7 9.8 0.1 
Table 4.3 Comparison of 13C NMR data of natural25 and synthetic trienomycin F  
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